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Abstract 
 
Classic kappa opioid receptor (KOPr) agonists have shown anti-addictive properties in 
rat models of addiction (Heidbreder et al. 1998; Schenk et al. 1999; Sun et al. 2010), 
and this has been shown to be partially through modulation of dopamine and serotonin 
in the synapse (Thompson et al. 2000; Zhang et al. 2004; Zakharova et al. 2008a).  
However, they have side effects such as depression and dysphoria and therefore have 
not been moved into the clinic.  The novel KOPr agonist salvinorin A has a completely 
different structure compared to the classic agonists, and along with its novel analogues 
has opened up a new family of KOPr agonists which may possess anti-addictive 
properties and have the potential to have decreased side effects.  Salvinorin A has also 
demonstrated anti-addictive properties (Morani et al. 2009).  In this study the novel 
KOPr agonist salvinorin A and its analogues DS-1-240 and DS-3-216 were 
investigated, along with the classic agonists U50,488H and U69,593.  Their effects on 
the dopamine transporter (DAT) were measured using isolated rat brain tissue and cell 
models.  The effects of U50,488H and salvinorin A on the serotonin transporter (SERT) 
was also measured in rat striatum using rotating disk electrode voltammetry, which was 
established to measure serotonin uptake in our lab during this study. 
 
We found that all of the kappa opioid receptor agonists studied in isolated rat brain 
tissue caused dose dependent increases in uptake of dopamine by the dopamine 
transporter and a decrease in uptake of serotonin by the serotonin transporter.  The 
effect on the serotonin transporter was observed after a 15 min incubation with the 
agonists.  Salvinorin A had a faster effect on the dopamine transporter than the other 
compounds investigated, with increases measured at 1 min rather than 4 min.  DAT 
kinetics showed increases in Vmax for all agonists investigated, and both U69,593 and 
DS-1-240 also showed increased Km values.  This demonstrates an overall increase in 
function, with the possibility of increased cell surface expression.  
 
Further investigation using cell models also found an increase in uptake of the 
fluorescent monoamine transporter substrate ASP
+
 by YFP tagged human DAT (YFP-
hDAT).  This effect was seen with all the agonists studied after incubations of less than 
5 min and was YFP-hDAT trafficking-independent.  The increase in uptake seen may 
be due to increased active YFP-hDAT found on the cell membrane as ASP
+
 binding 
studies demonstrated an increase in binding.  The acute increase in YFP-hDAT function 
 ii 
 
was found to be ERK1/2 dependent for all compounds studied, and was also dependent 
on intact lipid rafts in the cell membrane.  After a 30 min incubation, salvinorin A and 
U50,488H still caused increased uptake of ASP
+
 by YFP-hDAT, whereas DS-1-240 and 
DS-3-216 did not.  Increases in cell surface expression of YFP-hDATwas seen at this 
time point with salvinorin A, U69,593, and DS-3-216.  Further investigation into this 
found that the increase in cell surface expression of YFP-hDAT after salvinorin A 
treatment was ERK1/2 dependent, whereas the increase seen with U69,593 appeared to 
be ERK1/2 independent.   
 
Overall, this data demonstrates that KOPr rapidly regulates DAT function by a 
trafficking-independent, ERK1/2-, and lipid raft-dependent mechanism. The classic 
KOPr agonist U50,488H and salvinorin A also caused a decrease in serotonin uptake by 
SERT, confirming that the KOPr also regulates SERT.  The data from this study 
provides more information on how these classic and novel KOPr agonists function to 
regulate DAT and SERT, which may help explain some of the anti-addictive properties 
displayed by these compounds.   
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Chapter 1: Introduction 
 
Drug abuse and addiction are major social and economic burdens world-wide.  
Currently there are limited therapeutics available to combat drug addiction, with none 
available to treat psychostimulant abuse.  The dopamine transporter (DAT) is involved 
in the process of addiction and the kappa opioid receptor (KOPr) has been shown to 
modulate DAT function. Therefore the design of novel KOPr agonists may lead to 
potential anti-addiction therapies through modulation of DAT.  This study investigates 
the unique KOPr agonist salvinorin A and novel analogues based on salvinorin A‟s 
structure. 
 
1.1 Drug addiction 
1.1.1 Introduction 
Drug addiction, also called substance dependence, is a chronic relapsing brain disorder 
defined as the compulsion to seek and take drugs even when the adverse consequences 
are known to the individual (Koob and Kreek 2007).  In New Zealand, it is estimated 
that 30% of the population abuse drugs such as nicotine, alcohol, psychostimulants and 
opioids (M.O.H. 2007) which in turn leads to large economic and social costs.  Most 
drugs of abuse currently have no successful long-term therapies, with studies showing 
that 80–90% of human addicts relapse back to drug taking behaviour, even after long 
periods of abstinence and with the aid of currently available pharmacotherapies 
(Reviewed in Shippenberg et al. 2007).  Available therapeutics for drugs of abuse such 
as nicotine have very low success rates, and others such as methadone, used for opiate 
addiction, are highly addictive themselves. Currently there are no pharmacotherapies 
available for psychostimulants such as cocaine, amphetamine, and methamphetamines.  
There is therefore a need for development of better pharmacotherapies that have fewer 
side effects and greater long term success rates.   
 
1.1.1.1 Definitions 
Drug abuse and drug addiction are defined as two separate disorders, with drug abuse 
the less debilitating of the two.  For a patient to be diagnosed with drug abuse syndrome 
they need to display repeated and clinically significant adverse consequences related to 
frequent substance use.  These consequences include: failing to fulfil major roles or 
obligations due to drug use; use of drugs in physically hazardous situations; legal 
 2 
 
problems due to drug use; and continued use of a drug despite social or interpersonal 
problems (A.P.A. 2000).  Drug abuse is often seen as a stepping stone to drug addiction. 
   
For a patient to be diagnosed with drug addiction, they need to exhibit at least three of 
the following symptoms: symptoms of tolerance; symptoms of withdrawal; the use of 
the substance for longer time periods or in larger amounts then intended; persistent 
desire, or inability to decrease or control use; the spending of larger periods of time in 
efforts to obtain the substance; a reduction in social, occupational, or recreational 
activities because of drug use; and continued use of the substance with the knowledge 
of health, social or economic problems (A.P.A. 2000).   
 
Sensitisation to a drug of abuse often occurs during early intermittent drug taking and is 
the process in which there is an increase in the expected effect of a drug after repeated 
use, or hypersensitivity to the effect of the drug.  This is often seen as locomotor 
sensitisation with psychostimulants such as cocaine in laboratory rats (Shippenberg and 
Rea 1997).  Sensitisation is one of the factors involved in drug cravings and relapse.  
Tolerance occurs after long term drug use, and is characterised by a blunted effect of the 
drug that leads to increased doses used. 
 
Cravings and withdrawal are interlinked.  Craving is a psychological dependence, i.e. an 
intense desire to re-experience the effects of a drug.  Withdrawal is a group of 
physiological and psychological factors that occur immediately after attenuation of drug 
taking.  Craving and withdrawal are also cue-induced and play large roles in relapse.   
  
1.1.2 Drug addiction in New Zealand 
The drugs used and abused in New Zealand can be quite unique from those abused in 
other parts of the world.  This is thought to be because of the isolation of New Zealand 
and the country‟s strict border control, which makes it harder to get drugs such as 
cocaine and opiates into the country (Braye et al. 2007).  There have been a number of 
surveys carried out over the past 10 years highlighting the fact that New Zealand has a 
high prevalence of alcohol, tobacco, cannabis and amphetamine use (M.O.H. 2007).  A 
mental health survey carried out in 2003 included a section on substance use disorders, 
in which the authors looked at both abuse and dependence of substances as defined by 
the American Psychiatric Association.  Of the 55,000 people surveyed, 12.7% had 
experienced a substance use disorder in their lifetime, with young male Maori the most 
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common demographic.  These statistics did not include tobacco use (20% of people 
surveyed smoked) or alcohol abuse (2.6% abuse and 1.3% dependence).  The survey 
also highlighted the high co-morbidity of substance use disorders with alcohol abuse 
and dependence, and mental health issues (Wells et al. 2007).   
 
In 2003 a New Zealand Ministry of Health survey found the top five most commonly 
used drugs in New Zealand were alcohol, tobacco, cannabis, amphetamines, and ecstasy 
(MDMA) (M.O.H. 2007).  An earlier survey carried out to investigate the use of 
amphetamine-type stimulants in New Zealand found that 1 in 10 people surveyed over 
the age of 18 had tried amphetamine-type stimulants, with one third of these being 
frequent users (Wilkins et al. 2004).  Methamphetamine, also known as „P‟, is a more 
recent amphetamine-type stimulant abused in New Zealand and appears to be growing 
in popularity.  This drug has greater appeal to young professionals, with users 
predominantly being young male Europeans (Wilkins et al. 2006).  There is also a 
population of intravenous opiate users in New Zealand, with estimates of about 10,000 
in 2008.  Of these, there were 4,608 who were on a methadone program  (Deering et al. 
2008).  Another study published in 2006 found that 76.6% of 27 year olds had used 
cannabis in their lifetime, with 12.5% meeting the criteria for cannabis dependence.  A 
further 3.6% were also dependent on other illegal substances (Boden et al. 2006).   
 
Drug use often leads to criminal behaviour, and a study carried out by the New Zealand 
police in 2005, in which they tested arrestees for illegal drugs in their system, found that 
of the arrestees that provided usable urine samples, 71% were positive for illegal drugs.  
Of those, 48% reported using drugs at the time of their arrest, 36% reported use of 
alcohol, 18% reported cannabis use, and 6% reported methamphetamine use (Hales and 
Manser 2007).   
 
These surveys highlight that drug abuse and dependence are major issues in New 
Zealand, with yearly costs estimated to be $16.5 billion (Slack et al. 2009).  Therefore, 
there is a need for further research into drug addiction and potential therapeutics to 
decrease drug use. 
  
1.1.3 The brain‟s natural reward pathway 
The brain‟s natural reward pathway is activated during rewarding events such as eating, 
drinking, and sex (Adinoff 2004).  Drugs of abuse act on this pathway, overwhelming 
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the system and leading to dysregulation of natural reward systems.  This pathway is 
known as the mesocorticolimbic pathway.  Dopaminergic neurons make up the core of 
this pathway, with inhibitory and excitatory systems, and other monoamine systems 
feeding into it.  Dopaminergic neurons have cell bodies that are found in the ventral 
tegmental area (VTA) that project forward to the nucleus accumbens (NAc) and 
prefrontal cortex (PFC) via the amygdala (Figure 1.1).  The NAc is the brain‟s reward 
centre, and the PFC is involved in „executive functions‟ such as distinguishing between 
good and bad, the consequences of actions, setting goals, and predicting outcomes 
(Robinson and Berridge 2000).  The amygdala is involved in assigning reward values to 
stimuli and in memory consolidation for emotionally arousing events (Robinson and 
Berridge 2000).  Dopaminergic neurons with cell bodies present in the substantia nigra 
project forward to the striatum, a brain region involved in motor control and habit 
learning (Robinson and Berridge 2000).  This pathway is known as the nigrostriatal 
dopamine pathway. Drugs of abuse hijack these pathways in the brain, leading to 
increased reinforcement compared to natural reinforcers.  A microdialysis study carried 
out by Hernandex and Hoebel (1988) demonstrates this increase in reinforcement. 
Microdialysis was used to measure extracellular dopamine (DA) levels in freely moving 
rats that were able to push a lever for food rewards, to receive electrical self-stimulation 
or to receive amphetamine or cocaine infusions.  Food reward increased extracellular 
DA concentrations by 37%, which was found to be the same for self-stimulation with or 
without a food reward.  Amphetamine and cocaine both caused large-scale increases in 
extracellular DA in the NAc, 5-fold higher than natural levels, clearly demonstrating the 
increased reinforcing nature of drugs of abuse compared to normal rewards.   
 
Dopamine is also involved in the tuberoinfundibular pathway that consists of 
dopaminergic neurons that project from the hypothalamus to the pituitary gland.  This 
pathway regulates secretion of prolactin from the anterior pituitary gland and is 
involved in hormonal regulation and sensory processes (Steyn et al. 2007; Lyons et al. 
2010).  
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Figure 1.1:  The brain’s natural reward pathway.  Dopaminergic neurons projecting 
from the ventral tegmental area (VTA) innervate the nucleus accumbens (NAc) and 
make up the mesolimbic pathway.  Dopaminergic neurons projecting from the VTA 
also innervate the prefrontal cortex (PFC), making up the mesocortical pathway.  
Dopaminergic neurons with cell bodies in the substantia nigra (SN) project to the 
striatum (STR) and make up the nigrostriatal pathway.  These dopaminergic pathways 
are all involved in natural reward and addiction.   
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1.1.4 Theories of drug addiction 
There are many theories of drug addiction, with no model on its own completely able to 
explain the complexities of the disorder.  Outlined below are two of the more widely 
accepted models of addiction: the opponent-process theory and the incentive-
sensitisation theory.  These theories of addiction are continually being remodelled as 
more information about drug addiction becomes available.  
 
1.1.4.1 Classic opponent-process theory of addiction 
This theory was first proposed by Solomon and Corbit in 1974 (Solomon and Corbit 
1974).  They postulated that there is a slow opposing process that counteracts the initial 
hedonic effects of a drug or its stimulus. This opposing effect increases over time, 
masking the hedonic effects of the drug or its stimulus.  Initial drug taking causes a 
large hedonic effect with only a small opposing negative effect.   As drug use increases, 
tolerance builds up, causing a decreased hedonic effect, and the negative effect 
increases as withdrawal and craving develop, changing the motivation of drug use from 
pleasure to prevention of dysphoric effects (Solomon and Corbit 1974). 
 
The model has been extended over time as understanding has increased about the 
processes involved in addiction.  The most recent version is Koob‟s theory of addiction, 
that includes homeostatic dysregulation (Koob and Le Moal 1997).  The hypothesis in 
this model is that drug addiction involves both the neural reinforcement of the drug and 
the neuroadaptation of the reward and stress systems (Koob 2008).  Together this  leads 
to changes in motivational systems that cause a shift in the brain from homeostasis to 
allostasis, leading to addiction (Koob and Le Moal 2001).  Allostasis in this case is 
defined as the process of maintaining stable reward function by changing the brain‟s 
reward mechanisms, effectively resetting the system parameters to a new set-point to 
match the demand on the system (Koob and Le Moal 2001).   
 
Koob‟s model suggests there are three stages from initial drug use to drug addiction.  
These stages form a “spiralling distress” cycle in which factors such as the DA system 
and the stress system play a role (Koob and Le Moal 1997).  The first stage of this 
model is preoccupation/anticipation, in which there is a preoccupation with obtaining 
the drug and a persistent desire to use it.  This involves conditioning of the positive and 
negative reinforcement of the drug that plays a role of sensitisation.  The second 
component is the binge/intoxication stage, in which drug use is increased to a point 
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whereby the drug is taken more often and in greater amounts than intended.  This leads 
to the drug becoming a positive reinforcer, and it continues to be sought out because of 
the rewarding effects.  After this stage it is hypothesized that there is a down-regulation 
of the reward pathway and an up-regulation of stress pathways within the brain.  The 
final component is the withdrawal/negative effect and the formation of tolerance.  
Withdrawal and drug use begins to affect social and occupational activities, and the 
drug becomes a negative reinforcer and is taken to alleviate these negative effects.  The 
hypothalamic-pituitary-adrenal (HPA) brain stress system, and the extra hypothalamic 
corticotrophin-releasing factor (CRF) brain stress system are involved in this step, 
leading to continued drug seeking, and often leading to relapse after long periods of 
abstinence (Koob and Kreek 2007).  This model explains the process of relapse by 
postulating that after long periods of abstinence, the brain returns to a somewhat 
„normal‟ homeostatic state, but that there is residual activation of the stress systems and 
underactivation of the reward system.  This leads to vulnerability to stress and drug 
related cues that can lead to relapse (Koob and Le Moal 2001)   
 
1.1.4.2 Incentive-sensitisation theory of addiction 
The incentive sensitisation model of addiction is seen as the more contemporary view of 
addiction.  This model separates „wanting‟ and „liking‟ and states that drug addiction 
occurs due to drug „wanting‟, which can often be subconscious, rather than drug „liking‟ 
or hedonic effects (Robinson and Berridge 1993).  This model is based around four 
main points.  The first is that potentially addictive drugs all share the ability to cause 
neuroadaptations in the brain in the form of persistent hypersensitivity (sensitisation) 
(Robinson and Berridge 2001).  This occurs during intermittent drug use but does not 
occur in every individual, only in those who are more susceptible to drug addiction 
(Berridge and Robinson 1995).  The second point is that the brain regions affected by 
sensitisation are those involved in reward and mediate drug „wanting‟ or incentive-
sensitisation.  Drug wanting is unconscious and is often paired with a drug related cue 
(Robinson and Berridge 2001).  The third point is that repeated drug use sensitises the 
neural substrates involved in drug „wanting‟ but not „liking‟, and there is an increasing 
dissociation between „wanting‟ and „liking‟ (Berridge and Robinson 1995).  Finally, this 
effect is not conscious, and often the individual is unaware of cravings for the drug 
(Berridge and Robinson 1995).  This theory suggests that „liking‟ or hedonic effects of 
drugs are not sensitised in addiction and are not mediated by the dopaminergic system, 
but that „wanting‟ or incentive is sensitised by drug use and is mediated by the 
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dopaminergic system (Robinson and Berridge 2001).  This prolonged neural 
sensitisation leaves former addicts at risk of relapse if they are in situations where drug 
cues are present or if they do use the drug again, and in relapse their responses will be 
even greater than before (Robinson and Berridge 2000).        
 
As DA and the brain‟s natural reward pathway play a central role in drug addiction, it is 
important to further understand the mechanisms of how drugs of abuse cause their 
effects and how they regulate DA levels in the synapse.  While none of the theories of 
drug addiction can fully describe how all drugs of abuse function in the brain, it is a 
good starting point for understanding the different ways in which drugs can modulate 
brain pathways.  It is also important to understand how pharmacotherapies for drug 
abuse work through these pathways so that future pharmacotherapies can be developed 
that have higher success rates and can be used for drugs which currently have no 
therapeutics available.      
  
1.1.5 Genetic susceptibilities to drug addiction 
As mentioned above, some individuals are more susceptible to drug addiction than 
others.  Genetic variabilities are thought to be involved in increased vulnerability to 
drug addiction.  Outlined below are some genetic variations that have shown links with 
increased susceptibility to general addictive behaviour.  For a detailed review see 
Khokhar et al. (Khokhar et al. 2010). 
 
1.1.5.1 Dopamine receptor genes  
An important neurotransmitter in the brain that plays a major role in drug addiction is 
DA. Links between DA receptor genes and susceptibility to drug taking have been 
found.  The gene for the D2 dopamine receptor (DRD2) has been linked to addiction to 
many different drugs.  The DRD2 restriction fragment length polymorphism (RFLP) 
Taq1A has been shown to cause a decrease in DRD2 density in the brain of healthy 
volunteers (Pohjalainen et al. 1998; Jonsson et al. 1999), although this response has also 
been disputed (Laruelle et al. 1998).  This polymorphism is a C>T substitution 10 kb 
from the 3‟ end of the DRD2 gene that has been found in the coding region of the novel 
serine/threonine kinase ankyrin repeat domain protein 1 (Neville et al. 2004).  The 
polymorphism causes an amino acid substitution in the 11
th
 ankyrin repeat, which is 
thought to alter the function of the protein (Neville et al. 2004).  This polymorphism has 
been associated with susceptibility to abuse of a wide range of different substances, 
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although again there are conflicting reports.  The Taq1A polymorphism has been 
associated with alcoholism (Noble et al. 2000), tobacco use (Huang et al. 2009a), 
psychostimulant abuse and polydrug use (Persico et al. 1996), and heroin use (Lawford 
et al. 2000).  In heroin use, the polymorphism was also linked with decreased 
effectiveness of methadone treatment (Lawford et al. 2000).  
 
Another DRD2 polymorphism, Taq1B, is a single nucleotide polymorphism (SNP) 
found 913 bp upstream of exon 2 (Blum et al. 1993).  The B1 allele has been associated 
with tobacco use (Spitz et al. 1998), psychostimulant polysubstance abuse (Persico et al. 
1996), alcohol abuse (Blum et al. 1993), and cocaine dependency (Noble et al. 1993). 
 
The dopamine receptor 3 (DRD3) functional polymorphism rs6280 substitutes serine 
residue 9 to a glycine and has been linked to increased nicotine dependence in European 
Americans (Huang et al. 2008).  The dopamine receptor 4 (DRD4) L allele of the 48 bp 
variable number tandem repeat (VNTR) polymorphism is linked to smoking in African-
Americans and has been associated with decreased cessation therapy success (Shields et 
al. 1998).   
 
1.1.5.2 Dopamine transporter genes 
The dopamine transporter (DAT) plays an important role in modulating DA levels 
within the reward pathway.  The gene for DAT, SLC6A3, is found on chromosome 
5p15 and is about 64 kbp long.  Many genetic studies have been carried out to 
investigate if there are associations between polymorphisms of this gene and 
susceptibility to addiction.  The 3 allele of a 30 bp VNTR in intron 8 of SLC6A3 has 
been associated with cocaine abuse in a Brazilian population (Guindalini et al. 2006).  
Another polymorphism, a G to A substitution in the 3‟ untranslated region of SLC6A3 
has been associated with a susceptibility to an early onset of smoking (Ling et al. 2004) 
and a 9 allele of the 3‟ VNTR of 40 bp polymorphism, which leads to decreased DAT 
expression, is linked with protection from smoking dependence (Lerman et al. 1999). 
 
1.1.5.3 Serotonin transporter genes 
The serotonin transporter (SERT) gene SLC64A is found on chromosome 17q11, and 
due to the SERT proteins involvement in mood disorders, the gene has been 
investigated for links to drug addiction susceptibility (Ramamoorthy et al. 1993).  The 
short allele of SLC64A linked promoter region leads to decreased expression of the 
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gene and decreased serotonin (5-HT) uptake and has been associated with alcohol 
dependence (Feinn et al. 2005) and heroin dependence (Gerra et al. 2004). 
 
1.1.5.4 Monoamine oxidase A genes 
Monoamine oxidase A (MAO-A) is an enzyme that functions to degrade monoamine 
neurotransmitters, specifically norepinephrine, epinephrine, 5-HT, and DA (Bach et al. 
1988).  The MAO-A gene is a sex-linked gene with a 30 bp repeat sequence that is 
repeated 3, 3.5, 4, or 5 times 1.2 kb upstream of the coding sequence (Sabol et al. 1998).  
This polymorphism has been shown to be associated with smoking in male Chinese, 
with the 3 repeat being more common with smoking individuals then non-smoking (Jin 
et al. 2006).  Other polymorphisms have also been associated with alcohol abuse in 
Chinese (Hsu et al. 1996) and Europeans (Vanyukov et al. 1995). 
 
1.1.5.5 Catechol-O-methyl transferase genes 
Catechol-O-methyl transferase (COMT) is an enzyme involved in degradation of 
catecholamines such as DA, norepinephrine, and 5-HT.  A polymorphism in this gene at 
codon 158 codes for either a valine, which produces a high activity COMT enzyme, or a 
methionine, which produces a lower activity COMT (Vandenbergh et al. 1997).  The 
high activity COMT is associated with susceptibility to polysubstance abuse 
(Vandenbergh et al. 1997), heroin abuse (Horowitz et al. 2000), and nicotine 
dependence (Beuten et al. 2006).  Interestingly the lower activity COMT is associated 
with  alcohol abuse (Tiihonen et al. 1999).    
 
1.1.6 Current therapeutics 
There are a number of different pharmacotherapies available for different drug 
addictions, particularly alcohol, nicotine, and opiates.  These therapies in general have a 
relatively low long-term success rate.  Currently there are no food and drug 
administration (FDA) approved pharmacotherapies to treat psychostimulant abuse, 
highlighting the need for an understanding of how these drugs function so that new 
treatments can be developed. 
 
There are two different types of pharmacotherapies that can be developed to prevent 
drug use: therapies to attenuate drug taking and therapies to prevent relapse.  
Pharmacotherapies to attenuate drug seeking usually either block or imitate the effects 
of the drug of abuse, leading to a decrease in drug taking.  Currently most available 
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pharmacotherapies for drug addiction work in this manner.  Two of the major factors 
that lead to drug relapse are stress and depression.  Therefore, development of 
pharmacotherapies that can be taken long-term after initial drug taking has ceased may 
help to decrease the high rates of relapse to drug taking after long periods of abstinence.  
While there are currently no FDA approved anti-relapse drugs available, there have 
been promising clinical trials carried out in animal models (Reviewed in Yahyavi-
Firouz-Abadi and See 2009)   
 
1.1.6.1 Alcohol 
There are several pharmacotherapies available for alcohol addiction.  Nalmefene and 
naltrexone are opioid antagonists that block the „high‟ gained from alcohol use.  A 
meta-analysis study carried out investigating the success of naltrexone concluded that 
naltrexone is a successful short-term therapy for alcohol abuse, but not for long-term 
treatment (Srisurapanont and Jarusuraisin 2005).  Acamprosate calcium (Campral) is a 
pharmacotherapy that is used to reduce the incidence of relapse on already abstinent 
alcoholics. Its mode of action is not known, but it appears to interact with N-methyl-D-
aspartate (NMDA) glutamate receptors in the brain and has been shown to have 
protective effects against glutamate toxicity in alcohol-exposed neural cultures (al 
Qatari et al. 2001).   Campral does not affect the pharmacokinetics of alcohol in any 
way and therefore is not a cessation therapy as such, but is more of an „anti-craving‟ 
therapy (Brasser et al. 2004).  Disulfiram (Antabuse) is a drug that makes the patient 
sick if they drink alcohol.  It also causes headaches and facial flushing and is used as a 
deterrent to alcohol drinking.  As it is often reliant on the patient to administer it 
themselves it is therefore not always very successful, but it can be useful in alcoholism 
if supervised administration is available (Fuller 2004).     
 
1.1.6.2 Nicotine 
Nicotine replacement therapy is the most common form of smoking cessation therapy 
and comes in a number of different forms: nicotine patches, gums, lozenges, and nasal 
sprays.  This therapy slowly releases nicotine into the body in an attempt to curb 
cravings.  The main issue with this therapy is that nicotine is not thought to be the only 
addictive component in cigarettes, and therefore this therapy has  low success rates of 7-
10% after a 1 year period (Balfour et al. 2000).  Bupropion is a non-nicotine 
pharmacotherapeutic for smoking cessation and has a 14.6% success rate after 1 year 
(Jorenby et al. 2006).  Buproprion is an atypical anti-depressant that is a non-selective 
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DAT and norepinephrine transporter (NET) inhibitor and a partial nicotinic 
acetylcholine receptor (nAChR) inhibitor.  It is unclear as to how bupropion helps 
patients quit smoking, but it is thought that the inhibition of DAT and NET help to 
alleviate withdrawal symptoms, and the inhibition of nAChR leads to decreased 
rewarding effects of cigarette smoking (Carroll et al. 2010).   Varenicline is another 
non-nicotine smoking cessation therapy that has a success rate of 23% after 1 year 
(Jorenby et al. 2006).  Varenicline is a partial nicotinic agonist and binds to the α4β2 
nAChR to prevent nicotine from binding, but it still causes release of DA in the NAc, 
although to a lesser degree than nicotine.  The increase in DA in the NAc is believed to 
cause a decrease in cravings by counteracting the decreased DA levels found during 
abstinence from nicotine (Coe et al. 2005).  
 
1.1.6.3 Opiates 
Opiate addiction is usually treated by a replacement or maintenance pharmacotherapy.  
This treatment involves replacement of the opiate being abused with another opiate that 
has a longer half-life and decreased abuse potential.  As these therapies are also 
addictive, many patients continue taking these therapies rather than ceasing from all 
opiate use.  The most commonly used replacement therapeutic is methadone.  
Methadone acts in a similar way to abused opiates and is addictive, but it has a longer 
half-life, which reduces cravings.  It is administered either daily or every second day so 
that its use can be monitored and controlled (Corkery et al. 2004).  This monitoring also 
helps to decrease the amount of methadone sold on the „black market‟ to opiate abusers, 
decreasing the number of methadone-related deaths (Corkery et al. 2004).  The use of 
methadone allows patients to integrate into normal society, increases the success of 
getting jobs and allows them to socialise more normally.  Naltrexone can also be used to 
treat opiate addiction.  Naltrexone is an opioid receptor antagonist and works by 
blocking the euphoric effects of the abused opiate.  As with methadone, naltrexone 
treatment requires the patient to take supervised oral medication every day, which often 
leads to large drop-out rates in treatment programs (Hulse et al. 2009).  Recently 
progress has been made on the use of a long-term, sustained release, naltrexone implant 
that increases success rates of opiate cessation as patients do not need to take supervised 
oral natrexone daily (Hulse et al. 2009).  Buprenorphine is a more recently approved 
drug for opiate maintenance therapy that was first synthesised for use in pain relief.  
From the 1970‟s it has also been used as a treatment for opiate addiction and is 
successful in decreasing opiate use (Soeffing et al. 2009; Wesson and Smith 2010).  As 
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it is a partial mu-opioid receptor (MOPr) agonist and kappa-opioid receptor (KOPr) 
antagonist, it is thought to be safer to use than methadone, as it has similar efficacy and 
success and has less potential for overdose.  Buprenorphine binds to the receptors to 
prevent opiates from binding and activates the receptors to a lesser extent then heroin or 
morphine (Wesson and Smith 2010).    
 
1.1.6.4 Amphetamines/Cocaine 
There is currently no FDA approved therapeutic available for cocaine, amphetamine, 
and methamphetamine addiction, although there are many studies investigating 
potential compounds.  A large amount of research has gone into investigating the effects 
of DAT, NET, and SERT agonists for treatment of cocaine, amphetamine, and 
methamphetamine addiction.  Positive results have been seen in animal studies and 
laboratory-based human studies, but there has been little success in clinical trials.  
Methylphenidate (Ritalin), modafinil (treatment for narcolepsy), and bupropion have 
been investigated for their effect on cocaine, methamphetamine, and amphetamine 
addiction in clinical trials with mixed results.  Methylphenidate has shown promise as a 
potential therapeutic for amphetamine (Tiihonen et al. 2007), but had no effect on 
cocaine users.  Modafinil has shown promise as a pharmacotherapeutic for drug abuse 
by decreasing cravings for cocaine and increasing the length of abstinence (Dackis et al. 
2005; Dackis and O'Brien 2006). It also reduces methamphetamine use in patients who 
are only abusing methamphetamine and are undertaking counselling (Shearer et al. 
2009).  In 2004, a case study reported that self-administration of bupropion reduced 
cravings for amphetamine after seven days use, suggesting this drug may have promise 
as a therapeutic for amphetamine abuse (Tardieu et al. 2004).  The overall data from 
these studies show promise for the successful development of a therapeutic that is able 
to treat cocaine, methamphetamine, and amphetamine addicts.   
 
In summary, this section demonstrates that current available pharmacotherapies for 
treatment of drug addiction have low success rates and in the case of opiates are 
addictive themselves.  There are also no current FDA approved therapeutics for 
amphetamine, cocaine, and methamphetamine abuse.  Therefore, there is a need for 
investigation and trialling of new compounds with potential anti-addictive effects so 
that success rates for patients withdrawing from drug use can be increased.    
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1.2 Dopamine and the dopamine transporter 
1.2.1 Introduction 
DA is a neurotransmitter that is found primarily in the brain and is involved in reward, 
motivation, motor function, decision making, compulsion, and stress (Mortensen and 
Amara 2003).  DA is unable to cross the blood-brain barrier and is therefore synthesised 
within the brain from tyrosine by tyrosine hydroxylase to the dopamine precursor L-3,4-
dihydroxyphenylalanine (L-DOPA) that is then decarboxylated by DOPA carboxylase 
to DA (Flatmark 2000).  DA is then packaged into vesicles for release into the synapse.  
Depolarisation of a DA neuron causes an increase in intracellular Ca
2+
, leading to 
release of DA by exocytosis. The DA then binds to postsynaptic receptors to continue 
the signal or to presynaptic receptors to regulate its release.  DA is released in brain 
regions such as the NAc, PFC, striatum, and amygdala (Adinoff 2004).   
 
The major regulator of DA concentration in the synapse is DAT.  DAT is found 
perisynaptically on the presynaptic neuron and acts by taking DA back up into the 
synapse, where it is either recycled for further release, or degraded by MAO or COMT 
(Guo et al. 2007).  The DA receptors, DRD1-5, also play a role in the regulation of DA 
concentration, in part by regulating DAT.  These receptors are G protein-coupled 
receptors (GPCR) found on the pre- and post-synaptic membranes.  The receptors are 
divided into two types, the DRD1-like and DRD2-like, with DRD1 and DRD5 receptors 
belonging to the DRD1-like group and DRD2, DRD3, and DRD4 belonging to the 
DRD2-like group.  Both DRD2 and DRD3 act as DA autoreceptors on the presynaptic 
neuron, and via a feedback mechanism cause an increase in DAT function, and also a 
decrease in DA release.  Dysregulation of the amount of DA found in the synapse leads 
to disorders such as Parkinson‟s disease and schizophrenia (Mehler-Wex et al. 2006).  
 
 All drugs of abuse either directly or indirectly cause increases in DA in the synapse, 
either through direct interactions with DAT or by interactions with inhibitory neurons 
that communicate with dopaminergic neurons.  This leads to prolonged activation of 
pre- and post-synaptic receptors that increase the strength of the signalling pathways.  
After repeated drug taking, the dopaminergic pathway is desensitised, leading to a state 
of allostasis, as described in section 1.1.4. 
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1.2.2 The dopamine transporter 
The dopamine transporter is a Na
+
/Cl
-
 symporter protein from the gene family SLC6.  
Other transporters belonging to this family include SERT, NET, and transporters for γ-
aminohydroxybutyric acid (GABA), glycine, amino acids, creatine, and organic 
osmolytes (Howell and Kimmel 2008).  The members of this family are characterised 
structurally by their 12 transmembrane domains, large extracellular loop 2 that contains 
glycosylation sites, and intracellular C and N termini (Figure 1.3).  The structure of the 
Na
+
/Cl
-
 symporter protein family has been estimated using the bacterial homologue 
leucine transporter LeuTAa from the bacteria Aquifex aoelicus (Yamashita et al. 2005).  
While this bacterial transporter has a low sequence homology to mammalian 
transporters, it shows high protein sequence homology, and the binding site of LeuTAa 
shows high sequence homology with DAT.  Experiments using LeuTAa have been 
carried out to identify the binding site of leucine and the 2 Na
+
 ions that are co-
transported, and models of how transport occurs have also been theorised for both 
LeuTAa and the catecholamine transporters (Yamashita et al. 2005; Beuming et al. 2006; 
Wang and Lewis 2009).  Based on the LeuTAa structure, the binding position of the 
substrate and Cl
-
 (Forrest et al. 2007), the selectivity of the Na
+
 ions (Yamashita et al. 
2005) and the transport and release of Na
+
 and substrates inside the cell of monoamine 
transporters have been modelled (Yamashita et al. 2005; Shi et al. 2008b).   
 
DAT is found selectively expressed in neurons located in the VTA and substantia nigra 
(Ciliax et al. 1995), and DAT protein is found in very high amounts in the dorsal 
striatum and NAc where it is involved in reward (Boja and Kuhar 1989; Scheffel et al. 
1991).  A study carried out looking at dopaminergic neurons that innervate the NAc 
found that DAT protein is expressed on the axons, dendrites or cell body of the cells, 
but not in the synapse (Nirenberg et al. 1997).  
 
During tonic DA firing periods, DAT can also act as an ion channel, which causes an 
increase in neuronal depolarisation leading to an increase in exocytotic DA release.  
During phasic firing, this role is over-ridden by the presynaptic DRD2 receptors that 
decrease DA release (Sonders et al. 1997; Elliot and Beveridge 2005). 
 
The rat (Kilty et al. 1991; Shimada et al. 1991) and human DAT (Giros et al. 1992) 
genes were first cloned and expressed in cell systems in the early 1990‟s.  This allowed 
more detailed research to take place on the structure, mechanism, and pharmacology of 
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DAT, as cell lines that do not usually express DAT could be transfected and easily 
manipulated.  Interestingly, DAT appears to function differently in cell models 
compared to rat tissue.  This could be due either to differences in the human DAT and 
rat DAT (Giros et al. 1992) or could be because of differences in the native and non-
native expression systems (McElvain and Schenk 1992; Povlock and Schenk 1997; 
Chen et al. 1999b; Earles and Schenk 1999b).  Studies using human embryonic kidney 
(HEK-293) cells transfected with the human DAT showed that 2 Na
+
 ions bound to 
DAT, followed by DA, then 1 Cl
-
 ion before transport occurs (Chen et al. 1999b; Earles 
and Schenk 1999b).  Other studies using isolated rat striatal (McElvain and Schenk 
1992) and nucleus accumbens (Povlock and Schenk 1997) tissue found that binding of 
DAT substrates was partially random, with  2 Na
+
 or 1 DA binding, followed by Cl
-
, 
before DA transport occurred.   
 
All drugs of abuse either directly or indirectly lead to an increase in DA in the synapse.  
Cocaine acts by directly binding to DAT, preventing uptake of DA into the presynaptic 
neuron (Figure 1.2).  This leads to accumulation of DA in the synapse, causing 
increased activation of the DA receptors.  Amphetamine-like drugs such as 
amphetamine and methamphetamine act as substrates for DAT and are taken up into the 
cell where they are transported by vesicular monoamine transporters (VMAT) into 
vesicles.  Here they cause transport of DA out of vesicles by VMAT-2 and then reverse  
transport of cytosolic DA through DAT, leading to increases in DA in the synapse.  
Other drugs of abuse such as nicotine, alcohol, and morphine work in a more indirect 
fashion.  In the NAc, nicotine binds to nAChRs found in dopaminergic cell bodies, and 
this leads to release of DA into the synapse.  Opioids bind to opioid receptors which in 
turn inhibit GABA neurons that usually act to inhibit the dopaminergic neurons.  This 
leads to dis-inhibition of dopaminergic neurons and release of DA into the synapse.  
Alcohol is also thought to act through a similar pathway as the opioids and has been 
shown to cause release of opioid peptides.   
 
1.2.3 Regulation of the dopamine transporter 
Regulation of DAT occurs through many different pathways, and most regulation has 
been linked to changes in cell surface expression of DAT.  Constitutive DAT exocytosis 
and endocytosis occur, and this is thought to be mediated through proteins including 
Rab proteins, which are involved in targeting proteins to recycling and degradation 
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pathways (Furman et al. 2009b). Some of the major regulators of DAT function are 
outlined below. 
 
1.2.3.1 Dopamine 
DA regulates DAT cell surface expression, with short-term exposure leading to an 
increase in DAT cell surface expression, and repeated and long-term exposures causing 
a decrease in cell surface expression.  In HEK-293 cells, 10 µM DA results in an 
immediate increase in DAT cell surface expression, with the maximal effect seen at 1 
min using total internal reflection fluorescence microscopy (TIRFM) and cell surface 
biotinylation (Furman et al. 2009a).  Longer incubations of between 40 and 60 min of 
single exposures to 10-100 µM DA, showed a decrease in DAT cell surface expression 
in both cell systems and in rat striatal synaptosomes (Saunders et al. 2000; Chi and 
Reith 2003). Short repeated applications of DA to Xenopus oocytes also showed 
decreases in [3H]-DA uptake and DAT cell surface expression (Gulley et al. 2002). In 
vivo application of DA into the rat striatum also caused a large decrease in DA uptake, 
as measured by high speed chronoamperometry, suggesting decreased DAT cell surface 
expression (Gulley et al. 2002).  Interestingly, this effect was not seen in the NAc.  
These short- and long-term effects were both mediated by protein kinase C (PKC) 
dependent pathways (Gulley et al. 2002; Furman et al. 2009a).  This decrease in cell 
surface expression of DAT is thought to be protective, since high concentrations of DA 
within the cell would be toxic and lead to cell death. 
 
1.2.3.2 Dopamine receptors 
DRD2 and DRD3 are pertussis toxin (PTX) sensitive GPCRs found on dopaminergic 
neurons (Dal Toso et al. 1989; Diaz et al. 2000).  These receptors both belong to the 
DRD2-like DA receptor family and have both been shown to modulate DA levels in the 
synapse by decreasing DA synthesis and release (Tang et al. 1994; O'Hara et al. 1996) 
and modulating DAT function and cell surface expression (Bolan et al. 2007; Zapata et 
al. 2007). This forms a feedback mechanism, allowing DA to regulate its own 
extracellular levels.   
 
DRD2 has been found both pre-synaptically and post-synaptically on dopaminergic 
neurons (Lindgren et al. 2003).  The receptor is found in two isoforms, long (DRD2L) 
and short (DRD2S), which differ in length by alternative mRNA splicing of a 29 amino 
acid segment in the third intracellular loop (Dal Toso et al. 1989).  Activation of DRD2 
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by the DRD2/D3 agonist quinpirole leads to increased DAT function in rat striatal tissue 
(Meiergerd et al. 1993) and in HEK-293 cells co-transfected with DAT and DRD2 
(Bolan et al. 2007).  This increase in function was found to occur through an 
extracellular-signal regulated kinase 1/2 (ERK1/2) and Akt pathway, and was ERK1/2 
dependent.  The increase in function was mirrored by rapid increases in cell surface 
expression, and these changes were hypothesised to be due to a direct protein-protein 
interaction between DAT and DRD2 (Bolan et al. 2007).  This was confirmed in 
another study that used co-transfected HEK-293 cells and rat striatal tissue to show that 
DRD2 and DAT were directly interacting through a protein-protein interaction, which 
caused recruitment of DAT to the plasma membrane, leading to increased DA uptake 
(Lee et al. 2007).       
 
The DRD3 receptor is more restricted in its distribution than DRD2, but has also been 
identified as a DA autoreceptor (Levesque et al. 1992).  Studies using fast-scan cyclic 
voltammetry and DRD2 and DRD3 agonists in the mouse have shown that DRD3 
receptors have a hierarchical activity in the NAc shell, followed by less activity in the 
core and the lowest activity in the striatum.  In contrast, DRD2 receptors were found to 
have a high activity in all three brain regions (Maina and Matthews 2010).  Knockout 
mouse studies have shown that DRD3 regulates extracellular DA levels, but the 
mechanisms underlying this effect were not elucidated (Zapata et al. 2001; Joseph et al. 
2002).  Further studies found that activation of DRD3 with the DRD3 agonist (+)-
PD128907 led to decreases in extracellular DA in mouse NAc and an increase in DAT 
function in rat NAc tissue (Zapata and Shippenberg 2002).  Antagonism of DRD3 
caused a decrease in DAT function in rat NAc tissue (Zapata and Shippenberg 2002) 
confirming that this affect was mediated by DRD3.  A further study was conducted in 
HEK-293 cells co-expressing DRD3 and DAT (Zapata et al. 2007).  Short-term addition 
of the DRD2/3 agonist quinpirole caused an increase in DAT function that was 
mediated through ERK1/2 and PI3K phosphorylation pathways and led to increases in 
DAT cell surface expression (Zapata et al. 2007).  Long-term incubation with quinpirole 
led to the opposite effect, with a decrease in DAT function and cell surface expression 
(Zapata et al. 2007).   
 
Overall, these studies demonstrate the close regulation that DA in the synapse has on 
DA autoreceptors and DAT function, and how important the regulation of DA in the 
synapse is for brain homeostasis.   
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1.2.3.3 Phosphorylation 
DAT function and cell surface expression has been shown to be altered by its 
phosphorylation states.  DAT has several ser/thr residues present in the N-terminal tail 
that are involved in DAT phosphorylation and regulation (Figure 1.3).  These ser/thr 
residues can be phosphorylated by a number of different kinases as follows. 
 
PKC is activated endogenously by diacylglycerol (DAG) and can be pharmacologically 
activated by phorbol esters such as phorbol 12-myristate 13-acetate (PMA).  Activation 
of PKC leads to a decreased DAT Vmax, without altering Km, due to internalisation of 
DAT in cell models and rat striatal synaptosomes (Copeland et al. 1996; Vaughan et al. 
1997; Pristupa et al. 1998).  A study carried out in LLC-PK1 cells found that after 4 min 
incubation with PMA, there was an increase in phosphorylation of DAT and a decrease 
in Vmax (Huff et al. 1997); however, other studies have shown that DAT is still 
internalised after PMA treatment when DAT ser/thr phosphorylation sites have been 
mutated (Granas et al. 2003).  Therefore, it is uncertain whether internalisation of DAT 
by PKC occurs by direct phosphorylation or if it is due to phosphorylation of other 
proteins that complex with DAT.  PKC-induced DAT endocytosis has been shown to be  
dynamin dependent (Daniels and Amara 1999).  It is unknown whether the internalised 
DAT is recycled or degraded, with reports showing evidence for both mechanisms 
(Daniels and Amara 1999; Melikian and Buckley 1999).  Differences in these reports 
may be due to the different cell models used and their differences in basal cell surface 
expression of DAT. 
 
Protein Kinase A (PKA) is activated by cyclic adenosine monophosphate (cAMP) in the 
cell.  This is determined by adenylyl cyclase, which is regulated by receptors such as the 
DRD2.  PKA activation increases DAT Vmax but not Km in rat stratial tissue, with 
increases seen from between 1 and 15 min (Batchelor and Schenk 1998).  An increase in 
DAT cell surface expression after PKA activation was also seen in a cell model 
(Pristupa et al. 1998).  Other studies have not seen changes in DAT expression with 
PKA activation, but this may be due to the time points they investigated being too long 
and therefore causing the effect to be missed (Copeland et al. 1996; Pristupa et al. 
1998).  In rat striatal synaptosomes, addition of 8-bromo-cAMP caused an increase in 
DAT function, and inhibition of PKA attenuated this effect, indicating that in this 
system PKA activation leads to increased DAT function (Page et al. 2004). 
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There are four major ser/thr protein phosphatases (PPs): PP1, PP2A, PP2B and PP2C.  
These phosphatases can be separately studied as they are inhibited by specific 
compounds.  PP1 and PP2A are strongly inhibited by okadaic acid, microscystin 
inhibits PP1 and PP2A, calcyculin A inhibits PP2A twice as strongly as PP1 and 
cyclosporin A selectively inhibits PP2B (Vaughan et al. 1997).  In rat straital 
synaptosomes, okadaic acid and calcyculin both increase phosphorylation of DAT and 
reduce DAT function; whereas, cyclosporin A and microcystin have no effect (Vaughan 
et al. 1997).  This suggests that PP2B is involved in DAT phosphorylation and down-
regulation in synaptosomes, and the authors postulated that cylcosporin A has no effect 
due to its poor membrane solubility.  
 
There is also some evidence that protein tyrosine kinases modulate DAT function and 
cell surface expression (Hoover et al. 2007).  Inhibition of tyrosine kinases by genistein 
and tyrphostin 23 in rat striatal synaptosomes, primary rat mesencephalic cultures, and 
Xenopus oocytes leads to rapid decreases in Vmax but not Km of DAT and causes a 
decrease in cell surface expression of DAT (Doolen and Zahniser 2001; Hoover et al. 
2007).  In primary rat mesencephalic cultures the addition of brain-derived neurotrophic 
factor also leads to an increase in DAT function (Hoover et al. 2007).  
 
Ca
2+
/calmodulin-dependent kinase II (CamKII) also appears to modulate the function of 
DAT (Page et al. 2004).  In rat striatal synaptosomes, the addition of a CamKII 
inhibitor, KN62, inhibited the increase in transporter function caused by 8-bromo-
cAMP (Page et al. 2004).  The CamKII inhibitor alone did not cause changes in DAT 
function, indicating that this process occurs through a cAMP dependent pathway. 
 
Mitogen-activated protein kinases (MAPKs) are ser/thr kinases that are involved in the 
regulation cell growth and differentiation (Moron et al. 2003) and are found throughout 
the central nervous system.  There are at least 12 different MAPKs, including ERK1/2, 
c-Jun N-terminal kinase (JNK1-3) and p38 (αβγδ) stress kinases (Bruchas and Chavkin 
2010).  MAPKs are activated through several mechanisms, including GPCRs, calcium 
and growth factors, and they can be activated by PKC-dependent or independent 
mechanisms.  The inhibition of MAPK in EM4 cells and rat straital synaptosomes 
caused a concentration and time dependent down-regulation of DA uptake that was 
found to be due to a decrease in cell surface expression of DAT (Moron et al. 2003).  
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This effect was seen with ERK1/2 inhibitors, but not with p38MAPK inhibitors, 
indicating that p38 MAPK is not involved in DAT regulation.   
 
To conclude, activation of many different phosphorylation pathways leads to 
modulation of DAT function, mostly caused by increased or decreased cell surface 
expression of DAT.  When activated, PKC and PP2B cause down-regulation of DAT; 
whereas, activation of PKA, tyrosine kinases, CaMKII and the ERK1/2 pathway all lead 
to increased DAT function and cell surface expression.  This highlights the tight 
regulation that DAT is under in the brain, and indicates that many different receptors 
and pathways have the ability to modulate its function. 
 
1.2.3.4 Glycosylation 
DAT proteins are post-translationally glycosylated on asparagines found on its 
extracellular loop 2.  Rat and human glycosylation sites are different (Figure 1.3) with 
four glycosylation sites for rat and three for human (Patel et al. 1993).  There have been 
several studies carried out to investigate if N-glycosylation of DAT is necessary for cell 
surface expression and function (Torres et al. 2003; Li et al. 2004b).  Two studies 
mutated the three glycosylation sites on human DAT and expressed the single mutants, 
double mutants and triple mutants in HEK-293 cells.  While their results differed, both 
groups showed that glycosylation was important for DAT function, but not crucial for 
insertion into the cell membrane.  Removal of N-glycosylation sites; however, led to a 
decrease in cell surface expression of DAT.  Reasons for this may be that non-
glycosylated DAT is vulnerable to degradation or less stably expressed on the cell 
surface (Li et al. 2004b). 
 
1.2.3.5 Ubiquitination 
Ubiquitination of DAT has also been shown to cause internalisation of DAT.  This is 
mediated by PKC activation (Miranda et al. 2005) and has been shown to involve 
Nedd4.2, an E3 ubiquitin ligase and the ubiquitin-conjugating enzymes ube2d2/3 and 
ube2l3 e2 (Vina-Vilaseca and Sorkin 2010).  Studies have found that DAT is poly-
ubiquitinated on the amino terminal end on Lys 19, 27, and 35, leading to internalisation 
of DAT (Figure 1.3) (Miranda et al. 2007).  Ubiquitination of either one or two of these 
lysines does not cause internalisation as shown by DAT mutant studies (Miranda et al. 
2007).  Ubiqutination of DAT forms a DAT which is 26 kDA larger then mature DAT, 
suggesting 4 ubiquitination sites (Miranda et al. 2005; Vina-Vilaseca and Sorkin 2010).  
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Ubiquitination of DAT has been shown to be important for sorting of internalised DAT 
proteins to recycling endosomes and lysosomes (Miranda et al. 2007).   
 
1.2.3.6 Drugs of abuse and dopamine signalling 
All drugs of abuse directly or indirectly lead to changes in DA signalling in the brain. 
The effects of amphetamine, cocaine, nicotine, alcohol, and opiates on DAT function 
and expression are outlined below. 
 
Amphetamine 
Amphetamine is a substrate for DAT and shows a biphasic effect on DAT, with the 
immediate effects being a rapid, short-lived increase in DAT cell surface expression of 
1 to 2 min (Furman et al. 2009a). Repeated or long-term exposure leads to a decrease in 
function and cell surface expression (Gulley et al. 2002; Richards and Zahniser 2009).  
This down-regulation is dependent on the PKC pathway (Gulley et al. 2002)  In vitro 
experiments carried out in Xenopus oocytes were carried out in which repeated short 
exposures to amphetamine led to decreased DAT function, and this decrease was 
inhibited by a PKC inhibitor (Gulley et al. 2002).  A decrease in function was also 
observed using in vivo electrochemistry in the rat dorsal striatum after repeated 
administration of amphetamine, but was not seen in the NAc (Gulley et al. 2002).  A 
later study investigated the apparent difference between the NAc and striatum with 
regard to the effects of amphetamine in synaptosomes prepared from these brain 
regions. In the striatum, a decrease in Vmax was found with no change in Km in 
synaptosomes treated with 20 µM amphetamine. No effect was seen in the NAc.  In this 
same study, synaptosomes prepared from rats exposed to amphetamine (2 mg/kg) 45 
min before euthanasia showed decreases in Vmax in both brain regions.  These changes 
were PKC dependent, but there were no changes in cell surface expression of DAT 
when the cells were exposed to amphetamine for less than 1 h (Richards and Zahniser 
2009).  Experiments carried out in HEK-293 cells expressing FLAG-hDAT found that 
internalisation was also dynamin dependent, suggesting that it occurred via clatherin-
coated pit mediated endocytosis (Saunders et al. 2000).    
 
Amphetamine (10 µM) applied to EM4 cells expressing YFP-hDAT also caused an 
immediate reverse transport of DA through DAT, increasing the synaptic concentration 
of DA.  This is thought to occur in two main ways: a slow, transport-like mechanism, 
and a fast, channel-like mechanism (Kahlig et al. 2005).  In the slow transport-like 
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mechanism, amphetamine is a substrate for DAT and is taken up, increasing the number 
of „inward‟ facing transporters and leading to increased intracellular DA reverse 
transport.  In the channel-like mechanism, DAT has channel-like bursts of DA release.  
This process has been shown to be dependent on phosphorylation at the N-terminus of 
DAT, specifically at ser7 and ser12 which appear to be phosphorylated by PKC and 
MAPK kinase 1/2 (MEK1/2) (Khoshbouei et al. 2004).  In rat striatal slices, PKCβ was 
shown to physically interact with DAT and was necessary for amphetamine-induced 
efflux (Johnson et al. 2005).  Reverse transport has also been shown to be CamKIIα 
dependent, with CAMKIIα binding directly to DAT in dopaminergic neurons and in 
EM4 cells expressing DAT (Fog et al. 2006).  The SNARE protein syntaxin 1A also 
binds DAT, leading to CAMKII-dependent amphetamine-induced efflux (Binda et al. 
2008).   
 
Cocaine 
Cocaine acts as a DAT inhibitor, by binding to DAT and preventing DA uptake.  
Cocaine interacts with similar amino acids on DAT as DA but does not bind in the exact 
same place (Huang et al. 2009b) (Figure 1.3).  There are conflicting data on whether 
cocaine inhibits DA uptake in a competitive (Wu et al. 2001), uncompetitive (McElvain 
and Schenk 1992), or non-competitive (Povlock and Schenk 1997) mechanism, and 
these differences have been proposed to be dependent on the experimental technique 
used (Povlock and Schenk 1997).  There have also been conflicting data on how cocaine 
regulates DAT, i.e. whether there are increases or decreases in function and the nature 
of the effect on cell surface expression.  This is thought to be because of the different 
treatment schemes and models used to investigate cocaine‟s effects, and the different 
brain regions investigated.   A study was carried out in Rhesus monkeys given either 
low (0.03 mg/kg/injection) or high dose (0.3 mg/kg/injection) cocaine for 5 days or 3.3 
months (Letchworth et al. 2001). Some monkeys were also self-administering cocaine 
(0.03 mg/kg/injection) for 1.5 years.  The results showed that after the initial 5-day 
period, there was decreased [
3
H]WIN35,428
 
binding in the striatal regions of the brain, 
but after 3.3 months and 1.5 years there were increases in [
3
H]WIN35,428
 
binding in 
these brain regions. This suggests a decrease in DAT during short treatments, with long-
term treatments causing increased DAT protein.  A study carried out in post-mortem 
human cocaine users confirmed the increase in binding after long-term cocaine use, 
with an increase in [
3
H]WIN35,428
 
binding to DAT and an increase in DAT function in 
the striatum (Mash et al. 2002).  This effect was not seen in patients that had excited 
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cocaine delirium and who had paranoia and agitation before being admitted to hospital.  
This increase was proposed to be a feedback mechanism from long-term cocaine use, 
with an increase in cell surface DAT to counteract the increase in DA due to cocaine 
use, decreasing the rewarding effect and leading to increased drug use (Mash et al. 
2002).  In cocaine-dependent subjects, single-photon emission computed tomography 
(SPECT) studies have also shown an increase in DAT density in the caudate putamen 
region (Crits-Christoph et al. 2008).   
 
Cell model studies using cells transfected with human DAT show that cocaine causes an 
increase in DAT cell surface expression after acute (10 µM, 10 min; (Daws et al. 2002) 
and chronic (1 µM, 24 h, (Zhang et al. 1998); 1 µM 12 h, (Little et al. 2002))  treatment, 
and an increase in DA uptake (Zhang et al. 1998; Daws et al. 2002; Little et al. 2002).  
This effect appeared to be cell specific as these changes were seen with EM4 cells and 
N2A cells, but not COS7 cells (Zhang et al. 1998).  Experiments carried out after early 
abstinence in rats also show increased DAT function (Thompson et al. 2000), but there 
are conflicting data as some reports show down-regulation or no change in uptake 
during early abstinence (Chefer and Shippenberg 2002).  These differences are thought 
to be due to experimental design, such as the amount of cocaine given/self-
administered, the length of exposure time to cocaine, and differences in withdrawal 
times.  There is also evidence that cocaine causes release of DA from reserve pools of 
DA-containing synaptic vesicles in a synapsin dependent manner (Venton et al. 2006).  
This would further add to the DA in the synapse, increasing the reward signal.   
 
Nicotine 
Nicotine indirectly acts on the DA system through nAChRs.  There are much 
conflicting data on how nicotine modulates the dopaminergic system with reports 
suggesting up- and down-regulation of DAT. Acute nicotine administration of 0.8 
mg/kg causes an increase in [
3
H]-DA uptake and cell surface expression of DAT in the 
PFC but not the striatum, with a lower dose (0.3 mg/kg) having no effect (Zhu et al. 
2009).  Another study found that after 5, 10, and 40 min there was an increase in [
3
H]-
DA uptake in the striatum with acute 0.32 mg/kg injections of nicotine and no change in 
cell surface expression (Middleton et al. 2007).  Furthermore, in vivo voltammetry 
measurements showed increased DA clearance in the striatum and medial PFC of rats 
acutely treated with nicotine for 10 to 15 min (Middleton et al. 2004).  In contrast, 
SPECT studies in male smokers found that there was a decrease in DAT availability in 
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the striatum, with no changes in DRD2 or DRD3 receptors (Yang et al. 2008).   Chronic 
exposure to cigarette smoke and nicotine also increases DAT mRNA in the rat midbrain 
areas: the VTA and substantia nigra (Li et al. 2004c).  This was also observed in the 
human neuroblastoma cell line, SK-N-SH, transfected with human DAT in which 
nicotine caused an increase in transcription of human DAT, and this effect was neuronal 
cell line specific (Ohyama et al. 2010).  There are differences between studies carried 
out in brains of animals treated with nicotine and in cell systems, which suggest whole 
brain circuitry, or other unknown factors found within the brain cells, are required for 
these effects to be properly represented in a cell model.  
 
Alcohol 
Alcohol also indirectly acts on the dopaminergic system through inhibition of NMDA 
receptors and activation of GABAα receptors, although there is evidence that alcohol 
can directly stimulate dopaminergic neurons in the VTA causing DA release (Brodie et 
al. 1999).  Inconsistent results have been gained about the effect of alcohol on DAT, 
with animal studies suggesting that acute treatment with alcohol leads to increases 
(Wang et al. 1997), decreases (Lin and Chai 1995; Robinson et al. 2005) or no change 
(Yim and Gonzales 2000; Budygin et al. 2001) in DAT function in the striatum and 
NAc. These differences in results may be due to the varied procedures carried out, such 
as microdialysis, fast scan cyclic voltammetry, in vivo electrochemical detection, 
rotating disk electrode voltammetry and use of awake and anesthetised rats. However 
the majority of acute studies suggest that ethanol increases extracellular DA in the NAc 
and striatum due to increased release (Yim et al. 1998; Yim and Gonzales 2000; 
Budygin et al. 2001; Robinson et al. 2005).  Human alcoholic studies have shown that 
there is a decrease in DRD2 receptors in current alcoholics but not a decrease in DAT 
(Volkow et al. 1996). Using SPECT studies, alcoholics admitted for detoxification 
showed decreased DAT, but after 4 weeks of abstinence a significant increase in DAT 
was seen compared to healthy controls (Laine et al. 1999).   This implies that changes in 
the dopaminergic system vary depending on the length of time since consumption of 
alcohol.  Chronic animal studies have also shown decreases in DRD2 receptors and 
DAT in the NAc of rats exposed to 10% ethanol as their only water source for 30 days 
(Yoshimoto et al. 2000).  In rats fed a liquid diet for 1 year in which 36% of their source 
of calories was alcohol, there was a significant increase in DAT in the NAc and striatum 
and a decrease in tissue DA levels (Rothblat et al. 2001).  These studies differ in the 
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length of time the animals were exposed to alcohol, and this may explain the differences 
in data.   
 
Data collected from cell models show more consistency.  Most studies have found that 
alcohol leads to an increase in DAT function, and this is due to increased cell surface 
expression of DAT (Mayfield et al. 2001; Maiya et al. 2002). The differences between 
cell and animal studies are most probably due to the fact that alcohol targets more than 
one pathway in the brain, and many of its effects are due to interactions between brain 
regions.  As cell systems are more simplistic they are often unable to replicate the 
effects seen in animal studies where intra-regional interactions may play a role.  
 
Opioids 
Opioids also indirectly affect DA in the mesolimbic dopaminergic pathway.  They act 
on the inhibitory GABA neurons, dis-inhibiting their effect on dopaminergic neurons 
and leading to increases in synaptic DA in the NAc (Di Chiara and Imperato 1988a; 
Klitenick et al. 1992).   
 
Morphine 
Chronic, but not acute, morphine administration leads to decreased DAT in the NAc of 
rats (Simantov 1993).  DAT binding was measured by SPECT in Rhesus monkeys 
treated with increasing morphine doses (0.5, 1.6, 5.0, 8.0, 8.0, and 8.0 mg/kg for each 
successive day) twice daily for six days.  After the initial morphine injection, there was 
a sharp decrease in DAT binding in the striatum that slowly increased over five days 
following morphine administration (Xiao et al. 2006).  After the five days, DAT binding 
in the striatum was still lower then controls, suggesting that there was a semi-permanent 
change in DAT expression after morphine treatment.  A study carried out by Gudehithlu 
and Bhargava (1996) in morphine tolerant (rats who had six 75 mg morphine pellets 
implanted for 7 days) and withdrawn rats (rats treated with six 75 mg morphine pellets 
for 7 days, which were removed 16 h before euthanasia), it found that there was 
increased DAT in the hypothalamus in both the tolerant and withdrawn rats.  In tolerant 
rats a decrease of DAT was seen in the striatum and spinal cord. A decrease in 
hippocampal DAT was also seen following morphine withdrawal.  The authors 
speculated that these differences might contribute to abstinence syndrome (Gudehithlu 
and Bhargava 1996). 
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Heroin 
In positron emission tomography (PET) studies carried out on human heroin users 
following long term abstinence without pharmacotherapy (drug use for at least 3 years, 
free of illicit drugs for 6 months) or following treatment with methadone, a significant 
decrease in DAT function was seen in the bilateral caudate compared to drug naïve 
controls.  The patients on methadone also had a significantly lower DAT function in the 
putamen compared to controls and abstinent heroin users (Shi et al. 2008a).   In post-
mortem human studies, chronic heroin use caused decreased mRNA expression in the 
paranigral neurons and VTA and a decrease in DAT protein in the NAc (Kish et al. 
2001; Horvath et al. 2007).  These studies demonstrate that after chronic heroin use 
there is a significant decrease in DAT within the brain, similar to the effects of 
morphine, and that this effect is still seen after 6 months.     
 
Overall these studies indicate that drugs of abuse lead to changes in the dopaminergic 
system, with most drugs of abuse causing an acute increase in DAT function or 
expression in response to the increased DA available in the synapse.  Over a long period 
of drug taking or exposure, however, there appears to be a general decrease in DAT in 
the striatum and NAc that may continue after drug taking has ceased.  This decrease in 
DAT may contribute to an individual‟s susceptibility to relapse to drug taking due to the 
muted dopaminergic transmission in the reward pathway. 
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Figure 1.2:  Dopamine at the synapse.  DA is synthesised in the cell body from  
tyrosine where it is packaged into vesicles for release at the synapse.  At depolarisation 
of the neuron, an increase in Ca
+2
 occurs, and dopamine is released by exocytosis into 
the synapse.  In the synapse, DA binds to post-synaptic receptors which cause 
depolarisation in the post-synaptic neuron continuing on the signal.  DAT are found 
perisynaptically and act to take DA back into the pre-synaptic neuron, attenuating the 
signalling.  Cocaine binds to DAT and blocks its function, leading to an increase in DA 
in the synapse causing increased signalling.  Amphetamine acts as a substrate of DAT 
and is taken up into the cell where it interacts with VMAT, causing large-scale release 
of DA into the synapse by reverse transport and exocytosis.  This also causes an 
increase in DA in the synapse leading to increased signalling. 
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Figure 1.3:  Important glycosylation, phosphorylation, ubiquitination and binding 
sites for DA and cocaine on the rat and human DAT.  Ala – alanine, Asn – 
asparagine Phe – phenylalanine, Pro – proline, S- serine, T, Thr – threonine, Val – 
valine.  Compiled from  Volz and Schenk, 2005 (Volz and Schenk 2005) 
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1.3 The Serotonin Transporter  
Serotonin (5-HT) is a major brain neurotransmitter involved in many pathways, 
including mood, memory, reward, and sleep (Murphy et al. 2008). The release of 5-HT 
into synapses leads to the activation of pre- and post-synaptic receptors, and attenuation 
of this signalling is achieved through reuptake of 5-HT by SERT.  SERT belongs to the 
Na
+
/Cl
-
 dependent transporter gene family SLC6, along with the transporters for other 
neurotransmitters such as DA, norepinephrine, and amino acids such as glycine and 
GABA (Hoffman et al. 1998).  In the brain SERT is a target for drugs of abuse such as 
MDMA and cocaine, which cause an acute large-scale increase of 5-HT in the synapse.  
This increase results in amplification of 5-HT signalling and activation of the brain‟s 
reward pathways (Muller et al. 2003).  SERT has been implicated in a number of 
disorders including depression (Goldman et al. 2010), anxiety (Laucht et al. 2009), and 
substance abuse (Ramamoorthy et al. 1993), and is a pharmacological target for 
therapeutics such as the SSRIs (Jones and Blackburn 2002; Murphy et al. 2008).  Due to 
the behavioural significance of 5-HT tone in the brain, SERT activity is central to the 
understanding of many psychological disorders, and is a target for the development of 
novel therapeutics.   
 
SERT is found on the peri- and extra-synaptic regions as well as the axon and axon 
varicosities of serotinergic neurons in the striatum, NAc, hippocampus, substantia nigra, 
and PFC (Pickel and Chan 1996; Sur et al. 1996; Miner et al. 2000).  Uptake of 5-HT by 
SERT is dependent on the co-transport of Na
+
 and Cl
-
 ions in a 1:1:1 ratio 
(Ramamoorthy et al. 1993; Chang and Lam 1998).  It has been proposed that Cl
-
 is 
crucial for 5-HT binding to SERT, and that Na
+
 is necessary for 5-HT transport to occur 
(Chang and Lam 1998).  When Na
+
 is  replaced with ions such as choline (Blakely et al. 
1991), lithium (Gu et al. 1994; Chang and Lam 1998), or potassium (Chang and Lam 
1998), uptake of 5-HT is significantly decreased, and when Cl
-
 is replaced with acetate 
(Lingjaerde 1969), isothionate (Gu et al. 1994; Chang and Lam 1998; Oz et al. 2010b), 
and fluoride (Chang and Lam 1998), uptake is also decreased, highlighting the 
importance of the co-transport of these ions with 5-HT.     
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1.4 The Kappa Opioid Receptor 
1.4.1 Introduction 
The KOPr is a PTX-sensitive (Avidorreiss et al. 1995), 7-transmembrane GPCR that 
exerts its effects in the brain and in the intestines.  There are currently three known 
subtypes of KOPr: KOPr-1, KOPr-2, and KOPr-3, with KOPr-1 the only subtype 
currently cloned (Horan et al. 1993; Yasuda et al. 1993; Heyliger et al. 1999).  Binding 
of KOPr agonists, such as the endogenous peptide dynorphin, lead to a conformational 
change and activation of G protein trimers as described in Figure 1.4.  This leads to a 
cascade of events resulting in decreased neuron excitability.  KOPr activation leads to 
release of Gα-GTP and Gβγ subunits of the Gi and Go type G protein.  Gα inhibits 
adenylyl cyclase, leading to decreased cAMP and decreased PKC activation 
(Avidorreiss et al. 1995). Continuous treatment of cells with a KOPr agonist leads to an 
immediate decrease in adenylyl cyclase activity, but when the agonist is removed, 
cAMP „overshoot‟ occurs.  This may contribute to tolerance to KOPr agonists 
(Avidorreiss et al. 1995). The released Gβγ binds directly to the G-protein-gated, 
inwardly rectifying potassium channel (Kir3).  Binding of Gβγ activates the channel, 
leading to increased intracellular K
+
 and  cell hyperpolarisation (Clayton et al. 2009).  
Once the Gα subunit of the G protein is hydrolysed back to GDP, Gβγ dissociates from 
the channel and rebinds Gα, deactivating the channel.  It has been found that KOPr 
activation regulates Kir3.1 by phosphorylation of tyrosine 12 of the channel (Clayton et 
al. 2009). The Gβγ subunit also causes decreased Ca2+ currents through direct binding to 
N, L and P/Q type Ca
2+
 channels (Rusin et al. 1997). This pathway is thought to cause 
the analgesic effects of KOPr agonists, as it leads to a decrease in Ca
2+
 dependent 
release of neurotransmitters. Activation of the KOPr by agonists leads to a multitude of 
effects, including analgesia, immunomodulation, hypothermia, dysphoria, anhedonia, 
and water diuresis (Liu-Chen 2004).  Inhibition of the KOPr by antagonists causes anti-
depressant and anti-anxiety behaviours (Carlezon et al. 2009). 
 
Dynorphin is the endogenous agonist for the KOPr.  It is a highly basic peptide that is 
cleaved from prodynorphin by proprotein convertase 2 (Marinova et al. 2005).  
Prodynorphin can be cleaved into several types of active dynorphin: big dynorphin, 
dynorphin A, B, or α/β-neo-endorphin.  Dynorphin A is the most active form and 
preferentially activates KOPr, followed by MOPr and the delta opioid receptor (DOPr)  
(Merg et al. 2006).  Dynorphin is found throughout the brain, in the hypothalamus, 
medulla, pons, spinal cord and midbrain of rats (Goldstein and Ghazarossian 1980) and 
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is involved in many processes such as neuroendocrine regulation, pain regulation, motor 
activity, cardiovascular function, respiration, temperature regulation, feeding behaviour, 
and stress (Koob 2008).  Activation of KOPr by dynorphin leads to depressive 
behaviours, anxiety, and increased drug seeking behaviours (Liu-Chen 2004). 
 
1.4.2 KOPr desensitisation 
Chronic KOPr agonism by the endogenous agonist dynorphin, or synthetic agonists 
such as U50,488H or U69,593, leads to receptor desensitisation.  The G protein is 
released from KOPr, and KOPr is phosphorylated by a GPCR kinase GRK3 
(McLaughlin et al. 2003b), leading to the recruitment of non-visual arrestins.  This 
causes a decrease between receptor and G protein coupling, leading to receptor 
desensitisation.  KOPr is endocytosed by a clatherin and dynamin dependent pathway 
where it is then either dephosphorylated and recycled, or targeted to the lysosomal and 
proteasomal pathways for degradation (Chen et al. 2006).  Human KOPr is 
phosphorylated on ser358; whereas, rat KOPr is phosphorylated on ser369. Rats and 
humans give different responses to KOPr agonists (Li et al. 2002).  Rat and human 
KOPr expressed in Chinese hamster ovary (CHO) cells are differently regulated by the 
KOPr agonist U50,488H, with phosphorylation and desensitisation of  human KOPr but 
not rat KOPr (Li et al. 2002).  This study also found that the N-terminal 7 residues of 
dynorphin A (1-17) were crucial for desensitisation.  Another study using rat KOPr 
expressed in CHO cells found that peptide ligands of KOPr induced internalisation of 
rat KOPr, but nonpeptide ligands did not, even though both activated MAPK pathways 
(Jordan et al. 2000). There have been a number of studies demonstrating down-
regulation of rat KOPr with nonpeptide ligands (McLaughlin et al. 2003b; Bruchas et al. 
2006; Clayton et al. 2009), and these differences are thought to be due to differences in 
the cell systems used.   
 
1.4.3 Synthetic KOPr agonists 
There are two main synthetic arylacetamide KOPr agonists: (trans-(±)-3,4-dichloro-N-
methyl-N-(2-[1-pyrrolidinyl]-cyclohexyl) benzeneacetamide methanesulfonate 
(U50,488H) and (5α, 7α, 8β)-(+)-N-methyl-N-(7-(1-pyrrolidinly)-1-oxaspiro(4,5)dec-8-
yl)benzeneacetamide (U69,593).  U50,488H was first synthesized in the 1970‟s before 
KOPr had been discovered, and was recognised to be a specific KOPr agonist in the 
1980‟s (Von Voigtlander and Lewis 1982).  U69,593 was synthesised based on the 
structure of U50,488H (Figure 1.5) (La Regina et al. 1988).  Both are potent KOPr 
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agonists, with U50,488H and U69,593 having Ki values of 0.70 ± 0.09 nM  and 0.89 
nM, respectively when inhibiting [
3
H]U69,593 binding in monkey brain membranes 
(Emmerson et al. 1994). 
 
1.4.4 Synthetic KOPr antagonists 
There are three common KOPr-1 specific antagonists: nor-binaltorphimine (nor-BNI) 
(Portoghese et al. 1987), 5'-guanidinonaltrindole (GNTI) (Jones and Portoghese 2000), 
and (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-
piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide 
(JDTic) (Thomas et al. 2001).  nor-BNI,  JDTic and GNTI are selective KOPr 
antagonists with Ki binding values to the KOPr of 1.09 ± 0.14 nM, 0.32 ± 0.05 nM, and 
0.18 ± 0.1 nM, respectively with 60-, 10-, and  200-fold decreased binding to MOPr, 
and 80-, 1000-, and 380-fold decreased binding at DOPr (Jones and Portoghese 2000; 
Carroll et al. 2004).   All three antagonists exhibit long-lasting effects on the KOPr, 
with nor-BNI exhibiting antagonistic effects for up to 28 days (Horan et al. 1992) and 
JDTic and GNTI for up to 14 days (Negus et al. 2002; Carroll et al. 2004).  
 
Treatment of cultured cells with KOPr antagonists also causes up-regulation of 
transfected rat KOPr and human KOPr due to post-transcriptional modification (Chen et 
al. 2006; Wannemacher et al. 2007). The treatment of animals with antagonists such as 
nor-BNI has been shown to have anti-depressant and anti-stress effects (Mague et al. 
2003; McLaughlin et al. 2003a; Knoll et al. 2007).  Therefore, this pathway could be 
targeted to create anti-depressants rather than targeting the 5-HT pathway as with most 
other current therapies.  A recent meta-analysis study carried out by Kirsch et al (2008) 
highlighted the importance of further research into the action of anti-depressants. The 
study concluded that the selective serotonin reuptake inhibitors (SSRI‟s) that are 
currently used as anti-depressants have a lesser effect than first thought (Kirsch et al. 
2008).  The additions of new anti-depressants that target different pathways are 
therefore important in increasing the recovery statistics for depression.  
 
1.4.5 KOPr activation pathways 
Activation of the KOPr by agonists leads to the activation of a number of MAPK cell 
signalling pathways.  The known pathways are summarised below. 
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1.4.5.1 ERK1/2 
ERK 1/2 is the most studied MAPK activated by KOPr.  ERK1/2 is phosphorylated by 
MEK1/2 (Assenio et al. 2006), and its activation has been shown to be P13K, PKCδ and 
Ca
2+
 dependent (Fukuda et al. 1996; Belcheva et al. 2005).  In mice, repeated forced 
swim stress led to activation of ERK1/2 which was GRK3-independent and was not 
seen in KOPr knockout mice, or when KOPr was inhibited by the KOPr antagonist nor-
BNI (Bruchas et al. 2008).  Forced swim stress is often used to induce depressive-like 
behaviour and can lead to relapse of drug seeking behaviours in laboratory animals. 
Their study demonstrated the involvement of KOPr and ERK1/2 in these behaviours.  In 
rat primary astrocytes, activation of KOPr by the classic agonist U69,593 and the novel 
agonist MOM-SalB (DS-3-216) led to a Gβγ dependent biphasic activation of ERK1/2.  
The early phase was seen 5-15 min after agonist addition and was β-arrestin 
independent; whereas, the late phase was seen after 2 h and was β-arrestin dependent.  
As seen in other studies, this activation caused proliferation of these cells (Belcheva et 
al. 2005; McLennan et al. 2008).  However, in immortalised rat astrocytes, U69593 still 
had these effects but MOMSalB (DS-3-216) only induced early phase activation of 
ERK1/2, suggesting that a different mechanism occurs in immortalised cells with this 
novel agonist.   Activation of ERK1/2 by KOPr agonism has also been shown to 
encourage mouse embryonic stem cells to undergo limited proliferation and to 
differentiate into neural progenitor cells (Kim et al. 2006).  Treatment of these neural 
progenitor cells with U69,593 led to a decrease in their proliferation.  A follow up study 
investigated the effects of KOPr agonism on neural progenitor cell differentiation and 
found that KOPr inhibits neurogenesis and astrogenesis, but stimulates 
olidgodendrogenesis, and that this is regulated by both ERK1/2 and p38 MAPK (Hahn 
et al. 2010).  
 
1.4.5.2 p38 MAPK 
p38 MAPK is involved in stress and has been shown to control aversion in rat models 
(Bruchas et al. 2007a).  p38 MAPK activation in transfected cell models, primary 
mouse brain cultures, and mice is GRK3 and arrestin dependent (Bruchas et al. 2006; 
Clayton et al. 2009).  It appears that phosphorylation of KOPr by GRK3 after agonism, 
and then the recruitment of arrestin is necessary before phosphorylation of  p38 MAPK 
occurs (Bruchas et al. 2006).  In mice that have undergone repeated swim stress, there 
were increases in activation of both KOPr and p38 MAPK, and the activation of p38 
MAPK was not observed in KOPr knockout mice.  Furthermore the conditioned place 
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aversion caused by U50,488H was blocked when p38 MAPK was inhibited (Bruchas et 
al. 2007a), suggesting a direct role of P38 MAPK in this aversion.   In mice that had 
partial sciatic nerve ligation, which serves as a model for physiological stress, there was 
an increase in the potassium channel Kir3.1 phosphorylation that was not seen in KOPr 
or GRK3 knockout mice.  In a transfected cell system an increase in Kir3.1 
phosphorylation was also observed after U50,488H treatment, and this was p38 MAPK 
and src kinase dependent.  This suggests that KOPr agonism leads to p38 MAPK 
activation which then activates src kinases, which phosphorylate Kir3.1 leading to 
receptor desensitisation (Clayton et al. 2009).  KOPr activation of p38 MAPK in the 
dorsal raphe nuclei also causes conditioned place aversion in mice (Land et al. 2009), 
further strengthening the role of p38 MAPK as a modulator of stress and aversion.   
 
1.4.5.3 c-Jun N-terminal kinase  
The c-Jun N-terminal kinase (JNK) pathway has been implicated in stress, pain, 
apoptosis, and inflammatory responses (Leppa and Bohmann 1999).  There has been 
little research conducted on JNK and KOPr, but what has been conducted shows that 
KOPr activation leads to JNK activation.  The KOPr antagonists nor-BNI and JDTic 
both have a very long in vivo action, and in HEK-293 cells stimulate JNK 
phosphorylation, interestingly through a PTX insensitive manner (Bruchas et al. 2007b).  
nor-BNI also activates JNK in the mouse striatum and spinal cord, and this effect is not 
seen in KOPr knockout mice (Bruchas et al. 2007b).  In COS7 cells co-transfected with 
JNK and KOPr, activation of KOPr with U50,488H leads to an increase in JNK 
phosphorylation that is independent of P13K (Kam et al. 2004b).  A further study 
proposed that KOPr activation of JNK occurred through a Gi/o Gβγ, src tyrosine kinase, 
focal adhesion kinase and Rac, Cdc42 and son-of-sevenless (sos) dependent pathway 
(Kam et al. 2004a).  KOPr antagonists such as nor-BNI are thought to act by disrupting 
the KOPr signaling pathway, possibly by activation of the JNK phosphorylation 
pathway (Bruchas et al. 2007b). 
 
1.4.6 KOPr and dopamine 
It has been known for over 20 years that KOPr has an inhibitory role on dopaminergic 
neurons in the rat brain (Di Chiara and Imperato 1988b; Mananares et al. 1991).  These 
initial studies found that KOPr agonists cause a decreased release of DA in the NAc and 
dorsal caudate in freely moving rats and decreased motor activity (Di Chiara and 
Imperato 1988b; Kunihara et al. 1993), and that KOPr agonism inhibits stimulated 
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dopaminergic neurons in the nigrostriatal, mesolimic, tuberoinfundibular, and 
tuberohypophysial systems (Mananares et al. 1991).  These effects were reversible by 
KOPr antagonists, demonstrating that they were KOPr mediated.  The effects of KOPr 
on DA are thought to be in part due to an interaction with DRD1 and DRD2 receptors.  
The KOPr agonist spiradoline was substituted by rats with the DRD2 receptor 
angatonist sulpiride in drug discrimination tests, suggesting that KOPr effects are 
modulated through inhibition of DRD2 receptors (Ohno et al. 1992).  The inhibition of 
DA release by presynaptic KOPr has also been shown in rabbit caudate nucleus slices.  
This effect was shown to be PTX sensitive.  While DRD2 receptors were also found to 
decrease DA release, there was no direct link found for a specific interaction between 
the action of KOPr and DRD2 receptors (Jackisch et al. 1994).  KOPr also regulates 
DRD1 receptors in the ventral striatum in rats depleted of DA (Steiner and Gerfen 
1996).  Studies carried out using fast-scan voltammetry have also shown U50,488H 
inhibition of DA overflow in rat neostriatal slices.  After several doses of U50,488H, 
this effect was decreased, suggesting receptor desensitisation (Schlosser et al. 1995).   
 
Repeated exposure to U69,593 has the opposite effects to acute exposure.  In vivo 
microdialysis studies in the rat NAc (Fuentealba et al. 2006) and medial PFC 
(Fuentealba et al. 2010) found that treatment with U69,593 once a day for four days led 
to no change in basal DA levels, but an increase in K
+
-stimulated DA levels compared 
to control rats.  The DRD2 receptor agonist quinpirole decreased both basal and K
+
-
evoked DA levels in control rats but had no effect in U69,593-treated rats (Fuentealba et 
al. 2006).  This suggests that repeated exposure to KOPr agonists leads to changes in the 
dopaminergic neuron response to stimulation in the NAc.   
 
Other studies investigating the link between DRD2/3 receptors and KOPr have found 
that chronic administration of U69,593 along with a postsynaptic dose of quinpirole 
leads to increase in sensitisation to quinpirole (Perreault et al. 2006).  When presynaptic 
doses of quinpirole were given alongside U69,593 a switch from decreased locomotor 
to increased locomotor responses were observed.  A follow up study looked at the effect 
of these treatments on gene expression of DRD1, DRD2, DAT and dynorphin after 10 
injections of U69,593 followed by quinpirole (Perreault et al. 2006).  After 10 injections 
there was decreased DRD2 mRNA in the substantia nigra and increased dynorphin 
mRNA in the striatum and NAc core (Perreault et al. 2007).  These authors concluded 
that repeated treatment caused an increase in locomotor activity as seen in the previous 
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study due to the activation of DRD1 and dynorphin neurons and the inhibition of 
presynaptic DRD2 function.           
 
1.4.7 KOPr and serotonin 
There is also evidence to suggest that KOPr also regulates 5-HT in the brain.  Treatment 
with KOPr agonists causes depression in animal models which is inhibited by the use of 
the SSRI fluoxetine (A. Morani, personal communication).  Another study demonstrated 
that the KOPr agonists salvinorin A and U69,593 lead to inhibition of K
+
-evoked 5-HT 
release in mouse hippocampal synaptosomes (Grilli et al. 2009).  U69,593 also has been 
shown to inhibited RTI-55 induced cocaine seeking in rats but not WIN35,428 induced 
cocaine seeking (Schenk et al. 2000).  This implies that the effect of U69,593 on 
cocaine seeking in rats is in part due to interactions with SERT.  This was investigated 
further with cocaine self-adminstering rats pretreated with fluoxetine, or the KOPr 
aognists spiradoline or enadoline.  Pretreatment led to inhibition of cocaine self-
administration, and this effect was reversed by the 5-HT(1A) agonist R(+)8-hydroxy-2-
(di-n-propylamino)tetralin (Ruedi-Bettschen et al. 2010).  These studies demonstrate 
that not only can KOPr regulate DA in the synapse, but also 5-HT.  
 
1.4.8 KOPr and drug addiction 
Many studies have shown that after drug use the KOPr/dynorphin system is 
upregulated, leading to drug seeking and craving during withdrawal (Mash and Staley 
1999; Shippenberg et al. 2007).  Rat studies have shown that a single dose of 
amphetamine (2.5 mg/kg) leads to a release of dynorphin and long-lasting 
desensitisation of KOPr in the NAc shell (Turchan et al. 1998; Xia et al. 2008).   
Amphetamine (2.5 mg/kg) also caused an increase in mRNA expression of 
preprodynorphin in the striatum that was inhibited by a single dose of the KOPr agonist 
U69,593.  This treatment also led to a decrease in the amphetamine increased locomotor  
response of the rat (Tzaferis and McGinty 2001).  In post-mortem studies of human 
cocaine users there are large increases in dynorphin in the caudate, putamen, and  
ventral pallidum (Hurd and Herkenham 1993; Frankel et al. 2008) and increases in 
KOPr in the caudate, putamen, and NAc (Hurd and Herkenham 1993; Mash and Staley 
1999).  This effect was also seen in rats that had been treated chronically with cocaine, 
with increases in KOPr seen in the rostral cingulate cortex, rostral caudate putamen, and 
the VTA (Unterwald et al. 1994).   
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KOPr agonists and antagonists have demonstrated their ability to alter the effects of 
drugs of abuse and withdrawal in animal studies.  The KOPr agonist U69,593 inhibited 
the cocaine-stimulated increase in NAc basal DA overflow and cocaine behaviour when 
administered alongside cocaine for 3 days (Heidbreder and Shippenberg 1994).  A 
single dose of U50,488H before a single dose of cocaine inhibited the increase of DA 
overflow in the NAc by 50% in awake and freely moving rats, and this effect was nor-
BNI reversible (Maisonneuve et al. 1994).  In morphine or cocaine self-administering 
rats a single injection of the KOPr agonists U50,488H or spiradoline led to extinction of 
drug taking after 1 day, which is still seen in some rats up to 6 days later, and the effect 
is norBNI reversible (Glick et al. 1995).  Neither agonist had an effect on lever pushing 
for water, suggesting the effect is specific for drugs of abuse.         
 
Classic KOPr agonists such as U69,593 and U50,488H have been shown in vivo to 
attenuate self-administration of cocaine, amphetamine and alcohol in rodents 
(Heidbreder et al. 1993; Heidbreder et al. 1998; Schenk et al. 1999; Collins et al. 2001a; 
Schenk and Partridge 2001; Mague et al. 2003; Knoll et al. 2007; Zhang et al. 2007; 
Tomasiewicz et al. 2008; Logrip et al. 2009; Sun et al. 2010).  Classical KOPr 
antagonists in vivo have anti-depressant/anti-stress effects that prevent rodents from 
relapsing after attenuation of self-administration of cocaine (Redila and Chavkin 2008).  
Unfortunately, these classical agonists and antagonists lead to side effects such as 
diuresis, depression, and dysphoria and therefore have not successfully progressed to 
clinical trials (Thompson et al. 2000).  Thus, novel compounds that activate the KOPr 
pathway have the potential of attenuating addiction through modulation of the DAT, 
leading to cessation of drug taking (agonists) and prevention of stress-related relapse 
(antagonists).  
 
Cellular and behavioural studies have shown that the action of KOPr agonists attenuates 
the addictive properties of cocaine.  For example, Thompson et al. (2000) showed that 
the acute treatment of rats with U69,593 and cocaine caused an increase in DA uptake 
by DAT in the NAc, decreasing the rewarding effects of cocaine.  They also observed 
that U69,593 opposed the effects of cocaine withdrawal in the NAc after repeated 
administration of U69,593 with cocaine (Thompson et al. 2000).  Collins et al. (2001) 
carried out acute and chronic experiments to observe the locomotor activity of rats 
treated with cocaine and U69,593.  They found that prior treatment of rats with U69,593 
decreased locomotion following cocaine exposure compared to animals pre-treated with 
 39 
 
vehicle (Collins et al. 2001a; Collins et al. 2001b).   In C57BL/6J mice, dynorphin A (1-
17) inhibited the acute increase in DA in the striatum after cocaine treatment, and also 
inhibited cocaine conditioned place preference and locomotor activity (Zhang et al. 
2004).   In vivo microdialysis studies of abstinent rats that had been treated with cocaine 
for five days and intracranial administration of U69,593 for days 3-5 showed that 
U69,593 treatment prevented the basal increase in DA levels in the NAc but not PFC 
after 3 days of abstinence (Chefer et al. 1999).  Intracranial administration of U69,593 
into the NAc also prevented cocaine induced locomotor sensitisation.  This study 
suggested that NAc KOPr plays a role in the DA and locomotor effects of cocaine.  In 
vivo microdialysis studies in the medial PFC of rats that had been given cocaine for 10 
days and then abstained for 3 days found that U69,593 inhibited the sensitisation to 
cocaine when rats were given a single injection (Chefer et al. 2000).  This treatment also 
inhibited the decreased DA levels evoked by cocaine and increased basal DA levels in 
the medial PFC.  In medial PFC synaptosomes, U69,593 also inhibited the cocaine-
induced increase in DA uptake.  These data suggest that KOPr agonism has the ability 
to inhibit the early phase of abstinence from cocaine (Chefer et al. 2000).  In cocaine 
self-administering rats, an acute injection of U50,488H into the VTA dose dependently 
decreased cocaine-induced reinstatement in a nor-BNI reversible manner, demonstrating 
that the VTA KOPr are involved in this inhibition (Sun et al. 2010).  Mello and Negus 
(1998) have also shown that treatment of Rhesus monkeys with several different KOPr 
agonists, including U50,488, leads to decreased cocaine self-administration (Mello and 
Negus 1998).  This demonstrates the therapeutic potential of KOPr agonists in breaking 
the addiction cycle. 
 
The KOPr system has also been shown to modulate the locomotor effects of other drugs 
of abuse such as amphetamine (Gray et al. 1999; Vanderschuren et al. 2000) and 
nicotine (Hahn et al. 2000).  Acute KOPr agonism inhibits the locomotor effects of 
amphetamine in rats  (Gray et al. 1999; Vanderschuren et al. 2000), while chronic KOPr 
agonism leads to potentiation of amphetamines effects (Fuentealba et al. 2007).  A four 
day treatment with the KOPr agonist U69,593 (once daily for four days, subcutaneous.  
0.16 mg/kg days 1 and 2, 0.32 mg/kg day 3 and 4) caused increased locomotor response 
to amphetamine, as well as increasing amphetamine induced DA in the NAc 
(Fuentealba et al. 2007).  However, when KOPr agonists were given alongside 
amphetamine for 5 days and then the locomotor effect measured after 3 weeks, the 
KOPr agonists had no effect on locomotor sensitisation, suggesting that KOPr is not 
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involved in sensitisation in this model (Vanderschuren et al. 2000).  The KOPr agonist 
U69,593 also inhibits the effect of neurotoxic doses of methamphetamine, with 
complete inhibition of the methamphetamine-induced decrease in basal and K
+
-evoked 
DA release in mice (El Daly et al. 2000).  In wild-type mice treated with nor-BNI or in 
KOPr knockout mice, the effect of an acute ethanol exposure leads to augmentation of 
ethanol-induced increases in DA in the NAc, again demonstrating the modulation of DA 
by KOPr (Zapata and Shippenberg 2006).     
 
In animal studies, relapse to cocaine seeking was induced by foot shock in mice, and 
this effect was reversed by KOPr antagonists, suggesting that the stress-induced relapse 
was modulated by the KOPr system (Beardsley et al. 2005; Redila and Chavkin 2008).    
The repeated forced swim test is a test used to measure depressive-like behaviour in 
mice, such as immobility and analgesia.  This behaviour has been found to be KOPr 
dependent as it is blocked by KOPr antagonism and does not occur in KOPr or 
dynoprhin knockout mice (McLaughlin et al. 2003a; McLaughlin et al. 2006a).  Mice 
that are exposed to the repeated forced swim test have increased cocaine conditioned 
place preference, and this effect is mimicked by U50,488H (McLaughlin et al. 2006a), 
indicating the effect of KOPr activation and stress on drug seeking in this model.  
Another stress test carried out in mice is the social defeat stress test, which induces 
analgesia, immobility, and a defeated postural response.  This test also causes 
potentiation of cocaine conditioned place preference.  Treatment of mice with nor-BNI 
inhibits these behaviours and blocks the stress-induced cocaine condition place 
preference (McLaughlin et al. 2006b).  These studies all show that the KOPr is involved 
in addiction, with a particular role in stress-induced drug seeking and craving.         
 
 In the brain, KOPr plays a part in regulating the activity of DAT (Ramamoorthy et al. 
2002a; Margolis et al. 2003; Margolis et al. 2006; Gehrke et al. 2008) and SERT 
(Schenk et al. 2000; Collins et al. 2002).  Acute KOPr agonism leads to an increase in 
DAT function and a decrease in SERT function, and antagonism decreases DAT 
function and increases SERT function.  While the exact mechanism of how this occurs 
is unknown, it has been shown that KOPr agonists not only inhibit DA release by 
interacting with DRD2 receptors (Acri et al. 2001) but also alter the activity of DAT 
and SERT in single cells (Kivell et al. 2004).  These effects are caused by both 
activation of signalling pathways and also a physical interaction between KOPr and 
DAT (T. Shippenberg, unpublished data).   
 41 
 
 
While there are promising indications of KOPr effects in animal models of addiction, 
several KOPr agonists have been trialled in cocaine abusing humans and overall have 
shown no effect on drug taking behaviour.  The KOPr agonist, enadoline, is tolerated 
well up to 80 µg/70 kg body weight, alone and in combination with cocaine (Walsh et 
al. 2001a; Walsh et al. 2001b), but enadoline did not alter drug seeking or taking 
behaviour (Walsh et al. 2001a).  Another agonist, cyclazocine, had a possible effect on 
the acute effects of cocaine in patients with a history of cocaine and opiate use.  After 
six treatments with the agonist over 3 weeks, the effects of a single dose of cocaine 
appeared to be decreased in the presence of cyclazocine compared to controls, although 
this was only seen as suggestive by the authors (Preston et al. 2004).  Overall, this 
suggests that while these compounds have positive results in animals, in humans they 
do not have the same effect.   However, as KOPr agonists cause decreased mood, they 
do have potential as anti-mania pharmacotherapy. For example, the partial KOPr 
agonist pentazocine decreased manic episodes in patients with bipolar disorder when 
two doses of 50 mg were administered two hours apart (Cohen and Murphy 2008).  
 
Though acute treatment with KOPr agonists leads to a non-addictive behaviour, chronic 
treatments have been shown to lead to tolerance, and once treatment has stopped 
addictive properties are often seen.  This is thought to occur in three main stages: 
desensitization due to the phosphorylation of the receptors and uncoupling from G 
proteins, internalization of the receptors, and finally down-regulation of the number of 
receptors present on the cell surface (Liu-Chen 2004).  This occurs as the long-term 
inhibition of adenylate cyclase by the activated KOPr leads to the compensatory up-
regulation of cAMP through a different pathway.  Once KOPr agonist treatment has 
stopped, this compensatory pathway, along with the natural activation of adenylate 
cyclase, leads to an increase in cAMP levels, and this leads to symptoms of dependence 
and withdrawal (Nestler and Aghajanian 1997). 
 
The „anti-addictive‟ effects that KOPr demonstrate are most likely also mediated 
through the serotonergic system as well as the dopaminergic system.  A reinstatement 
study carried out in cocaine self-administering rats investigated if U69,593 could inhibit 
specific DAT inhibitors‟ induction of reinstatement.  Interestingly, U69,593 did not 
block the effects of the DAT inhitibor GBR12909 on reinstatement in rats, but it did 
prevent reinstatement by both cocaine and the cocaine analogue RTI-55, suggesting that 
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other pathways are involved with KOPr „anti-addictive‟ effects.  The authors suggested 
that the serotonergic system may be involved (Schenk et al. 2000).  Another study 
looked at the effect of continuous infusion in rat brains of cocaine or specific DAT 
inhibitors on KOPr expression.  Results showed that 14 days of continuous cocaine 
leads to an increase in KOPr expression in the NAc and caudate putamen, but 
continuous exposure to the specific DAT inhibitors GRB12909 and RTI-117 has no 
effect on KOPr expression (Collins et al. 2002).  This suggests that the increase in KOPr 
expression is not due to DAT.  Other studies have shown that depletion of 5-HT in the 
hippocampus led to the inhibition of the effects of U69,593 and cocaine on 
predynorphin mRNA expression (D'Addario et al. 2007), and that depletion of 5-HT in 
rats inhibits the effect of cocaine on locomotor activity in rats given repeated exposures 
to U69,593 (Zakharova et al. 2008b).  These studies demonstrate that the serotonergic 
system is involved in the pathway between cocaine and KOPr. Reinstatement 
experiments in self-administering squirrel monkeys also show that both KOPr agonists 
and SERT inhibitors prevent cocaine priming reinstatement of drug seeking, further 
establishing a role for 5-HT in this pathway (Ruedi-Bettschen et al. 2010). 
 
To conclude this section, KOPr agonists show anti-addictive properties in animal 
models of addiction and appear to exert this effect partially through the DA and 5-HT 
pathways in the brain.  However, the classic KOPr agonists which have been trialled in 
human studies, have little or no effect on cocaine taking.  Therefore, there is a need for 
the effects on drug addiction of novel KOPr agonists to be investigated, with further 
investigation on how they modulate the DA and 5-HT systems.   
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Figure 1.4:  Activity of KOPr.  The binding of a ligand to KOPr leads to a conformational 
change in the receptor.  This allows the pertussis toxin-sensitive Gi protein trimer to replace 
GDP with GTP, causing dissociation of the Gαi-GTP subunit from the Gβγ subunit.  The Gαi-
GTP subunit inhibits adenylate cyclase (AC), leading to a decrease in cAMP.  This causes a 
decrease in neuron excitability and also a decrease in PKA which reduces neurotransmitter 
release through the CREB pathway.  The Gβγ subunit causes membrane hyperpolarisation 
through the activation of K
+
 conductance and inhibition of Ca
2+
 channels, thus decreasing 
neuron excitability. 
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Figure 1.5:  Structures of the classic KOPr agonists U50,488H (A) and U69593 (B) 
and antagonists nor-BNI (C), JDTic (D), and GNTI (E).   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.6:  Structures of salvinorin A (A) and its analogues DS-1-240 (B) and DS-
3-216 (C). 
A B 
C D E 
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1.5 Salvinorin A 
Salvinorin A (Figure 1.5) is a unique non-nitrogenous hallucinogen that is purified from 
the plant Salvia divnorum.  Salvia divnorum is a rare member of the mint family and is 
traditionally used by Mazatec Indians in shamanistic rituals to induce short, intense 
periods of hallucination.  Traditionally this hallucinogen is taken either by chewing 
fresh leaves, or by drinking the juice of crushed leaves, and it enters the body through 
the oral mucosa (Siebert 1994).  When it is taken in this way it has a long and fairly 
mild duration of action (Valdes 1994).  Salvinorin A has also recently become a 
recreational drug that is usually smoked in the Western world. It currently shows no 
addictive properties in people, even though in conditioned place preference studies it 
can induce addictive behaviour in zebra fish and rats (Braida et al. 2007; Braida et al. 
2008).  Salvinorin A is the most potent naturally occurring hallucinogen, having a 
similar potency as the synthetic drugs lysergic acid diethylamide (LSD) and 4-bromo-
2,5-dimethoxy-phenylisopropylamine (DOB) (Siebert 1994; Valdes 1994).  Salvinorin 
A induces a short-lasting, intense period of hallucination when smoked that persists for 
a few minutes to an hour. It is rapidly hydrolysed by carboxylesterase to the weak KOPr 
agonist salvinorin B (Schmidt et al. 2005a; Teksin et al. 2009; Tsujikawa et al. 2009).  
Salvinorin A is not substituted for its discriminative stimuli by LSD or ketamine in rats 
demonstrating its unique mode of action (Killinger et al. 2010).   Salvinorin A is a 
controlled substance in Australia, Belgium, Canada, Denmark, Estonia, Finland, Italy, 
Japan, Russia, Spain, and Sweden, with many of the states of the USA also banning 
salvinorin A. 
 
There have been several surveys carried out questioning salvia users on their subjective 
thoughts on salvia use.  Surveys in the USA show that salvia is a more recently accepted 
recreational drug, with smoking the most common way of taking it, and the effects 
being a fast onset and a short duration (Gonzalez et al. 2006).  An interview of 
American college students found that 4.4% of students surveyed had used salvia, and 
that white male fraternity members who had a history of heavy episodic periods of 
drinking were most likely to take it (Lange et al. 2008).  Another study reported that the 
effects of salvia were more like marijuana than classic hallucinogens such as LSD 
(Albertson and Grubbs 2009).  The majority of salvia users reported no salvia-induced 
psychosis, and said that if saliva was to become illegal in their state they would still 
continue to use it (Sumnall et al. 2010).  There has been one person who was reported to 
use salvia successfully as an anti-depressant (Hanes 2001), and one report of persistant 
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psychosis and paranoia after smoking salvia (Przekop et al. 2009).  Overall, these 
surveys demonstrate that salvia is becoming increasingly popular, and that the majority 
of users find it to be a safe drug to take, with only one reported incident of serious side 
effects.    
 
Salvinorin A is biologically unique hallucinogen, as it has been shown to be a potent 
and selective KOPr agonist (Roth et al. 2002; Sheffler and Roth 2003; Chavkin et al. 
2004) rather than targeting 5-HT2A serotonergic receptors as is the case for classical 
hallucinogens.  It is also unique as a KOPr agonist as it has a non-nitrogenous structure 
(Figure 1.5).  Studies have shown that salvinorin A is a selective KOPr agonist and 
shows no affinity for MOPr or DOPr (Roth et al. 2002).  Therefore, salvinorin A has the 
potential to be chemically modified to form semi-synthetic analogues that act as KOPr 
agonists and antagonists, introducing a new class of compounds that have potential as 
therapeutic drugs to treat addiction and relapse.   
 
A number of experiments documenting salvinorin A‟s action in the cell and in vivo have 
been published.  A cellular study carried out by Wang et al. (2005) characterized 
salvinorin A‟s pharmacological activity alongside other KOPr agonists (Wang et al. 
2005).  They showed that salvinorin A had a Ki of 7.9 nM.  Roth et al. (2002) showed 
that salvinorin A had a Ki value of 16 nM, and that it was a full agonist of KOPr.  
Several studies have also reported that the discriminative stimulus effects of salvinorin 
A are mediated by KOPr in both non-human primates and rodents (Butelman et al. 
2004; Willmore-Fordham et al. 2007; Baker et al. 2009; Butelman et al. 2010) and that 
MOPr agonists, DOPr agonists, and  other hallucinogens such as psilocybin or ketamine 
are not generalised (Butelman et al. 2010).  This demonstrates that the effects of 
salvinorin A are mediated through the KOPr pathway, rather than MOPr, DOPr, or the 
serotonergic pathways.  Salvinorin A has overlapping effects with the non-selective 
NMDA receptor antagonist ketamine, as JDTic, a KOPr-1 antagonist, inhibited some of 
ketamine‟s effects in a rat model (Nemeth et al. 2010).  Carlezon et al (2006) carried out 
behavioural experiments with rats given salvinorin A and showed that administration of 
salvinorin A before a number of behavioural tests led to behaviour that was consistent 
with effects characteristic of other depressant drugs (Carlezon et al. 2006).  The same 
results were gained in studies with salvinorin A in mice (Zhang et al. 2005).  These 
experiments showed how salvinorin A exerted its effects through the KOPr and that its 
physiological effects were consistent with other KOPr agonists. 
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Studies in rodents have shown that salvinorin A decreases DA overflow and locomotor 
activity caused by cocaine administration (Zhang et al. 2005; Chartoff et al. 2008; 
Gehrke et al. 2008).  Salvinorin A also attenuates self-administration in rats when 
acutely administered before cocaine reinstatement tests (Morani et al. 2009).  Recent 
studies in rats have shown that an active dose of salvinorin A (0.32 mg/kg) leads to a 
decrease in phasic DA release, with no changes in uptake in the NAc.  This occurred 
alongside a decrease in motivation of these animals, measured by intracranial self-
stimulation (Ebner et al. 2010).  Another study found that salvinorin A stimulates DRD2 
receptors, which may account for the results seen in the previous study (Seeman et al. 
2009).  In mice, a single dose of salvinorin A leads to a rapid, short-lived induction of 
sedation or motor incoordination which is nor-BNI reversible (Fantegrossi et al. 2005).  
This effect was similar to that induced by U69,593.  KOPr agonists cause increased pain 
thresholds (antinociception).  Mice exposed to a single dose of salvinorin A demonstrate 
a nor-BNI reversible antinociception to both thermal and chemo-nociceptive stimuli, 
with the peak seen after 10 min of salvinorin A administration (John et al. 2006; 
McCurdy et al. 2006).  Antinociception and hypothermia after salvinorin A treatment is 
not seen in KOPr-1 knockout mice, suggesting that salvinorin A binds specifically to 
KOPr-1 receptors (Ansonoff et al. 2006).  Another study that links the effects of 
salvinorin A to DA was conducted in mouse hippocampal synaptosomes and showed 
that salvinorin A presynaptically mediates norepinephrine, 5-HT, and DA exocytosis 
(Grilli et al. 2009).  
 
 Salvinorin A has a very short half-life as it is quickly metabolised into the more stable 
but inactive salvinorin B derivative, and this may be problematic for development of 
salvinorin A into an anti-addiction therapeutic.  A PET study carried out in baboons 
showed that C-11 labelled salvinorin A peaked in the cerebellum and cortex within 40 s 
of administration (i.v.) and had a half-life of only 8 min (Hooker et al. 2008).  These 
data mirror that seen with human users, with salvinorin A showing a fast onset and short 
duration.  The same group recently used PET and a brain metabolic tracer to find where 
in the brain salvinorin A (i.p.) exerts its effects (Hooker et al. 2009).  They found that 
salvinorin A had an effect on brain metabolism in areas that contain high KOPr, for 
example the periaqueductal grey, the vermis of the cerebellum, the caudate putamen, 
and the bed nucleus of the striata terminalis.  Interestingly, brain metabolism is also 
increased in areas that are not densely KOPr populated, for example, the hippocampus 
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and medial brainstem.  The authors hypothesized that these other regions may be 
involved in the physiological effects of salvinorin A and may be areas that can be 
further studied with new analogues.  After an intravenous injection of salvinorin A into 
Rhesus monkeys it took only 1 min for salvinorin A to reach the central nervous system, 
and 1 to 2 min to cause facial relaxation and ptosis (drooping of the eyelid) (Butelman 
et al. 2009).  Physiological and histological studies on the effect of salvinorin A on rats 
and mice have shown that salvinorin A exhibits low toxicity, even at doses much higher 
than those that humans administer (Mowry et al. 2003). 
 
Recent studies have interestingly shown that low doses of salvinorin A have a 
rewarding effect in rats and zebrafish, but higher doses are aversive (Braida et al. 2007; 
Braida et al. 2008; Braida et al. 2009). This rewarding effect was attenuated by pre-
treatment with the cannabinoid receptor 1 (CB1) antagonist, rimonabant.  This suggests 
that at low doses, the KOPr interacts with the CB1 receptor to cause these rewarding 
effects. Another later study, however, suggests that these affects are due to rimonabant 
acting at KOPr to inhibit its effects (Walentiny et al. 2010).  Locomotor studies using 
salvinorin A and a DRD1 receptor agonist SKF 82958 showed that acute administration 
of salvinorin A blocked the locomotor stimulation effects of the agonist in the dorsal 
striatum but that after chronic salvinorin A treatment the locomotor stimulation was 
increased.  These results parallel those found with cocaine locomotor studies, and show 
that salvinorin A regulates the locomotor effects of cocaine through DRD1 receptor 
signalling (Chartoff et al. 2008).  Locomotor studies in rats with salvinorin A co-
administered with the DRD2/DRD3 receptor agonist quinpirole showed that salvinorin 
A produced a bidirectional effect, with low doses causing attenuation of the locomotor 
effect, middle doses causing no effect, and high doses causing potentiated effects 
(Beerepoot et al. 2008). This biphasic response has not been seen with other KOPr 
agonists, possibly because of the narrow range of concentrations used, and further 
investigation is needed.  It has also been suggested by Rothman et al. that salvinorin A 
allosterically inhibits binding of ligands to MOPr (Rothman et al. 2007).  In a series of 
experiments, it was shown that salvinorin A weakly inhibits the binding of DAMGO 
and diprenorphine to MOPr, suggesting that salvinorin A is not as selective as first 
thought.  These experiments demonstrate the increasing interest in salvinorin A and how 
it exerts its effects within the brain. 
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Salvinorin A is also unique in that it does not cause water diuresis in rats, possibly due 
to its short duration of action (Inan et al. 2009).  Salvinorin A is traditionally used as a  
medication for treatment of gastrointestinal problems such as diarrhoea (Valdes et al. 
1983).  Studies carried out in guinea pigs and mice have shown that salvinorin A and 
Salvia divinorum leaf extract decrease enteric cholinergic transmission, which confirms 
its use as an anti-diarrhoeic (Capasso et al. 2006).  In mouse inflamed intestines, 
salvinorin A leads to a decreased motility of a fluorescent marker, and this decrease in 
motility was inhibited by both nor-BNI and rimonabant, the CB1 receptor inhibitor 
(Capasso et al. 2008b).  This CB1 and KOPr cross-talk was only observed in inflamed 
intestines and not in normal mouse intestines (Capasso et al. 2008a).  Another study 
investigated the effect of salvinorin A on colonic transit in mice and showed that in vivo 
salvinorin A prolonged colonic propulsions and slowed upper gastrointestinal transit, 
and in vitro it acted to inhibit contractions of the isolated colon, stomach, and ileum.  
These effects were mediated by KOPr and CB1 and CB2 in the in vitro studies and 
KOPr in the in vivo studies, with a slight activation at CB2 (Fichna et al. 2009).   
  
There have been a number of studies carried out with the aim of detecting salvinorin A 
and its metabolites in blood, plasma, and urine samples so that the pharmacokinetics of 
salvinorin A can be investigated.  One method employed was liquid chromatography-
mass spectrometry/atmospheric pressure chemical ionisation (Schmidt et al. 2005b) 
which could accurately detect salvinorin A at concentrations of 2 ng/mL to 100 ng/mL 
in human and rhesus monkey plasma, monkey cerebrospinal fluid, and human urine.  In 
a method using gas chromatography followed by mass spectrometry, salvinorin A could 
be identified in human plasma, urine, saliva, and sweat at concentrations between 15-
5000 ng/mL for plasma, urine and saliva, and 10-50 ng per patch for sweat.  In human 
smokers of salvinorin A, this method was able to detect salvinorin A in urine and saliva 
(Pichini et al. 2005).  In the leaves of Salvia divinorum, salvinorin A and other 
salvinorins and divinatorins were identified using liquid chromatography/electrospray 
ionisation multistage mass spectrometry (Medana et al. 2006).  Another study used thin 
layer chromatography and gas chromatography/mass spectrometry to identify Salvia 
divinorum from 13 other Salvia species and from Cannabis sativa L (Jermain and Evans 
2009).  Futher use of thin layer chromatography was utilised along with desorption 
electrospray ionisation mass spectrometry to identify salvinorin A and other salvinorins 
in leaf material (Kennedy and Wiseman 2010).         
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The first full synthesis of salvinorin A was published in 2007 (Scheerer et al. 2007) and 
took 29 steps to produce salvinorin A.  Since then, several studies have been carried out 
to decrease the number of steps and reduce the cost of synthesis of salvinorin A, with 
one study requiring only 20 steps (Nozawa et al. 2008) and a more recent study by the 
same group taking only 13 (Hagiwara et al. 2009).  
 
The binding site of salvinorin A on the KOPr has been investigated, and is of particular 
interest because of its radically different structure compared to classic KOPr agonists.  
A number of different amino acid residues have been shown to stabilise salvinorin A in 
the putative binding pocket, including  Gln115 (Kane et al. 2006; Kane et al. 2008), 
Tyr119 (Kane et al. 2006; Kane et al. 2008), Tyr313 (Yan et al. 2005; Kane et al. 2006; 
Kane et al. 2008), Ile316 (Kane et al. 2008) and Tyr320 (Yan et al. 2005; Kane et al. 
2006; Kane et al. 2008) in helix 7. In helix 2, an important residues is Tyr119 (Yan et 
al. 2005; Kane et al. 2006).  Ile316 was found to be particularly crucial for salvinorin A 
binding to KOPr (Kane et al. 2008).  A number of residues are also necessary for 
activation of KOPr by salvinorin A, including Tyr312 (Yan et al. 2005), Tyr313 (Yan et 
al. 2005) and Tyr320 (Yan et al. 2005) from helix 7 and Tyr139 (Yan et al. 2005) from 
helix three. 
 
1.5.1 Analogues of salvinorin A 
Analogues of salvinorin A have been synthesized by altering a number of different 
residues of the compound.  These alterations have not only highlighted important 
domains for binding and specificity but also produced analogues with increased affinity 
and prolonged half-lives.  These studies have identified the importance of the furan ring, 
C2 carbon, C4 carbon, and C12 carbon for affinity and specificity to KOPr (Fig. 1.5).  
The furan ring is critical for KOPr affinity (Harding et al. 2006; Beguin et al. 2009); 
whereas, alterations in the C2 carbon lead to increased stability and changes in affinity 
(Chavkin et al. 2004; Beguin et al. 2005; Beguin et al. 2006; Bikbulatov et al. 2007), 
with the beta isomer binding better then the alpha isomer (Lee et al. 2010).  Studies of 
the C4 carbon side chain have shown that long or bulky side chains lead to decreased 
affinity for KOPr (Lee et al. 2006), and alterations at the C12 carbon lead to decreased 
affinity for all opioid receptor isotypes (Yang et al. 2009).  One salvinorin A analogue, 
herkinorin, has been generated that has selective affinity for the MOPr (Holden et al. 
2007), and other compounds have been produced with affinity for both the KOPr and 
MOPr (Bikbulatov et al. 2008).  Another analogue that has an N-methylacetamide at the 
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C2 carbon shows KOPr selectivity, high affinity, slower metabolic transformation and 
oral efficacy, showing promise therefore as a potential therapeutic (Beguin et al. 2008).  
Modification of the C1 ketone creates weak KOPr antagonists, or KOPr agonists that 
show antagonism of the MOPr and DOPr (Munro et al. 2005; Holden et al. 2007). 
These compounds, with affinities for more than one receptor, may have important 
therapeutic potential, since simultaneous activation of the MOPr and DOPr might, along 
with the primary effect of the KOPr, decrease some of the unwanted side effects of the 
KOPr and may lead to better therapies.   
 
The two salvinorin A derived compounds that we currently have access to, DS-1-240, 
and MOMSalB (DS-3-216), both have modified C2 regions, as shown in Figure 1.5.  
DS-1-240 shows KOPr selectivity with an EC50 value lower then salvinorin A and a 
longer half-life (Harding et al. 2005).  DS-3-216 has been studied quite extensively and 
shows a higher affinity, efficacy, and longer half-life then salvinorin A in animal studies 
(Wang et al. 2008; Inan et al. 2009).  DS-3-216 also induces ERK1/2 phosphorylation 
and primary astrocyte proliferation, but only induces the early phase ERK1/2 activation 
in an immortalised cell line, rather than both the early and late phase as seen with 
U69,593 (McLennan et al. 2008).  Both of these compounds have also shown anti-
addictive properties in a rat model of cocaine addiction (A. Morani, unpublished data).  
These compounds therefore would be interesting to study further to see how they 
modulate DAT in both cell systems and in isolated tissue. Due to the large potential for 
altering the structure of salvinorin A to make analogues, and the effects that these 
analogues have, derivatisation of salvinorin A has led to a novel chemical class of other 
KOPr agonists and possibly antagonists that may not possess the classical side effects of 
KOPr ligands and may be more suitable for the clinic.  
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1.6 Aims and Objectives 
The overall aim of the present study is to investigate the effects of the novel KOPr 
agonist salvinorin A, and two of its analogues, DS-1-240 and DS-3-216, on DAT in 
both tissue and cell models.  This study investigated how these compounds act on DAT 
and if their effects are different from classic agonists.  By investigating the effects of 
these compounds and comparing them to classic agonists it may be possible to identify 
differences in their mode of action.  This may lead to greater understanding about how 
these compounds work, and possibly aid the development of novel pharmacotherapies 
for drug addiction. 
 
The specific objectives of the study were (1) to investigate the effect of the novel KOPr 
agonists on DAT function in isolated rat brain tissue; (2) to investigate the effects of the 
novel KOPr agonists on DAT function in a cell model, and whether any changes 
observed occur via increased cell surface expression of DAT; (3) to investigate if the 
ERK1/2 pathway and lipid rafts are involved in the interaction between KOPr and DAT 
and (4) to establish rotating disk electrode voltammetry techniques to measure SERT 
function so that the effect of KOPr activation on SERT could be measured in rat brain 
tissue. 
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Chapter 2: General methods 
 
2.1 Tissue culture 
All tissue culture work was carried out in a sterile Email Air Handling Class II 
Biological safety cabinet (AES Environment Pty LTD, Auburn, Australia).  Sterile 
plasticware was purchased from BD Biosciences and Greiner Bio One. Cells were 
grown in a Heracell incubator (Kendro Laboratory Products, GmbH, Germany) under 
humid conditions at 37°C with 5% CO2.  For this study, three different cell lines were 
used: human embryonic kidney cells (HEK-293), green monkey kidney cells (COS7), 
and mouse neuroblastoma cells (N2A).  All cell lines were purchased from American 
Type Culture Collection (ATCC, Manassas, VA, USA) and were used between passage 
number seven and 50. 
 
2.1.1 Cell lines used in this study 
2.1.1.1 Human embryonic kidney cells (HEK-293) 
HEK-293 are adherent immortalised human embryonic kidney cells that are transformed 
with adenovirus 5.  They were cultured in Dulbecco‟s Modified Eagle‟s Medium 
(DMEM) high glucose medium (Gibco, Invitrogen, Auckland, NZ) containing 10% 
fetal calf serum (FCS, ICP biologicals, Auckland, NZ),  200 µM L-glutamine (Gibco, 
Invitrogen), and 1% penstrep antibiotic (Penicillin G sodium 5000 units/mL, 
streptomycin sulphate 5000 units/mL in 0.85% saline, Gibco, Invitrogen).  Non-
penstrep medium was made from DMEM containing 200 µM L-glutamine and 10% 
FCS and was used for cell transfections.  For confocal microscopy, biotinylation, and 
Western blotting experiments, cells were plated at a density of 5 x 10
5
 cells in 1 mL in 
35 mm dishes.  For rotating disk electrode voltammetry experiments (RDEV) cells were 
plated at a density of 3.5 x 10
6
 cells in 7 mL in 100 mm dishes. 
 
2.1.1.2 Green monkey kidney cells (COS7) 
COS7 are adherent kidney cells from the African monkey Cercopithecus aethiops. 
transformed with SV40.  These cells were cultured in DMEM high glucose medium 
containing 10% FCS, 200 µM L-glutamine and 1% penstrep.  Non-penstrep medium 
was made from DMEM containing 200 µM L-glutamine and 10% FCS and was used 
for cell transfections.  Cells were plated for confocal experiments at a density of 3 x 10
5
 
cells/ in 1 mL in 35 mm dishes. 
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2.1.1.3 Mouse neuroblastoma cells (N2A) 
N2A are adherent mouse brain neuroblastoma cells from Mus musculus.  They were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% FCS 
and 1% penstrep antibiotic.  Non-penstrep media contained RPMI with 10% FCS.  Cells 
were plated for confocal microscopy experiments at a density of 1 x 10
6
 cells in 1 mL in 
35 mm dishes. 
    
2.1.2 Cell growth and passaging 
Cell stocks were stored in liquid nitrogen and were thawed for use in experiments.  To 
defrost cells, a vial was removed from the liquid nitrogen dewer and defrosted in a 37°C 
waterbath.  Cells were immediately added to a 15 mL Falcon tube containing 10 mL of 
their respective culture medium and centrifuged at 300 g for 5 min.  The cells were then 
resuspended in 7 mL of culture medium and added to a 75 mL flask to grow.  The 
following day, cells were fed by removal of old culture medium and the addition of 
fresh medium.  When the cells had reached 80% confluency they were passaged into a 
250 mL flask.  Once these cells had reached 80% confluency they were passaged into 
two separate 250 mL flasks, one for use in experiments and the other for freezing down 
to replace stocks removed from the liquid nitrogen.   
 
Cells were passaged when they were 80-90% confluent.  Cells were washed twice with 
5 mL of sterile 1 x phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 8.1 
mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) (Appendix 1) and then incubated at 37°C in 
1.5 mL of TrpLE Express (Gibco, Invitrogen) for 5 min.  When cells had detached they 
were removed by washing with medium, transferred into a sterile 15 mL Falcon tube 
and centrifuged at 300 g for 5 min.  The supernatant was poured off and cells 
resuspended in culture medium.  The concentration of live cells was then determined by 
counting using a haemocytomter and 0.4% trypan blue (Sigma).  To continue the cell 
line, cells were diluted 1:4 and reseeded in 250 mL flasks.  For confocal microscopy, 1 
mL of cells was plated on to a 35 mm glass bottom dishes (Mattec, Loveland, OH, 
USA), and for cell surface biotinylation and Western blotting experiments, 1 mL of 
cells was plated on 35 mm plastic petri dishes.  
 
To freeze cells, cells in log growth phase were passaged and resuspended to 1 x 10
6
 
cells/mL in their respective culture medium containing 10% dimethyl sulfoxide 
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(DMSO).  Aliquots of 1 mL were frozen in cryovials overnight at -80°C and then 
transferred to liquid nitrogen.   
 
2.1.3 Cell transfection 
Cells were transfected the day after plating, when cells were 60-70% confluent.  Cells 
were transfected using Lipofectamine 2000 reagent (Invitrogen) and Optimum 1 
medium (Invitrogen).  For HEK-293 cells, 3 µL of Lipofectamine 2000 was made up to 
50 µL with Optimum 1 and incubated for 5 min.  In a separate tube, myc-tagged rat 
kappa opioid receptor (myc-rKOPr, kindly donated by L. Devi) plasmid DNA and 
yellow fluorescent protein-tagged human dopamine transporter (YFP-hDAT, kindly 
donated by J. Javitch) plasmid DNA were made up to 50 µL with Optimum 1, to a final 
concentration of 0.6 µg/mL and 0.4 µg/mL respectively.  After the 5 min incubation, the 
2 tubes were mixed and incubated at room temperature for 20 min.  Cells that were to be 
transfected were fed with 1 mL of penstrep-free medium, and 100 µL of the transfection 
mixture was added.  For RDEV experiments cells were transfected following the above 
protocol with 1 µg/mL of green fluorescent protein-tagged human serotonin transporter 
(GFP-hSERT, kindly donated by S. Ramamoorthy).  Cells were used 48 h after 
transfections.  For COS7 and N2A cells, 4 µL of Lipofectamine 2000 was used, and 1.2 
µg/mL of myc-rKOPr and 0.8 µg/mL of YFP-hDAT DNA was used.   
 
2.2 Plasmid Preparation 
2.2.1 Transformation of MAX Efficiency® DH5α™ Competent Cells 
A 100 µL aliquot of MAX Efficiency® DH5α™ Competent Cells (Invitrogen) was 
thawed on wet ice and then divided into 50 µL aliquots in ice-cold microcentrifuge 
tubes. To one of the tubes, 15 ng of plasmid DNA (Table 2.1) was added and incubated 
on ice for 1 h.  The other tube acted as a negative control.  Both tubes were then heat 
shocked at 42°C for 2 min in a heat block (Global Science) and then placed on ice for a 
further 5 min.  After cooling, 450 µL of room temperature SOC medium (Invitrogen) 
was added to each of the tubes, and the tubes were placed in a 37°C Shaker (Bioline, 
Edwards Instrument Company, Australia) set at 225 rpm for 1 h.  Following this, 100 
µL of each culture was spread onto a Luira Broth (LB) agar plate (10 g/L NaCl, 5 g/L 
Yeast extract, 10 g/L Yeast agar, 10 g/L Bactotryptone) (Appendix 1) containing either 
100 µg/mL ampicillin or 50 µg/mL kanamycin to create a „lawn‟ culture.  The plates 
were incubated overnight in a 37°C humid incubator (Bioline), and the following day 
the procedure below was carried out.        
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Table 2.1 Plasmid information 
Gene Vector Resistance Provided by 
myc-rKOPr pcDNA3 Ampicillin (100 µg/mL) L. Devi (Jordan and Devi 1999) 
YFP-hDAT pciHyg Ampicillin (100 µg/mL) J. Javitch (Daws et al. 2002) 
GFP-hSERT peGFP-
C1 
Kanamycin (50 µg/mL) S. Ramamoorthy (Scholze et al. 
2000) 
 
 2.2.2 Escherichia coli cultivation 
To cultivate single colonies, a scraping of the transformation plate was taken and 
streaked onto LB agar plates containing the appropriate antibiotic and incubated 
overnight at 37°C with humidity.  This was only carried out if the negative control plate 
showed no growth since growth on this control indicated contamination of the bacterial 
cells and a new transformation was then conducted.  The following day, individual 
colonies were removed from the plate using a sterile pipette tip and added to 2 mL of 
LB Broth (10 g/L NaCl, 5 g/L Yeast extract, 10 g/L Bactotryptone) (Appendix 1) 
containing the appropriate antibiotic.  This culture was incubated for 24 h in a shaking, 
humid 37°C incubator (Bioline).  After 24 h, 200 µL of bacteria was removed and 
added to 200 mL of LB broth containing the appropriate antibiotic, and this culture was 
incubated for another 24 h in a shaking, humid 37°C incubator.  After 24 h the plasmid 
preparation (Section 2.2) was carried out.   
 
2.2.3 Plasmid purification using the Qiagen HiSpeed Maxi Kit 
Plasmid DNA was purified from 200 mL bacterial culture following the manufacturer‟s 
protocol.   
 
Briefly, the 200 mL bacterial culture was centrifuged at 6,000 g for 25 min at 4°C in a 
Sorvall Evolution RC centrifuge (Kendro Laboratory Products, Bath, UK) and the 
supernatant discarded.  The bacterial pellet was resuspended in 10 mL of resuspension 
buffer containing RNase A (Buffer P1).  To lyse the cells, the resuspended E. coli was 
transferred to a sterile 50 mL tube, and 10 mL of lysis buffer (Buffer P2) was added and 
mixed by inverting 4-6 times.  The solution was incubated for 5 min at room 
temperature then 10 mL of chilled neutralisation buffer (Buffer P3) was added to stop 
cell lysing and mixed by inverting the tube 4-6 times.  This lysate was then transferred 
into the QIAfilter Cartridge and incubated for 10 min at room temperature.  During this 
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time a HiSpeed Maxi Tip was placed over a waste container and equilibrated by the 
application of 10 mL of Buffer QBT through the filter.  The lysate was then filtered 
through the HiSpeed Maxi Tip into a waste container, trapping the DNA within the tip.  
The tip was then washed with 60 mL of wash buffer (Buffer QC), and then the DNA 
was eluted into a sterile 50 mL tube using 15 mL of elution buffer (Buffer QF).  The 
DNA was precipitated by incubation with 10.5 mL of room temperature molecular 
grade isopropanol (Sigma) for 5 min.  The isopropanol mixture was transferred into a 30 
mL syringe attached to a QIAprecipitator Maxi Module and filtered through the 
precipitator into a waste container.  The DNA remained trapped in the filter.  The 
precipitator filter was then rapidly washed with 2 mL of 70% ethanol (Ajax Chemicals, 
Auckland, NZ) via the syringe.  The filter was then air dried by quickly pushing air via 
the syringe through the filter twice, and then the filter was dried on a paper towel to 
prevent ethanol carryover.  The precipitation filter was then attached to a 5 mL syringe 
and placed over a microcentrifuge tube, 500 µL of endotoxin free buffer (Buffer TE) 
was added to the syringe and the DNA was eluted into the microcentrifuge tube.  The 
eluted DNA was then transferred back into the syringe and filtered a second time 
through the precipitator into the same tube.   
 
The yield of DNA was determined using a Nanodrop ND-1000 spectrophotometer 
(BioLab, Auckland, NZ).  The Nanodrop was initialised and then blanked using 1 µL of 
double distilled water.  A 1 µL sample of eluted DNA was placed onto the sensor and 
the amount of DNA present was measured at 230 nM.  Yields of above 500 ng/µL with 
a 260/280 ratio of 1.6-2.0 were deemed acceptable and used for transfections.      
 
If yields of 1 mg/µL or above were purified, the 2 mL culture of bacteria was frozen in 
500 µL aliquots in 20% glycerol at -80°C for future use so that transformations were not 
necessary each time plasmid was needed.  In this case, a scraping from the frozen 
bacteria stock was streaked onto a LB agar plate containing the appropriate antibiotic to 
obtain a single colony that could then be cultured in 2 mL of LB broth containing the 
correct antibiotic.   
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2.3 Cell surface biotinylation 
HEK-293 cells were plated and transfected as described in sections 2.1.2 and 2.1.3, and 
cell surface biotinylation was carried out 48 h after transfection.  Methods were carried 
out as previously described (Bolan et al. 2007; Zapata et al. 2007). 
 
KOPr agonists were dissolved in DMSO at a stock concentration of 75 mM and diluted 
further in KREBS to a working concentration of 210 µM.  From this working stock, 50 
µL of compound was added to 1 mL of medium in the cell culture dishes to give a final 
concentration of 10 µM.  Compounds were added to the dishes, and incubated for either 
the time required for maximal effect to occur, as determined by confocal microscopy 
experiments, or for 30 min.  Cells were then washed twice with ice-cold PBS/Ca-Mg 
(PBS containing 0.1 mM CaCl2 and 1 mM MgCl2, pH 8.0) (Appendix 1), and incubated 
for 30 min with 1 mg/mL of EZ-link NHS-Sulfo-SS-biotin (Pierce) in ice-cold PBS/Ca-
Mg in the dark at 4 ºC with shaking.  Cells were then washed twice with ice-cold 100 
mM glycine in PBS/Ca-Mg, and then incubated for 20 min with 100 mM glycine in 
PBS/Ca-Mg in the dark at 4 ºC with shaking.  Cells were lysed in 400 μL of RIPA 
buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 0.1% SDS, 
1% sodium deoxycholate, pH 7.5, (Appendix 1)) containing 10 μL/mL of protease 
inhibitor (Sigma) for 1 h in the dark at 4 ºC with shaking.  Lysates were transferred to 
microcentrifuge tubes and centrifuged at 16,000 g in a benchtop centrifuge (Eppendorf, 
Eppendorf South Pacific, Australia) for 30 min at 4 ºC.  A 50 μL sample of the 
supernatant was removed for the total fraction, and kept on ice and in the dark until 
needed.  Then 400 μL of the supernatant was applied to filter columns containing 100 
μL of streptavidin beads (Pierce) and incubated for 1 h at room temperature with gentle 
mixing.  The plugs were removed from the columns, and the columns were spun down 
at 4 ºC for 1 min at 500 g.  A 50 μL sample of the spun down liquid was then removed 
for the internal fraction and kept on ice in the dark until needed.  The columns were then 
washed 3 x with 400 μL of RIPA buffer by spinning at 16,000 g for 1 min.  Plugs were 
replaced in the columns, and the bound proteins were eluted with 40 μL of 5 x reducing 
buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 20% glycerol, 1% bromophenol blue 
(Appendix 1)) containing 10% β-mercaptoethanol (Sigma) for 30 min with gentle 
mixing.  The plugs were then removed from the columns, and the columns were placed 
into microcentrifuge tubes and centrifuged at 4 ºC for 1 min at 500 g to retrieve the cell 
surface fraction.  Five times reducing buffer containing 10%   β-mercaptoethanol (15 
µL) was then added to the total and internal fractions and 20 μL of the samples were 
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loaded onto 10% acrylamide gels and electrophoresed, then transferred to Western 
blotting membranes as described in section 2.4.  Using Western blotting, GAPDH 
immunoblotting was carried out as a control to ensure cells were not lysed before biotin 
was added, as GAPDH is only found intracellularly in HEK-293 cells.   
 
DAT expression was measured by the intensity of the YFP tag in the polyacrylamide 
gels prior to Western transfer and was analyzed using Image-J software. The integrated 
density of the bands from each lane was measured as one using the analyze measure, 
integrated density command.  Background readings were taken and subtracted from the 
sample bands.  The background corrected internal and cell surface bands were then 
normalized to the background corrected total protein bands, giving an arbitrary number.  
The normalised internal and cell surface numbers were then normalised to the vehicle-
treated samples for each gel so that between-gel comparisons could be made.  The 
numbers were graphed using Graphpad Prism 4 software (GraphPad Software Inc, La 
Jolla, CA, USA) and a one-way ANOVA, with a Bonferroni post test, was conducted to 
test for significance between treatment groups.       
 
2.4 SDS polyacrlyamide gel electrophoresis and Western blotting 
Protein samples from experiments were run on 10- or 15-well SDS-PAGE gels with a 
10% separating gel and a 4% stacking gel (Appendix 1).  Gels were made the day 
before the experiment and stored wrapped in double distilled soaked paper towels at 
4°C.  Gels were run for 90 min at 120 V in 1 x running buffer (3.5 mM SDS, 25 mM 
Tris base, 190 mM glycine) (Appendix 1), or until the blue dye front had run off the gel.  
After electrophoresis, the gels were removed from the electrophoresis set up and placed 
in containers containing distilled water, and YFP-hDAT was visualised with a Fuji film 
laser scanner (Fujifilm FLA-5100, Tokyo, Japan) using a 473 nm laser and BPB1 filter 
set at 800 V. 
 
After scanning, proteins were transferred onto a polyvinylidine difluoride (PVDF) (0.2 
µM pore size, Millipore Corporation, MA) membrane.  The membrane was pre-soaked 
in methanol for 1 min followed by transfer buffer (190 mM glycine, 25 mM Tris, 20% 
methanol) (Appendix 1) for 5 min before being used for transfer.  The transfer cassette 
was assembled (from back to front – black side of cassette, sponge, 3 MM filter paper, 
gel, membrane, 3 MM filter paper, sponge, clear side of cassette) and inserted into the 
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Bio-Rad Tetracell transfer set (Bio-Rad) containing an ice-pack, and the tank was filled 
with transfer buffer.  The transfer was run at 20 V for 17 h at 4°C.   
 
The following day, the membranes were washed for 5 min in 1 x Tris buffered saline 
(TBS, 50 mM Tris base, 150 mM NaCl, pH 7.5) (Appendix 1), blocked for 1 h in 5% 
bovine serum albumin (BSA) in TBS containing 0.1% Tween 20 (T-TBS) or 10% milk 
powder in T-TBS (Appendix 1) at room temperature on a rocker, and then the 
appropriate antibodies were applied as detailed in Table 2.2.  The primary antibody was 
diluted in the appropriate blocking buffer, and membranes were incubated for either 1 h 
at room temperature or overnight at 4°C on a rocker.  After the incubation with the 
primary antibody, membranes were quickly washed 3 x in T-TBS and then washed 3 x 
for 5 min in T-TBS.  The secondary antibody was then added in T-TBS and incubated 
for 1 h in the dark at room temperature with gentle rocking.  The membranes were then 
washed 3 x in T-TBS and then 3 x in TBS and read on a Fujifilm FLA5100 fluorescent 
scanner (Fujifilm, Tokyo, Japan).   Secondary antibodies labelled with Cy5 were read 
using a 635 nm laser and DBR1 filter and secondary antibodies labelled with Cy3 were 
read using a 532 nm laser with a DGR1 filter.   
 
ImageJ software was used to analyse data.  The integrated densities of the YFP-hDAT 
and immunoblotted proteins had the average background subtracted and then the density 
values were normalised to the control so that results could be compared between gels or 
membranes.  These numbers were graphed using GraphPad Prism 4 software, and 
statistical analysis was carried out.   
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Table 2.2: Antibodies used for Western blotting 
Antibody Blocking solution 
used 
Dilution 
factor 
Incubation 
time 
Secondary 
antibody 
Mouse monoclonal anti-
GAPDH (Abcam, 
supplied by Sapphire 
Bioscience, Hamilton 
NZ) 
5% BSA in T-TBS 1:6,000 1 h Anti-mouse Cy5 
(1:5,000) 
(Amersham, 
supplied by 
Global Science) 
Rabbit polyclonal anti-
tubulin 
(Abcam) 
10% milk powder 
in T-TBS 
1:5,000 1 h Anti-rabbit Cy3 
(1:5,000) 
(Amersham) 
Mouse monoclonal anti-
P-ERK42/44 (P-ERK1/2) 
(Santa Cruz supplied by 
Thermofisher, Auckland, 
NZ) 
5% BSA in T-TBS 1:500 overnight Anti-mouse Cy5 
(1:5,000) 
(Amersham) 
Rabbit monoclonal 
ERK42/44 (ERK1/2) 
(Cell Signalling supplied 
by Thermofisher)  
5% BSA in T-TBS 1: 1,000 overnight Anti-rabbit Cy3 
(1:5,000) 
(Amersham) 
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2.5 trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP
+ 
) uptake 
HEK-293 cells were plated and transfected for confocal microscopy as described in 
2.1.2 and 2.1.3 and used 48 h after transfection. 
 
2.5.1 Acute ASP
+
 uptake studies 
Methods were carried out as previously described (Schwartz et al. 2003; Bolan et al. 
2007).  The fluorescent monoamine transporter substrate 4-(4-(dimethylamino)-styryl)-
N-methylpyridinium (ASP
+
 Tocris) was made into a 10 mM stock solution in sterile 
KREBS buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4.6H20, 1.2 
mM KH2PO4, 10 mM HEPES, 10 mM D-glucose, pH 7.4) (Appendix 1).  This stock 
was diluted to a 10 μM working concentration in KREBS buffer and placed in a 37°C 
water bath with KREBS buffer.  An Olympus Fluoview FV1000 confocal laser 
scanning biological microscope (inverted model 1X81) was used to monitor ASP
+
 
uptake and binding of cells, using a 40X water immersion objective (NA = 0.9).  To 
maintain the temperature of the cells at 37ºC during confocal microscopy, a heat-plated, 
insulated, double-layer heating chamber (INU-21LCS-F1 model, Tokai Hit Co., Ltd, 
Japan) mounted on the microscope stage was filled with distilled water and allowed to 
warm to 37ºC.  ASP
+
 fluorescence was measured using a 558 nm laser (ASP
+
 filter: 570 
nm excitation; 670 nm emission) at settings of 1.7% power, high voltage (HV) 600 V, 
offset 9%, and gain 1%.  YFP fluorescence was measured using a 473 nm laser (YFP 
filter: 485 nm excitation; 545 nm emission) at settings of 0.7% power, HV 700 V, offset 
10%, and gain 1%.  Differential interference contrast (DIC) was used to visualise the 
collection of cells.  The microscope pinhole was opened to 500 μm to allow for more 
light from a greater z plane to get through.  This decreases confocality and allows ASP
+
 
accumulation to be more representative of uptake from the whole cell rather than just a 
single plane.  Agonists were made up to a stock concentration of 75 mM in DMSO and 
then diluted in KREBS buffer to a working stock of 1.01 mM so that when 10 µL was 
added to the dish of cells, the final concentrations of the agonists were 10 μM.  The 
working stock was further diluted for experiments where 5 μM and 1 μM were required.  
Control experiments were carried out using DMSO-matched solutions.  Images were 
acquired using Olympus FV10-ASW software.   
 
Acute ASP
+
 experiments were conducted as previously described (Bolan et al. 2007; 
Zapata et al. 2007).  Culture medium was removed from the 35 mm glass bottom petri 
dish by aspiration and replaced with KREBS buffer at 37ºC.  Dishes were mounted on 
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the microscope stage, and the microscope was focused on the cell layer.  Once an 
appropriate area of cells was located, KREBS buffer was removed and the time course 
started (120 scans, every 5 s).  Once the first image was collected, ASP
+
 at 37ºC was 
added.  At 250 s (DS-1-240, DS3-214, and U50,488H) or 300 s (Salvinorin A) after 
ASP
+
 was added, 10 µL of the agonist was added.  For experiments in which the KOPr 
antagonist norbinaltorphimine (nor-BNI in sterile KREBS buffer, Sigma) was used, 
dishes were incubated with 1 μM nor-BNI 30 min prior to the addition of ASP+.  For 
experiments in which pertussis toxin (PTX in sterile PBS, Sapphire Bioscience) was 
used, dishes were incubated with 100 ng/ml of PTX for 16 – 24 h before the ASP+ was 
added.   
 
2.5.2 30 min ASP
+
 studies 
For 30 min ASP
+
 experiments, the agonist or an equal volume of DMSO (control) was 
added to the cells in their culture medium at a final concentration of 10 µM, and cells 
were returned to the incubator for 30 min.  After the 30 min incubation, culture medium 
was replaced with fresh KREBS buffer containing the agonist, and an appropriate area 
of cells was chosen for measuring uptake.  The same microscope settings were used as 
for the acute ASP
+
 uptake experiments except that a time course of 70 images, 5 s apart 
was used.  The KREBS buffer was removed and the time course started.  After the first 
image was collected, ASP
+
 containing the agonist was added and the subsequent 
uptakes were measured.    
 
2.5.3 ASP
+
 binding studies   
A single image was taken of the cells used in the ASP
+
 uptake experiments using the 
DIC, YFP and ASP
+
 filters (settings same as in section 2.5.1 above).  The KREBS 
buffer was then removed, and 10 µM of the agonist was added in fresh KREBS buffer.  
The cells were incubated for the time taken for the maximal effect to be reached as 
determined in the uptake studies (Section 4.3.1).  A solution of ASP
+
 containing the 
agonist was then added, and a time-course of 100 scans was started, imaging DIC and 
ASP
+
 at maximum speed.  This allowed the initial binding of ASP
+
 to DAT to be 
measured.   The slope of the line was analysed as described below. 
 
2.5.4 Data analysis for ASP
+
 uptake and binding studies   
Cells expressing YFP-hDAT were manually outlined using Fluoview FV1000 software, 
and these regions of interest (ROI) were graphed over time to show the changes in ASP
+
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fluorescence.  The data from these graphs were then transferred into a Microsoft Excel 
spreadsheet, and each cell‟s ASP+ uptake was graphed individually.  Cells that did not 
have linear ASP
+
 uptake graphs were discarded as this indicated that the cells moved or 
drifted over the period of the experiment.  The initial YFP fluorescence was also 
recorded so that cells could be selected based on their YFP-hDAT expression.  Cells 
expressing less than 250 arbitrary fluorescence units (AFU) or more then 1000 AFU of 
YFP-hDAT were not used. 
  
To analyse ASP
+
 uptake data, a linear trendline was generated for a period of 60 s, 10 s 
before KOPr agonist addition, and compared to a linear trendline created for a period of 
60 s after drug addition at the time of maximal change in uptake.  The change in slope 
was then calculated as a percentage change ((slope after drug/slope before drug)x100) 
and graphed using Graphpad Prism.  For 30 min agonist treatment experiments, the 
AFU at 300 s was taken and normalised to the YFP-hDAT expression from the first 
image.  This normalised number was compared to DMSO-treated controls.  For binding 
studies the change in binding was analysed using data from 3 to 7 s after ASP
+
 addition.  
The slope of this line was normalized to the amount of YFP expressed on each cell, as 
seen from the initial scan at t = 0.  Maximal change in uptake was determined by taking 
the slope of the 60 s-trendline 30 s, 60 s, 100 s, 150 s, 200 s, 250 s after agonist addition 
to find the time where the greatest change was seen. 
 
GraphPad Prism was used to carry out one-way ANOVAs followed by Bonferroni Post 
tests on ASP
+
 uptake and binding data. 
 
2.6 Total internal reflection fluorescence microscopy (TIRFM)  
TIRFM methods followed the protocol of Furman et al. (Furman et al. 2009a) 
(Appendix 2, see DVD for representative movie).  HEK-293 cells were plated and 
transfected for confocal microscopy as described in section 2.1.2 and 2.1.3 and used 48 
h after transfections.  An Olympus Fluoview 2000 microscope and a QImaging Digital 
Camera 6.2.0.6 (QImaging ROLERA-MGI Fast1394; Surrey, BC, Canada) were used to 
conduct TIRFM.  The cell heating chamber from section 2.5.1 was placed on the 
microscope stage and heated to 37°C, and carbogen gas (95% O2, 5% CO2) was gently 
blown through the cell chamber throughout the experiment to maintain optimal pH.  A 
300 μL syringe containing the compound to be tested was inserted into an inlet port of 
the cell chamber, and the dishes containing the transfected cells were placed in the cell 
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chamber.  Cells were focused on using the 100X objective lens (Olympus, PLAPO 
100X, OTIRFM, NA 1.45), and cells were left to equilibrate in the enclosed cell 
chamber for 20 min.  A region of cells was then chosen using FITC epi-fluorescence, 
the TIRFM camera and Image Pro Plus 7.0 acquisition software (MediaCybernetics, 
Bethesda, MD, USA).  The microscope was then set to TIRFM, with a penetration 
depth of 100 nm, a FS of 11 mm and a refractive index of the sample of 1.52 and the 
microscope was focused on the cell membrane where it adhered to the glass-bottom 
dish.  Cells were chosen that were expressing YFP-hDAT and were able to be clearly 
seen at a laser power of 0.5% (473 nm laser, YFP filter: 485 nm excitation; 545 nm 
emission).  The camera (QImaging Digital Camera, 6.2.0.6) was set to an acquisition 
area of 512 x 512 pixels, with a capture depth of 14 bit mono (16 bit image class) and 
an exposure preview of 00.902.580 s with a capture exposure time of 3 s using Image 
Pro Plus Software.  
 
For short time-courses, images were captured every 5 s for 60 images.  After 20 images, 
50 µL of agonist was added through the syringe.  For 40 min time courses, the first 
image was captured at time 0, and then images were captured every 1 min for 40 min 
(40 total scans).  After 10 min, 50 μL of KOPr agonist was added using the inlet port 
syringe so that the final concentration in the dish was 10 µM.   For the 40 min 
experiment the laser had to be manually turned off and on between scans so that the 
samples were not photo-bleached over the 40 min.  Controls showed no significant 
photo-bleaching over either of these time-courses.  
 
Images were analysed using Image J.  Each cell was manually traced around at each 
scan time and the average pixel intensity was taken.  These numbers were normalised to 
the first scan, and the normalised values were graphed in Graph Pad Prism. 
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Chapter 3:  Effect of KOPr agonists on the function of DAT and SERT 
in minced brain tissue from the rat 
 
3.1 Introduction 
The KOPr regulates DA concentrations in the synapse, with acute treatment leading to 
an overall decrease in DA, and chronic KOPr treatment appearing to cause an increase 
in DA in the synapse.  This effect has been shown to be mediated both by a decrease in 
release of DA (Di Chiara and Imperato 1988b), and an increase in DAT function 
(Thompson et al. 2000).  KOPr activation has also shown anti-addictive affects in 
animal models.  Acute KOPr agonist treatment inhibits the locomotor-stimulated effects 
of cocaine (Collins et al. 2001a; Collins et al. 2001b) and prevents cocaine-primed 
reinstatement in rats (Schenk et al. 1999; Morani et al. 2009).   Previous RDEV studies 
have shown that acute addition of KOPr agonists leads to increased function of DAT in 
rat NAc tissue (Thompson et al. 2000).  An acute treatment following intraperitoneal 
injection (0.32 mg/kg) of the classic KOPr agonist U69,593 leads to a significant 
increase of DAT function after 2 h, and this effect is inhibited by prior treatment with 
the KOPr antagonist nor-BNI (Thompson et al. 2000). 
 
Chronic treatment with KOPr agonists decrease DAT density in the caudate putamen 
(Collins et al. 2001a; Collins et al. 2001b) but decreases DAT function in the NAc 
(Thompson et al. 2000).  This indicates that long-term administration of KOPr agonists 
have the opposite effect to acute treatment with agonists given as a single dose.  
However, there have also been studies reporting no change in DAT function after KOPr 
agonist addition, with the decrease in DA in the tissue solely due to decreased DA 
release through interactions with D2 autoreceptors (Izenwasser et al. 1998).  Therefore, 
while stimulation of the KOPr affects the DA system, the role of DAT in this process is 
not completely clear.    
 
SERT function also plays an important role in drug addiction due to involvement in 
depression and withdrawal symptoms.  Common techniques used to measure SERT 
function in cells, synaptosomes, and in vivo tissue systems include high-speed 
chronoamperometry (HSC), fast scan cyclic voltammetry (FSCV), and radioactive 
uptake studies.  These studies have characterised Michaelis-Menten kinetics for 5-HT 
uptake (Kokoshka et al. 1998; Zhu et al. 2005), clarified the ion dependence of SERT 
 67 
 
function (Ramamoorthy and Blakely 1999), highlighted differences in 5-HT uptake in 
different brain regions (Daws et al. 2005), determined the binding orders of substrates to 
SERT (Ramamoorthy et al. 1993), and defined the inhibition constants of drugs and 
therapies for SERT function (Kokoshka et al. 1998; Zhu et al. 2005; John and Jones 
2007a).  While FSCV and HSC both provide detailed kinetic information both in vivo 
and in vitro, they are technically difficult and require expensive, specialised equipment.  
Radioactive uptake studies have provided information on transporter densities and 
kinetics, but the technique is unable to measure real-time uptake of 5-HT or initial 
uptake kinetics due to the extended time required for radioligand addition and washing 
steps.   
 
RDEV is an established electrochemical technique for the measurement of real-time DA 
and norepinephrine uptake and release in both cells and tissues (Meiergerd and Schenk 
1995; Burnette et al. 1996; Earles and Schenk 1998; Burgess et al. 1999; Chen et al. 
1999a; Chen and Justice 2000; Chefer and Shippenberg 2002).  The RDEV set-up 
consists of three electrodes: a rotating glassy carbon electrode, a reference Ag/AgCl 
electrode, and an auxiliary platinum electrode.  The rotating glassy carbon electrode is 
rotated at 2000 rpm which keeps the sample in the chamber well mixed and also leads 
to the formation of a diffusion layer around the submerged electrode (Earles and Schenk 
1998).  As the DA, norepinephrine, or 5-HT in this layer are oxidised to their quinone 
counterparts, they release 1 or 2 electrons, generating a current.  As these substrates are 
oxidised, new species from the surrounding liquid move into the diffusion layer and are 
also oxidised.  Therefore, as DA, norepinephrine, or 5-HT are transported into cells or 
tissue in the chamber there is a decrease in free monoamine substrate, leading to a 
decrease in oxidation, and a decrease in current.  As this method can take up to 1000 
measurements per second, real-time uptake can be measured in both cells in suspension 
and tissue homogenates.  
 
The theory of RDEV is described by the Levich equation: 
 
IL = 0.62nFACD
2/3
v
-1/6ω1/2 
 
in which IL is the limiting current, n is the number of electrons transferred per mole, F is 
Faraday‟s constant (96,485 coulombs/equivalent of electrons), A is the area of the 
electrode in cm
2
, D is the diffusion coefficient of the electroactive species in cm
2
/sec, C 
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is the concentration of the electroactive species in the bulk solution in mM, v is the 
kinematic viscosity of the solution in cm
2
/sec, ω is the angular velocity of rotation in 
rad/sec, where ω = 2πN, and N is the number of rotations per second (Earles et al. 
1998).  This equation defines the current that is measured at the solid electrode surface.  
RDEV is a simple and relatively cheap technique to set up and gives detailed 
information about Michaelis-Menten kinetics (Earles et al. 1998), drug effects (Earles 
and Schenk 1999a; Thompson et al. 2000), ion dependency of transporters (Chen et al. 
1999a; Bjorklund et al. 2007), and binding information (Chen et al. 1999a; Earles and 
Schenk 1999a).  
 
There are two different methods of RDEV which can be used to determine kinetic 
values of monoamine transporters.  The first is known as the zero trans model where a 
single addition of monoamine neurotransmitter is added to a single piece of tissue.  This 
is repeated over a range of neurotransmitter concentrations, with each concentration 
being added to a fresh piece of tissue.  The other method is known as the low to infinite 
trans model in which the neurotransmitter is added to the tissue sequentially from the 
lowest concentration to the highest, allowing the nA to reach baseline between each 
addition.  This method gives comparable results to single addition studies (Povlock and 
Schenk 1997) and was used here to decrease the number of animals needed in the study.     
 
At the beginning of this study there were no published data using RDEV to measure 
SERT function.  However, a recent publication has used RDEV to measure SERT 
function in mouse whole brain synaptosomes, comparing uptake between SERT 
knockout and wild type mice (Hagan et al. 2010).  It was found that SERT kinetics 
could be easily measured using RDEV, with wild type mice having much higher uptake 
than heterozygous and homozygous SERT knockout mice. The uptake was inhibited by 
the SSRI paroxetine hydrochloride (Hagan et al. 2010).  This study demonstrated that 
RDEV could be used to sensitively measure SERT kinetics within tissue samples, with 
the differences seen in uptake between the three genotypes of mice not always able to 
be measured using other, less sensitive techniques. Radioactive uptake studies of SERT 
function, for example, have been unable to distinguish between the heterozygous SERT 
knockout mice and normal mice (Bengel et al. 1998).  
 
A recent paper by Volz et al., also established the use of frozen tissue for RDEV 
experiments, measuring the activity of DAT and vesicular monoamine transporter 2 
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(VMAT2) from frozen rat striatum (Volz et al. 2009).  In this paper the brain regions of 
interest were removed, weighed, cooled in ice-cold KREBS buffer for up to 45 min and 
then stored dry at -80°C for up to 8 weeks.  Uptake by DAT was decreased by 55-60% 
after 1 to 8 weeks of freezing (Volz et al. 2009).  The ability to carry out RDEV on 
frozen rat tissue is valuable as it allows for greater consistency (since measurements of 
frozen tissue can be carried out at the same time) when carrying out chronic 
experiments involving injecting animals over several days.  This means that all the brain 
samples can be processed on one day within a short time period and frozen for RDEV 
measurements later.  This leads to tighter data as the time of death after the last drug 
treatment is less variable between the animals; therefore, any changes to the transporter 
caused by the drug will still be present.  As our laboratory carries out many experiments 
requiring drug treatment of animals over a number of days, one of our aims was to 
investigate whether tissue frozen for one week still had measurable SERT function. 
    
In this chapter, we characterise SERT function in more commonly used RDEV samples: 
a cultured cell model and homogenised striatal tissue of rat brain, and find that SERT 
function is ion and temperature dependent, increased by activation of p38 MAPK and 
decreased by the SSRI fluoxetine (Prozac).  Rat striata frozen for 1 week still exhibited 
SERT function, making it possible to freeze brain samples of rats after experiments that 
required chronic drug treatment, thus, increasing the number of brain regions that could 
be analysed and improving the accuracy of the results. KOPr activation was also shown 
in our study to affect 5-HT levels in the brain. At least some serotonergic neurons in the 
medial rostral ventral medulla express KOPr (Kalyuzhyny and Wessendorf 1999), and it 
has been suggested there is a direct link between  KOPr and SERT (Schenk et al. 2000).   
 
Some studies using acute KOPr agonist treatment have reported increased 5-HT in the 
rat and human neocortex through increased 5-HT release (Berger et al. 2006), although 
others have shown no change of 5-HT release in the dorsal and median raphe nucleus or 
the NAc (Tao and Auerbach 2002; Carlezon et al. 2006), or an inhibition of 5-HT 
release after KOPr addition in mouse hippocampal synaptosome preparations (Grilli et 
al. 2009).  The interaction between KOPr and 5-HT also appears to have a role in 
addiction, especially in relation to cocaine abuse.  Cocaine-induced locomotion was not 
inhibited by chronic KOPr agonist treatment after depletion of 5-HT by 
parachloroamphetamine, suggesting that 5-HT has a role in this KOPr effect (Zakharova 
et al. 2008b).  After this treatment there was also a brain region-specific decrease in 
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SERT in the olfactory tubercle, claustrum, endopiriform and lateral septal nucleus 
(Zakharova et al. 2008b).  Another study carried out in squirrel monkeys found that 
fluoxetine as well as the KOPr agonist spiradoline led to inhibition of cocaine-induced 
reinstatement, and this effect was reversed for both drugs by the 5-HT1A agonist 8-OH-
DPAT, implying that the effect of the KOPr agonist involves a 5-HT pathway (Ruedi-
Bettschen et al. 2010).  Overall, these data suggest that 5-HT plays an important role in 
the link between cocaine and the KOPr.   
 
As DA and 5-HT play major roles in addiction, compounds that alter their function may 
be useful as pharmacotherapies.  Classic KOPr agonists have anti-addictive properties 
in animal models, but also lead to side effects such as dysphoria and depression, 
especially after long-term use (Negus et al. 1997).  While several KOPr agonists have 
been trialled in cocaine-abusing humans, these agonists have had little effect on drug 
taking behaviour (Walsh et al. 2001a; Preston et al. 2004).  This may be due to the 
relatively low dose used in most studies since the drug needs to be tolerated by the 
patients, or it could be that the KOPr agonists investigated did not have high enough 
affinities for the KOPr.  Therefore, while KOPr agonism has potential to attenuate drug 
taking in humans, the classical KOPr agonists do not show promise as 
pharmacotherapies.  The KOPr agonist salvinorin A possesses a novel structure and has 
similar anti-addictive properties to classical KOPr agonists in rats self-administering 
cocaine (Morani et al. 2009).  The two novel agonists DS-1-240 and DS-3-216 have 
also shown anti-addictive effects in rats self-administering cocaine (A. Morani, 
unpublished data).  There have been many structural analogues of salvinorin A 
synthesised, and screening of these compounds has identified a new set of highly active 
KOPr agonists.  As these compounds are highly selective and have a novel structure, 
they may have potential for use in anti-addiction pharmacotherapies, and therefore the 
effects of these compounds on DAT and SERT need to be investigated. 
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3.2 Aim 
The KOPr modulates DA and 5-HT levels in the brain, and this is partially thought to be 
due to changes in DAT and SERT function.  The aim of this chapter was to investigate 
the effects of KOPr agonists on the function of DAT in a tissue model from drug naïve 
rats.   This chapter also aimed to establish measurement of SERT function by RDEV in 
a cell model and minced rat striatal tissue and the effect of KOPr on SERT modulation 
was investigated.    
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3.3 Methods 
3.3.1 Standard curve 
For the RDEV, each day before starting an experiment a standard concentration-
response curve was created in KREBS buffer using different concentrations of DA.  A 
linear regression was then calculated from the increase in current (nA) at each DA 
concentration so that data collected from tissue samples could be transformed into μM 
based on the measured nA values. 
 
3.3.2 Tissue sample preparation 
Male Sprague-Dawley rats (250–325 g), housed in the School of Psychology animal 
facility of VUW, maintained on a 12-hour light/dark cycle and given free access to food 
and water were euthanized according to VUW animal ethics guidelines.  Ethics 
approval was obtained from the VUW animal ethics committee prior to the study.  Rats 
were decapitated after CO2 euthanasia, and the brain was rapidly removed and placed in 
an acrylic stereotaxic brain matrixes block (Alto, AgnTho‟s AB, Sweden).  A 2 mm 
coronal section from between the interaural co-ordinates +9 to +11
 
mm was removed, 
and the striatum (one side) and NAc (both sides) were removed.  A 2 mm coronal 
section from between the interaural coordinates +12 to +14 mm was also removed, and 
the medial PFC was dissected from the section.  Tissue was weighed and then minced 
with an ice-cold razor blade on an ice-cold glass petri dish for 30 s in 300 μL of ice-cold 
KREBS buffer.  Samples that were not used straight away could be kept on ice for up to 
20 min before a measurable loss in transporter function was seen.  Samples that needed 
to be kept for longer than this were incubated in KREBS buffer in a 37ºC incubator and 
aerated with 95%O2/5%CO2 (Carbogen).  The minced tissue was then put into a 
microcentrifuge tube and left to settle.  Tissue pieces were washed 8 times in warmed 
KREBS buffer allowing for tissue to settle between each wash.  The tissue suspension 
was then added to the RDEV chamber (kindly donated by J. B. Justice Jr.) in 294 µL of 
37ºC KREBS buffer.  The rotating glassy carbon electrode (Pine Instruments, special 
order AFMDO3GC, Pennsylvania) was lowered into the chamber and rotated at 2000 
rpm with an MSR rotator (Pine Instruments).  A potential of +450 mV relative to the 
Ag/AgCl reference electrode was applied to the electrode by an eDAQ potentiostat 
EA161 (eDAQ, NSW, Australia).  The resulting current was recorded by an eDAQ 
ecorder 210 (eDAQ, NSW, Australia) and saved using Chart software (eDAQ, NSW, 
Australia). 
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3.3.3 Experimental procedure 
Once the nA reading in the absence of substrate had reached a stable baseline, the KOPr 
agonist (500 nM, unless stated otherwise) or vehicle control (DMSO-matched) was 
added for the required time followed by DA.  For the low to infinite trans model 
(Meiergerd et al. 1994a; Povlock and Schenk 1997), increasing concentrations of DA 
were added, and the nA output was allowed to reach baseline between each addition.  
For single additions, once the nA had reached baseline, the single addition (2 µM) was 
made and the measurement of nA was continued for 30 s.  For medial PFC experiments, 
once baseline had been reached the NET inhibitor desipramine-HCl (1 µM, Sigma) was 
added for 5 min prior to the DA addition.  For the nor-BNI experiments, tissue was 
incubated with 1 µM nor-BNI (Sigma) in carbogen-aerated, 37°C KREBS buffer for 30 
min in an incubator at 37°C.  Every 2 min, after the tissue pieces had settled, the 
KREBS buffer was removed and fresh KREBS buffer containing 1 µM nor-BNI was 
added.  This washed the tissue and prevented tissue degradation.  For the controls in this 
experiment, tissue was treated the same but not in the presence of nor-BNI.  This 
incubation technique allowed other brain regions to be investigated for other studies 
during the 30 min incubation to save on the number of rats needed for the study.  
 
For 5-HT tissue experiments, procedures were carried out as stated above except that 1 
µM of the DAT inhibitor GBR12909 was used to inhibit DAT function.  For frozen 
tissue samples, the protocol was followed as previously described (Volz et al. 2009).  
Briefly, rat striata were removed, weighed, and then frozen at -80ºC for 1 week.  Before 
use, striata were thawed at 22ºC for 20 min, and then minced and washed as above. For 
experiments with fluoxetine (10 µM, Tocris, UK) and anisomycin (1 µM, Sigma), 
compounds were added 5 min before the first addition of 5-HT.  For Na
+
 and Cl
-
 free 
assays, and temperature dependent assays, a single addition of 5-HT to a final 
concentration of 1.5 µM was made after baseline had been reached.Between each 
measurement within an experiment, the rotating electrode was cleaned with milliQ 
water on a Buechler Microcloth (Pine Instruments) for 30 s, rotating at 2000 rpm.  After 
each set of experiments, the electrode was then cleaned by hand with a 0.05 micron 
aluminium slurry on a Buechler Microcloth (Pine Instruments) followed by milliQ 
water before initiating another set of experiments.  This prevented inconsistency due to 
fouling of the electrode, a problem seen with 5-HT that is more serious than with DA as 
a substrate. 
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3.3.4 RDEV with GFP-hSERT transfected HEK-293 cells 
HEK-293 cells were seeded into 100 mm tissue culture dishes and transfected as 
described previously (Sections 2.1.2 and 2.1.3) except that they were transfected only 
with GFP-hSERT at a plasmid concentration of 1 µg/mL  After 48 h, when the cells 
were 80-100% confluent, RDEV experiments were conducted on a suspension of cells 
following detachment by trituration of the dish.   
 
Cells were washed twice with 37ºC saline (138 mM NaCl, 4.1 mM KCl, 5.0 mM 
KH2PO4, 2% w/v D-glucose, pH 7.3) (Appendix 1) and then harvested by mechanical 
agitation with 37ºC KREBS buffer saturated with 5%CO2/95%O2.  Cell suspensions 
were then centrifuged at 300 g for 5 min.  The cells were resuspended in 1.2 mL 37ºC 
KREBS buffer saturated with 5%CO2/95%O2, and stored in an incubator at 37ºC until 
needed, but for no longer then 30 min.  For temperature dependent experiments cells 
were treated the same way as above, but the KREBS buffer was 20ºC rather than 37ºC.  
For Na
+
-free experiments, the Na
+
 in the KREBS buffer was replaced with choline (130 
mM choline, 1.3 mM KCl, 2.2 mM CalCl2, 1.2 mM MgSO4.6H2O, 1.2 mM KH2PO4, 10 
mM HEPES, 10 mM D-glucose) (Appendix 1), and for Cl
-
-free experiments, Cl
-
 was 
replaced with acetate (130 mM NaCH3CO2, 1.3 mM KCH3CO2, 2.2 mM Ca(CH3CO2)2, 
1.2 mM MgSO4.6H2O, 1.2 mM KH2PO4, 10 mM HEPES, 10 mM D-glucose) 
(Appendix 1).   
 
For 5-HT cell uptake assays, 300 µL of the cell suspension was added to the RDEV 
chamber, the rotator lowered and turned on, and the cells and incubated until a constant 
baseline was reached.  Then a single addition of 5-HT was added to a final 
concentration ranging from 0.1 to 3 µM.  Uptake was recorded for 30 s.  For Na
+
 and 
Cl
-
 free assays and temperature dependent assays, a single addition of 5-HT to a final 
concentration of 1.5 µM was made after baseline had been reached.   After each 
experiment the cells were placed into a separate tube and cell number was determined 
using a haemocytometer and 0.4% trypan blue.  Transfection percentages were 
calculated by visualisation of eGFP-hSERT using a fluorescence microscope (AX70, 
Olympus, Mt Waverly, Australia).  For experiments with anisomycin (Tocris, UK), a 
final concentration of 1 µM was added 5 min before 5-HT addition.  
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3.3.5 Data analysis 
To measure the initial uptake of the tissue or cells, 10 s of uptake data was collected 1 s 
after addition of DA or 5-HT.  These data were plotted in Microsoft Office Excel, and a 
linear regression was calculated.  Any linear regression with an R
2
 value of less than 
0.95 was not used in the study.  The uptake of DA or 5-HT by the tissue sample over 1 s 
was calculated from the change in current and then transformed into µmol using the 
standard concentration curve calculated at the beginning of the experiment.  For tissue 
experiments, the uptake in μmol per s was then divided by the tissue weight in g to work 
out the uptake in μmol per s per g. This was then expressed in pmol/s/g.  For cell 
experiments, the uptake in µmol/s was normalised to 10
6
 transfected cells and expressed 
as pmol/s/10
6
cells.  For the low to infinite trans model and cell kinetic experiments, 
initial uptake values were entered into GraphPad Prism, and a nonlinear regression 
(One-site binding hyperbole) was fitted to each repeat.  The Vmax and Km values were 
then obtained for each repeat and then the average Km and Vmax values were 
calculated.   
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3.4 Results 
3.4.1 Effects of KOPr agonists on DAT function in brain tissue samples from drug 
naïve rats 
Previous RDEV experiments have shown that acute injections of the KOPr agonist 
U69,593 into rats led to an increase in DAT function (Thompson et al. 2000).  To 
investigate the effects of KOPr agonists on DA uptake in isolated brain regions involved 
in reward behaviour, the striatum, NAc and medial PFC from drug-naïve rats were 
incubated with the test compounds (500 nM) for 1 or 4 min before addition of a single 
concentration of DA (2 µM).  Results showed that salvinorin A acted quickly, with a 
short duration.  Increases in uptake of between 215% and 300% were observed by 1 min 
(Figure 3.1) in these tissue regions.  The two novel compounds DS-1-240 and DS-3-216 
both had effects similar to those of U50,488H, with increases in uptake occurring of 
170%, 200%, and 180-270%, respectively, after 4 min in all brain regions (Figure 3.1).  
Uptake by DAT in the medial PFC is much lower than that in the striatum and NAc 
since the medial PFC has a much lower concentration of DAT (Sesack et al. 1998).  By 
4 min, the salvinorin A effect was lost, suggesting that it was degraded quickly by the 
tissue in the KREBS buffer. 
 
The kinetics of uptake provides information on changes in affinity of a substrate for a 
transporter (Km) and the maximum uptake velocity (Vmax).  Changes in Vmax with no 
change in Km also indicate changes in cell surface expression of DAT, with a decrease 
in Vmax indicating decreased cell surface expression and an increase suggesting an 
increase in cell surface expression.  Therefore, kinetic experiments were carried out to 
determine how the test compounds affected Km and Vmax values.   The classic KOPr 
agonist U69,593 was also used in this experiment as a positive control for the kinetic 
data (Thompson et al. 2000).  After a 1 min incubation with salvinorin A and a 4 min 
incubation with U69,593, U50,488H, DS-1-240, and DS-3-216, RDEV was carried out 
using the low to infinite trans model.  These results showed that all of the agonists led to 
a significant increase in Vmax with no change in Km (Figure 3.2, Table 3.1).  This 
suggests that an increase in cell surface expression occurs after incubation with these 
compounds.  Because of the apparent short duration of salvinorin A and its unexpected 
kinetics, single addition studies were carried out using a lower concentration (100 nM) 
of salvinorin A to see if decreasing the amount added would decrease the possible 
degradation of the compound, which we proposed to have been fouling the electrode.  
This concentration is also the one used in the previous study that demonstrated 
 77 
 
increased uptake of DA after a 5 min incubation with salvinorin A (T. Shippenberg, 
unpublished data).  Single additions of DA, added 1 or 4 min after incubation of NAc 
tissue with 100 nM salvinorin A showed significant increases in DA uptake (*p<0.05, 
One-way ANOVA followed by Bonferroni post test) (Figure 3.3).   
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Figure 3.1:  Effect of KOPr agonists on DA uptake in the striatum, nucleus 
accumbens, and medial prefrontal cortex.  The striatum (A), NAc (B) and medial 
PFC (C) were pre-incubated with KOPr agonists for 1 or 4 min before DA (2 µM) 
addition.  Salvinorin A showed a fast onset of action, with an increase in uptake seen at 
1 min that was lost by 4 min, whereas U50,488H, DS-1-240, and DS-3-216 had their 
maximum effect after 4 min. (n = 5-8 tissue homogenates).  One way ANOVA, 
followed by Bonferroni post test.  *p<0.05, **p<0.01, ***p<0.0001 compared to 
appropriate control. 
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Figure 3.2:  The effect of KOPr agonists on DAT kinetics in the nucleus 
accumbens.  Nucleus accumbens tissue was pre-incubated with vehicle, the classic 
KOPr agonists U50,488H and U69,593, salvinorin A for 1 min or the novel KOPr 
agonists DS-1-240 and DS-3-216 for 4 min before sequential addition of DA.  Data 
points shown are average ± SEM (n = 6-8 tissue homogenates).  
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Table 3.1:  Uptake kinetics of DAT in the nucleus accumbens 
Treatment Vmax (pmol/s/g) Km (µM) 
Control 1026 ± 181 1.5 ± 0.6 
U50,488H 1979 ± 335* 2.3 ± 0.8 
U69,593 2424 ±  255** 2.7 ±  0.6 
Salvinorin A - - 
DS-1-240 1509±  115* 1.5 ±  0.5 
DS-3-216 1592 ± 176* 1.6 ± 0.4 
*p<0.05, ***p<0.001 compared to control of Vmax or Km.  Student‟s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.3:  The effect of 100 nM salvinorin A on uptake of 2 µM DA in the rat 
nucleus accumbens.  Addition of 100 nM salvinorin A for 1 and 4 min caused an 
increase in DA uptake, One-way ANOVA followed by Bonferroni post test, *p<0.05.  
(n = 5-7 tissue homogenates). 
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3.4.2 The effect of KOPr agonists on DAT function is reversed by the KOPr antagonist 
nor-BNI 
To confirm that the increase in DAT function after KOPr agonist incubation was 
mediated through the KOPr, the KOPr antagonist nor-BNI was added 30 min prior to 
the incubation with the KOPr compounds.   After rat striatal tissue had been minced, it 
was placed in a 37°C incubator in carbogen-bubbled (aerated) KREBS buffer containing 
vehicle (KREBS buffer) or 1 µM nor-BNI.  The KREBS buffer containing vehicle or 
nor-BNI was replaced with freshly aerated buffer every 2 min to wash the tissue and to 
prevent tissue death.  The tissue was then transferred to the RDEV chamber, where, 
once a  steady baseline had been reached, 500 nM KOPr agonist was added at 1 min 
(salvinorin A) or at 4 min (U50,488H, DS-1-240, DS-3-216).  A single 2 µM addition 
of DA was made, and uptake was measured.  Incubation of tissue for 30 min prior to 
addition of KOPr agonist led to an inhibition of the agonists‟ effect.  Figure 3.4a shows 
that all the compounds led to a significant increase in uptake compared to DMSO (One-
way ANOVA followed by Bonferroni post test, p<0.05-0.001).   Prior incubation with 
nor-BNI led to a significant reversal of the effect of these compounds (One-way 
ANOVA followed by Bonferroni post test, p<0.05-0.001).  Incubation of tissue with 
nor-BNI followed by treatment with vehicle led to no change in DA uptake (Figure 
3.4b). 
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Figure 3.4:  Nor-BNI inhibition of the effects of KOPr agonists on DAT function in 
the rat striatum.  A) Incubation of striatal tissue with the KOPr agonists led to a 
significant increase in DA uptake, which was reversed by pre-incubation for 30 min 
with nor-BNI.  B) Addition of nor-BNI on its own had no effect on DA uptake.  One-
way ANOVA followed by Bonferroni post test, *p<0.05, ***p<0.001 compared to 
DMSO control, #p<0.05, ###p<0.001 compared between agonist treated and nor-BNI 
pre-treated (n = 3-6 tissue homogenates).  
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3.4.3 Establishment of RDEV for measurement of SERT in cells transfected with GFP-
hSERT and in rat striatal tissue  
3.4.3.1 Transfected cell model 
Initial experiments were carried out using non-transfected HEK-293 cells that lack 
SERT to establish the non-specific decay or uptake of 5-HT in the system (Figure 3.5).  
The baseline decay occurred in a linear fashion, with the slope of the line equalling 
6.355 pmol/s/10
6
 cells (r
2
 = 0.9891).  The non-specific decay was subtracted from 
subsequent recordings obtained in GFP-hSERT transfected cells.  The addition of 5-HT 
to HEK-293 cells transfected with GFP-hSERT led to uptake of 5-HT that followed 
Michaelis-Menten kinetics (Figure 3.5). An average Vmax of 92 pmol/s/10
6
 cells and a 
Km of 1.91 µM were obtained (Table 3.2).   
 
Effect of ions and temperature on 5-HT uptake 
As 5-HT uptake is Na
+
/Cl
-
 dependent, with 1 Na
+
 and 1 Cl
-
 transported per 5-HT 
molecule, decreasing the concentrations of these ions should lead to decreased uptake of 
5-HT (Ramamoorthy et al. 1992).  Experiments were carried out with single additions 
of 5-HT at 1.5 µM as this is close to the Km value gained in the above kinetic 
experiments.  When extracellular Na
+
 was replaced with choline, uptake of 5-HT was 
significantly decreased compared to normal conditions (Figure 3.6), with only 24% of 
control uptake being obtained (p<0.001).  When extracellular Cl
-
 was replaced with 
acetate, a significant decrease in uptake was also observed at 29% of control uptake 
(Figure 3.6) (p<0.001).  This demonstrates the importance of Na
+
 and Cl
-
 in 5-HT 
transport in this cell system. Uptake of 5-HT by SERT is temperature dependent, with 
maximal uptake occurring at 37ºC.  When temperature was decreased to 20ºC, uptake 
was significantly decreased to only 16% of control uptake at 37°C (p<0.001). 
 
Effect of the p38 MAPK activator anisomycin on 5-HT uptake  
 p38 MAPK is a signalling pathway that activates SERT function, causing an increase in 
the affinity of SERT for 5-HT and no change in Vmax (Zhu et al. 2005).  A 1 µM 
concentration of the p38 MAPK activator anisomycin has previously been shown to 
increase SERT function in cell models after a 2 – 10 min incubation (Oz et al. 2010b).  
In the present study, after a 5 min incubation with anisomycin, there was a trend 
towards a decrease in Km (0.96 µM, p = 0.1) with no change in Vmax (Figure 3.7, 
Table 3.2). 
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Figure 3.5: Uptake of 5-HT in non-transfected and GFP-hSERT transfected HEK-
293 cells.  Non-transfected and GFP-hSERT transfected HEK-293 cells were treated 
with single doses of 5-HT, and initial decay/uptake was measured by RDEV.  Uptake 
from non-transfected cells (non-specific) decay was subtracted from transfected cell 
data (total) to give the specific initial uptake of 5-HT by GFP-hSERT.  Data points 
represent the mean ± SEM (n = 6 preparations). 
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Figure 3.6:  Ion and temperature dependence of 5-HT uptake in HEK-293 cells 
transfected with GFP-hSERT.  Transfected cells were treated with a single 1.5 µM 
dose of 5-HT in normal conditions, in Na
+
 free conditions, in Cl
-
 free conditions and at 
20ºC.  Uptake was measured by RDEV. Buffer lacking extracellular Na
+
 or Cl
-
, or 
experiments carried out at 20ºC had significantly decreased uptake compared to controls 
treated at 37ºC.  Data points represent the mean ± SEM (n = 5-6 preparations).  One-
way ANOVA followed by Bonferroni post test, ***p<0.001. 
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Figure 3.7: The effect of anisomycin on SERT function in HEK-293 cells 
transiently transfected with GFP-hSERT.  Anisomycin (1 µM) was added to cells for 
5 min before uptake was measured by RDEV.  Data points are mean ± SEM (n = 4-6 
preparations). 
 
 
 
Table 3.2:  Kinetic data from RDEV for control and anisomycin treated cells 
Treatment Vmax (pmol/s/10
6
cells) Km (µM) 
Control 92 ± 6.8 1.91 ± 0.35 
Anisomycin 86 ± 2.3 0.96 ± 0.38 (p=0.1) 
Values are the mean ± SEM (n = 4-6 preparations). Student t-test  
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3.4.3.2 Tissue model 
RDEV was carried out on rat striatal tissue blocked with the DAT antagonist 
GBR12909 (1 µM, 5 min incubation (Zhou et al. 2005)) (Figure 3.8).  Uptake studies 
carried out on rat striatal tissue in which DAT was not blocked led to a much higher 
level of 5-HT uptake compared to tissue incubated with GBR12909 (increases between 
15 and 50%, Km and Vmax values of 0.67 µM and 642 pmol/s/g wet weight, 
respectively, Table 3.3).  DAT-inhibited uptake followed Michaelis-Menten kinetics, 
with average Km and Vmax values of 0.94 µM and 466 pmol/s/g wet weight, 
respectively (Table 3.3).  
 
Effect of ions and temperature on 5-HT uptake 
As mentioned above 5-HT uptake is Na
+
/Cl
-
 dependent (Ramamoorthy et al. 1992).  
Experiments were carried out with single additions of 5-HT at 1.5 µM as this is close to 
the Km value gained in the above kinetic experiments.  When extracellular Na
+
 was 
replaced with choline, uptake of 5-HT was significantly decreased compared to normal 
conditions (Figure 3.9), with 71% of control uptake being obtained (p<0.001).  When 
extracellular Cl
-
 was replaced with acetate, a significant decrease in uptake was also 
observed at 73% of control uptake (Figure 3.9) (p<0.001).  This demonstrates the 
importance of Na
+
 and Cl
-
 in 5-HT transport in the rat striatum. Uptake of 5-HT by 
SERT is temperature dependent, with maximal uptake occurring at 37ºC.  When 
temperature was decreased to 20ºC, uptake was significantly decreased to 55% of 
control uptake at 37°C (p<0.001). 
 
Effect of the p38 MAPK activator anisomycin on 5-HT uptake  
As shown above p38MAPK leads to a trend towards decreased Km and no change in 
Vmax.   Incubation of rat striatal tissue for 5 min with anisomycin led to a small 
increase in SERT function with a trend towards a decrease in Km (p = 0.07) and no 
change to Vmax (Figure 3.10, Table 3.3). 
 
Effect of the SERT inhibitor fluoxetine  
The SSRI, fluoxetine (Prozac), inhibits 5-HT uptake by SERT in the striatum (Rutter 
and Auerbach 1993).  In the present study, the addition of fluoxetine (10 µM) for 5 min 
before 5-HT addition led to a decrease  of 5-HT uptake in the rat striatum (Figure 3.11) 
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wtih a significant decrease in Vmax (p<0.01) and Km (p<0.05) (Table 3.3), 
demonstrating down-regulation of SERT. 
 
Effect of one week of freezing on SERT activity 
A recent study showed that DA uptake can still occur in rat brain tissue that has been 
frozen at -80ºC for up to 8 weeks (Volz et al. 2009).  Therefore, we wanted to validate 
the use of frozen tissues for uptake studies with SERT.  After dissection, tissue was 
weighed and frozen at -80 ºC for 1 week, and then defrosted at 22ºC for 20 min before 
mincing and using for RDEV experiments. 5-HT uptake still occurred in frozen tissue, 
but at a slower rate to that of fresh tissue (Figure 3.12).  Vmax values were decreased to 
76% of fresh tissue (466 to 354 pmol/s/g) but were not significantly different from non-
frozen tissue (p=0.1992). Km values were decreased to 64% of fresh tissue (0.94 to 
0.61), but this decrease in Km was not significantly different from fresh tissue (Table 
3.3). 
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Figure 3.8:  Inhibition of 5-HT uptake of DAT by GBR12909.  DAT takes up 5-HT 
when 5-HT is present in high concentrations.  Addition of the specific DAT blocker 
GBR12909 at 1 µM decreased 5-HT uptake in the striatum, measured by RDEV,.  This 
concentration has previously been used to inhibit 5-HT uptake by DAT (n = 3-6 
homogenates). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9:  Ion and temperature dependence of 5-HT uptake in rat striatal tissue.  
After a 5 min incubation with GBR12909, rat striatal tissue was treated with a single 1.5 
µM dose of 5-HT in normal conditions, in Na
+
 free conditions, in Cl
-
 free conditions 
and at room temperature.   Uptake was measured by RDEV. Buffer lacking extracellular 
Na
+
 or Cl
-
, or experiments carried out at 20ºC had significantly decreased uptake 
compared to controls treated at 37ºC.  Data points represent the mean ± SEM (n = 5-6 
preparations).  One-way ANOVA followed by Bonferroni post test, *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 3.10: The effect of anisomycin on SERT function in rat striatal tissue.  
Anisomycin (1 µM) was added to the tissue for 5 min before uptake was measured by 
RDEV.  Data points are mean ± SEM (n = 4-6 preparations). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11:  The effect of the SERT inhibitor fluoxetine on 5-HT uptake.  
Incubation with fluoxetine (10 µM) 5 min after addition of GBR12909 (1 µM) led to a 
decrease in 5-HT uptake in the rat striatum  (n = 5-10 homogenates). 
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Figure 3.12:  Uptake of 5-HT by SERT in the rat striatum and in frozen tissue 
samples.  Rat striatal tissue was treated with GBR12909 5 min prior to measuring 5-HT 
uptake by RDEV.  Rat striata were frozen for 1 week at -80°C before defrosting at room 
temperature for 20 min and then using for 5-HT uptake studies (n = 4-6 tissue 
homogenates).  
 
 
 
Table 3.3:  Kinetic data for tissue model 
Treatment Vmax 
(pmol/s/g) 
Km (µM) 
Non-inhibited 642 ± 41 0.67 ± 0.05 
DAT-inhibited control 466  ± 61 0.94 ± 0.27 
Anisomycin 550 ± 53 0.40 ± 0.11 
(p=0.07) 
Fluoxetine  93.8 ± 27** 0.1885 ± 
0.082* 
Frozen  354 ± 54 0.61 ± 0.25 
Kinetic data were collected by RDEV, Student‟s t-test compared to the relevant control.  
Data are the mean ± SEM (n = 4-6 tissue homogenates). 
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3.4.4 The effect of KOPr agonists on SERT function in the striatum 
It has been suggested that the KOPr also regulates SERT function (Schenk et al. 2000).  
Activation of SERT by U69,593 leads to decreased 5-HT uptake in rat striatal 
synaptosomes (Ramamoorthy et al. 2002b).  The effect of KOPr activation on SERT 
activity takes longer to occur compared to that of DAT (B. Kivell, personal 
communication); therefore, different time points were investigated to find when SERT 
function decreases after the addition of the classic KOPr agonist U50,488H.  All tissues 
used for SERT experiments were first incubated with 1 µM GBR12909 for 5 min to 
block DAT, which has been shown to take up 5-HT in addition to DA when 5-HT is 
present in high concentrations (Zhou et al. 2005).  A significant 25% decrease in uptake 
of 2 µM 5-HT occurred after a 15 min incubation with U50,488H (Figure 3.13), and this 
incubation time was therefore used for further studies.  Salvinorin A and DS-1-240 also 
decreased 5-HT uptake by 25% in rat striatal tissue (Figure 3.14), demonstrating that 
KOPr also modulates SERT in the rat striatum.  The effect of DS-3-216 on SERT 
function were unable to be measured due to the RDEV machine being broken at the 
time designated for the experiments. 
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Figure 3.13:  The effect of U50,488H on SERT function at 4, 10, and 15 min.  Rat 
striatal tissue was incubated with 500 nM KOPr agonist U50,488H for 4, 10, and 15 
min to find when it exerts its action.  A significant decrease in 5-HT uptake was seen at 
15 min (Student unpaired t test, **p<0.01, n = 1-6 tissue homogenates).  This time point 
was used for all further studies with SERT and KOPr agonists.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14:  KOPr agonists decrease 5-HT uptake in the rat striatum.  The 
striatum was treated for 15 min with KOPr agonist (500 nM) and uptake of 2 µM 5-HT 
was measured using RDEV (One-way ANOVA, Bonferroni post test.  *p<0.05, 
**p<0.01, n = 4-5 tissue homogenates). 
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3.5 Discussion 
The dopamine transporter is one of the major proteins in the brain that is directly 
affected by drugs of abuse.  All drugs of abuse either directly or indirectly lead to 
regulation of DAT, which causes short-term increases in DA in the synapse, where it 
can bind to DA receptors, and continue on reward signalling.  As already mentioned, 
KOPr agonists attenuate the effects of acute cocaine challenge, and also prevent self-
administration of cocaine-primed cocaine seeking (Collins et al. 2001a; Collins et al. 
2001b; Morani et al. 2009).  This demonstrates the ability of KOPr to prevent drug 
taking after acute drug experiences and also after chronic drug taking.  However, classic 
KOPr agonists have shown no significant effect on drug taking in limited human 
clinical trials (Walsh et al. 2001a; Preston et al. 2004).  The interaction between the 
KOPr and DAT is a potential pharmacotherapeutic route if new compounds are found 
that affect drug taking in humans, and further investigation into the effects of the novel 
salvinorin-based compounds on this pathway may lead to identification of analogues 
that function differently from the classic agonists, giving rise to new therapeutics. 
 
In this chapter the effects of the traditional KOPr agonists U50,488H, U69,593, and the 
novel compounds salvinorin A, DS-1-240, and DS-3-216 on DAT and SERT function 
in isolated brain regions was investigated.  It was found that all of the KOPr agonists 
investigated increased DAT function in the striatum, NAc, and medial PFC.  This 
increase in uptake occurred after 1 min for salvinorin A and after 4 min for U50,488H, 
DS-1-240, and DS-3-216.  Kinetic studies showed that incubation with all compounds 
except salvinorin A led to an increase in Vmax but no change to Km.  Salvinorin A 
produced a linear substrate concentration vs. velocity graph, and therefore further 
studies were conducted using a lower concentration of this agonist as we postulated, as 
salvinorin A is known to be easily degraded, that it was being broken down in the 
RDEV chamber and fouling the electrode.  Single addition uptake studies found that 
100 nM salvinorin A led to a significant increase in uptake after 1 and 4 min (n = 4-6).  
The increased DAT function caused by the KOPr agonists was confirmed to be due to 
KOPr activation as prior incubation of the striatum with the KOPr antagonist nor-BNI 
led to inhibition of the effect of these compounds.  The increased DAT function caused 
by the KOPr agonists was confirmed to be due to KOPr activation as prior incubation of 
the striatum with the KOPr antagonist nor-BNI led to inhibition of their effects.  The 
KOPr agonists U50,488H, salvinorin A, and DS-1-240 also decreased SERT function in 
 95 
 
the striatum after a 15 min incubation, demonstrating the importance of KOPr for 
regulation of both DAT and SERT.   
 
3.5.1 The effect of acute DA additions in the striatum, NAc and medial PFC 
Pilot studies were conducted to investigate the time taken for the KOPr agonists to have 
an effect in minced rat striatal, NAc, and medial PFC tissue.  These brain regions were 
chosen as they all play important roles in addiction and all three express both DAT and 
KOPr (Boja and Kuhar 1989; Meshul and McGinty 2000; Svingos et al. 2001; Mazei et 
al. 2002).  The three brain regions investigated had varying levels of control DA uptake, 
with the striatum showing the largest uptake, followed by the NAc and then the medial 
PFC (Figure 3.1).  This correlates with the amount of DAT that is expressed in each 
brain region, with the striatum having the highest DAT density, followed by the NAc 
and then the medial PFC (Sesack et al. 1998; Thompson et al. 2000).  The medial PFC 
expresses a large amount of NET, which is thought to be involved with the majority of 
DA uptake in this brain region (Mazei et al. 2002); therefore, the NET inhibitor 
desipramine-HCl was used in all medial PFC samples to inhibit NET function.   
 
Addition of all of the KOPr agonists tested in the striatum, NAc, and medial PFC led to 
an increase in DAT function, decreasing extracellular DA by 170 to 300% (Figure 3.1).  
As mentioned earlier, previous studies have shown that KOPr regulates DA levels in 
these brain regions (Chefer et al. 1999; Gray et al. 1999; Chefer et al. 2000; Thompson 
et al. 2000; Carlezon et al. 2006), with the majority of studies show a decrease in basal 
DA in these regions.  A possible shortcoming of the present study is that the effect of 
KOPr agonists on DAT function was studied in rat brain regions that had been isolated 
and then treated with the KOPr agonist, rather than removing brain regions from 
animals that had been treated in vivo with the agonist.  While the data gained match 
previous studies in which animals were pre-treated with KOPr agonists, there may be 
subtle differences.  For example, KOPr neurons projecting from the ventral tegmental 
area inhibit DA release in the medial PFC, but have no affect on DA release in the NAc 
(Margolis et al. 2006).  This difference highlights the complexity of regulation within 
the brain, which is not accounted for in the simple model used in our study.  However, 
the model used in our study does demonstrate that KOPr does modulate DAT and 
suggests that whole brain circuitry is not required for this modulation to occur.  This 
suggests that further studies can be conducted in cell models. 
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The KOPr agonists investigated all caused similar increases in DAT function between 
brain regions, with salvinorin A and U50,488H showing the most variability (increases 
of 240% to 300% and 170% to 280%, respectively).  For these compounds, the largest 
increase was observed in the NAc, with the striatum and medial PFC exhibiting similar 
increases in uptake.  There have been many studies that show differences between 
regulation of DA in these brain regions, especially between the NAc and striatum 
(Roitman et al. 1999; Wu et al. 2001; Richards and Zahniser 2009).  There is also 
evidence that regulation of DAT by KOPr is different between these brain regions 
(Chefer et al. 1999; Thompson et al. 2000).  Overall, DS-1-240 and DS-3-216 had 
similar effects on uptake, with increases of between 170% and 210% observed.  
Salvinorin A had a slightly greater effect than the other compounds studied, and also 
had a much earlier onset of action, which may correlate to its fast onset of action in the 
brain (Hooker et al. 2008).   
 
Overall, acute treatment with the KOPr agonists investigated in our study increased 
DAT function in isolated rat striatum, NAc, and medial PFC, causing decreased 
extracellular DA.  These data suggest that increased DAT function contributes to the 
decreased DA measured in these brain regions after KOPr activation.  It also 
demonstrates that the novel salvinorin-based KOPr agonists investigated in this study 
have similar effects to the classic agonist U50,488H.  As these novel compounds also 
cause decreased extracellular DA levels, they may have potential for use in 
pharmacotherapies for addiction, but further investigation into their effects in animal 
models of addiction would need to be conducted.   
 
3.5.2 The kinetics of DAT after addition of KOPr agonists in rat NAc tissue 
The electrochemical technique RDEV can be utilised for kinetic studies, with Km and 
Vmax values giving information on how DAT is being modulated by KOPr activation.  
All of the agonists studied caused a significant increase in Vmax, which suggests 
increased cell surface expression of DAT.  Whether this increase occurs after a long- or 
short-term incubation with the agonists we cannot be sure, as with the low to infinite 
trans model, the KOPr agonist is present in the RDEV chamber during the entire 
experiment, and this can often be as long as an hour.  Interestingly, salvinorin A at 500 
nM gave a linear substrate concentration vs. velocity graph, which is normally 
representative of an ion channel.  It is possible that this concentration of salvinorin A is 
altering the transporter to cause it to act as a channel (J. B. Justice, personal 
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communication).  Another possibility is that prolonged incubation of salvinorin A 
within the chamber causes degradation of salvinorin A to its metabolite salvinorin B, 
which may foul the electrode..  Salvinorin A is an unstable compound that is rapidly 
degraded to its inactive metabolite salvinorin B by carboylesterase and serine esterase in 
rat plasma (Tsujikawa et al. 2009).  To further investigate whether this effect was seen 
due to the concentration of salvinorin A used experiments were carried out at a lower 
concentration (100 nM).  We found that this concentration caused a significant increases 
in DAT function at both 1 and 4 min. 
 
Overall these data help to give a broad understanding about how these compounds are 
modulating DAT function. The experiments show that the two classic agonists and the 
novel agonists have similar effects on DAT, with a possible increase in cell surface 
expression of DAT.   
 
3.5.3 The effect of KOPr agonists on DAT function is nor-BNI reversible in the rat 
striatum 
Nor-BNI is a KOPr antagonist that has long-term effects in inhibiting KOPr agonism 
(Horan et al. 1992).  To confirm that the increase in function that was found with the 
KOPr agonists was KOPr-mediated, rat striatal tissue was incubated with nor-BNI for 
30 min prior to KOPr agonist addition.  Addition of nor-BNI completely inhibited the 
effect of all the KOPr agonists studied.  This demonstrates that all of the compounds 
investigated cause increases in DAT function in a KOPr specific method. 
 
3.5.4 Establishing RDEV to measure SERT function in rat striatum and cells transfected 
with GFP-hSERT 
When the present investigation was started, there were no submitted reports for the use 
of RDEV to measure SERT function; therefore, this chapter aimed to establish RDEV 
to measure SERT function in both cells transfected with hSERT and in rat brain tissue 
samples.  A recent study by Hagan et al (2010), however, used RDEV to study SERT in 
mouse whole brain synaptosomes (Hagan et al. 2010), providing the first use of RDEV 
to measure SERT function.  In our study, which was largely carried out before the 
Hagan et al. paper appeared, we wanted to establish the technique using samples that 
were commonly used for monoamine transporter functional assays.  We found that 5-
HT oxidation was measureable in isolated cells and homogenised brain tissue by RDEV 
at +450 mV. This differed from the method used by Hagan et al, who measured the 
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current produced by 5-HT oxidation at +550 mV, but our values were still within the 
measureable range.  Because of the lower voltage used, our 5-HT signal was 2.5 times 
lower than their reported value (0.084 ± 0.004 nA/nM compared to 0.21 ± 0.01 nA/nM).  
Some of this difference could be due to the nature of the preparation, i.e. synaptosomes 
versus cells and tissue.  Apart from this, our protocols were very similar.  Uptake of 5-
HT by SERT in cells transfected with GFP-hSERT was dependent on temperature and 
ion concentration and was possibly activated by the p38 MAPK activator anisomycin.  
These responses of SERT validate the RDEV method for measuring its function in 
transfected cells. Measurements were also taken in rat striatal tissue, and SERT was 
slightly down-regulated by fluoxetine and was also measurable in rat striatal tissue that 
had been frozen for one week. 
 
HEK-293 cells transfected with monoamine transporters are often used for monoamine 
research as the cells are easily transfected and express the transporter at high levels.  In 
this model, cells transfected with GFP-hSERT took up greater amounts of 5-HT than 
non-transfected cells (Figure 3.5) in a Michaelis-Menten manner. „Non-specific‟ uptake 
in non-transfected cells was between 6-30% of the total uptake, with lower 
concentrations of 5-HT (below 500 nM) having much lower „non-specific‟ uptake than 
higher concentrations (above 500 nM), as expected.  Interestingly this was the opposite 
to what Hagan et al. found, in their study the lower concentrations of 5-HT used 
produced higher „non-specific‟ uptake compared to higher concentrations.  This 
difference  may be due to the generally higher concentrations of 5-HT used in our 
experiments as Hagan et al. used 0.05 µM to 1 µM 5-HT (Hagan et al. 2010); whereas, 
in our experiments we used 0.1 µM to 3 µM 5-HT. „Non-specific‟ uptake was 
subtracted from the total uptake in all cell experiments.  The Km and Vmax values 
gained in our experiments (1.91 µM and 92 pmol/s/10
6
, respectively) fall within the 
range of previously reported values in transfected cell suspensions, which have a wide 
range of values for Km of from 0.30 µM (Mao et al. 2000; Zhu et al. 2005; Tsuruda et 
al. 2010)  to 21.8 µM (Mochizuki et al. 2005).  This large range of values is probably 
due to the different techniques used to collect the kinetic data, and the different SERT 
plasmid and cell types used to express SERT in. Most kinetic studies in cells are carried 
out using radioactive ligands; however, the Vmax data from radioligand uptake cannot 
be directly compared to the data gained in our study due to the different units used 
(pmol/s/10
6
cells in our study vs. fmol/min/mg protein in radioactive uptake 
experiments).     
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We found that GFP-hSERT expressed in HEK-293 cells was sensitive to changes in Na
+
 
and Cl
-
 availability and temperature (Figure 3.6).  SERT is a Na
+
/Cl
-
 symporter and 
requires these ions in a 1:1:1 ratio with 5-HT for transport to occur (Ramamoorthy et al. 
1993).  Binding of the ions and 5-HT are crucial for uptake, though the order in which 
they bind to the transporter is not known (Chang and Lam 1998).  The replacement of 
Na
+
 with choline and Cl
-
 with acetate led to overall decreased uptake to 24% and 29% 
of control uptake, respectively (Figure 3.6).  This matches previously published data 
using hSERT (Ramamoorthy et al. 1992; Li et al. 2006; Oz et al. 2010b) in which 
uptake of radioactive 5-HT and ASP
+
  was 10-30% of control uptake for Na
+
-free 
conditions and 30-55% of control uptake for Cl
-
-free conditions (Li et al. 2006; Oz et al. 
2010b).  SERT function is also temperature dependent, with maximal uptake occurring 
at 37°C.  In the cell model in our study, decreasing the temperature to 20°C led to a 
significant decrease in 5-HT uptake, similar to that reported by others (Oz et al. 2010b).  
Overall, these data demonstrate that RDEV is sensitive enough to measure the 
dependency of SERT on ions and temperature to an equal degree as other more 
commonly used techniques. 
  
There have been several studies identifying p38 MAPK as a regulator of SERT function 
(Samuvel et al. 2005; Zhu et al. 2005; Oz et al. 2010b).  In these studies, activation of 
p38 MAPK causes a quick onset and short-lived increase in SERT activity (Zhu et al. 
2005; Oz et al. 2010b). Inhibition of p38 MAPK has been shown to lead to a decrease in 
SERT cell surface expression (Samuvel et al. 2005).  Anisomycin is a p38 MAPK 
activator that increases SERT function.  The addition of anisomycin to the GFP-hSERT 
expressing cells in our study, however, caused a trend towards a decrease in Km and no 
change in Vmax, suggesting that there may be an increase in affinity of SERT for 5-HT 
but no change in cell surface expression.  These data match that of Zhu et al., who also 
found that anisomycin (1 µM) decreased the hSERT Km but caused no change in Vmax 
(Zhu et al. 2005).  To confirm this further repeats could be conducted. 
 
Brain tissue is often used in RDEV experiments since animals can be treated with 
compounds and the effects on brain transporter function later measured, or compounds 
can be applied directly to brain regions containing the transporter of interest, either by 
intracranial cannulae additions or isolated tissue exposures.  Removal and analysis of a 
specific brain region, as carried out in our study, allows the effects of these compounds 
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to be measured in brain regions that are directly involved in the pathways being 
investigated.   Neuronal bodies are often found in different brain regions from their 
axons and synapses, where the transporters are found, and when severed, the cell closes 
up to form a complete unit, similar to a synaptosome.  This allows uptake studies to be 
carried out on these isolated regions.   
 
The striatum has a high density of SERT, but also contains DAT.  DAT has been shown 
to take up 5-HT when it is present in high concentrations (Zhou et al. 2005).  We carried 
out a control RDEV experiment to see if the addition of the specific DAT blocker 
GBR12909 (1 µM) decreased uptake of 5-HT in the striatum, as this concentration has 
previously been shown by FSCV to inhibit 5-HT uptake by DAT in striatal brain slices 
(Zhou et al. 2005).  GBR12909, however, has no effect on 5-HT uptake by its normal 
transporter SERT. In our RDEV experiments, addition of 1 µM GBR12909 led to a 
significant decrease (15-50%) in 5-HT uptake, and this concentration was therefore used 
for all further experiments to inhibit 5-HT uptake through DAT.  This allows for 
specific conclusions to be made on SERT function in our experiments without the 
complication of DAT uptake of 5-HT.  Uptake of 5-HT through SERT in rat striatal 
tissue followed Michaelis-Menten kinetics, with Km and Vmax values of 0.94 µM and 
466 pmol/s/g, respectively.  Other studies using rat striatal tissue have reported a very 
wide range of Km values. Km and Vmax values are dependent on the technique used 
and the type of preparation, for example, chopped tissue or synaptosomes (Near et al. 
1988).  Km values are much larger in chopped tissue compared to synaptosomes due to 
the larger diffusion barrier of intact tissue pieces compared to a homogeneous mix of 
small diameter synaptosomes or cells. Km values in the literature range between 30 nM 
for rat midbrain synaptosomes (Kokoshka et al. 1998; Samuvel et al. 2005) to 2.0 µM 
for whole rat brain measured by FSCV (Daws et al. 2005). Our Km value falls within 
this wide range of values.  As the previous RDEV study carried out on SERT by Hagan 
et al (2010) used mouse tissue, our data cannot be directly compared to their results 
either since kinetic values are probably species and brain region specific.  However, 
their Km and Vmax values from synaptosome preparations also fell within the 
published range.  
 
As seen in the cell studies, removing Na
+ 
or Cl
-
 from the assay buffer and decreasing the 
temperature at which the experiment was carried out at led to a decrease in SERT 
function (Figure 3.9).  While the effect seen with tissue was not as great as that seen in 
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cells it was still significant.  This difference may be due to the size difference between 
cells and tissue and although tissue was washed there would most likely still be ions 
present in the tissue.  Treatment of tissue with anisomycin 5 min before 5-HT uptake 
experiments also led to a decrease in Km and no change in Vmax (Figure 3.10), 
agreeing with our cell data and previously published data (Zhu et al. 2005).   
 
The SSRI anti-depressant fluoxetine is known to competitively act on SERT, preventing 
the uptake of 5-HT back into the neuron and thereby increasing synaptic cleft 
concentrations of 5-HT (Wang et al. 2006; John and Jones 2007b).  In the present study 
the addition of fluoxetine significantly decreased 5-HT uptake and decreased both Km 
and Vmax, demonstrating inhibition of SERT.  
 
A recent publication reported that isolated rat brain regions can be frozen at -80°C and 
defrosted for use with RDEV (Volz et al. 2009).  Being able to do this is useful for 
RDEV experiments as often many animals are treated with drugs over a long period of 
time. For the best consistency of the data, the animals need to be euthanized and RDEV 
carried out on all samples at about the same time after euthanasia so that the effect of 
the drugs on monoamine transporters are at similar levels when the animals are 
sacrificed.  This means that changes in the transporter due to the drugs in the brain will 
be similar between animals.  Freezing the tissue would also make it easier to carry out 
experiments when multiple brain regions are used.  We therefore wanted to investigate 
whether we could carry out SERT functional assays on brain tissue frozen for one week.  
In our experiment brain tissue was frozen at -80°C directly after removal and weighing 
rather than after removal and cooling, and similar results were observed compared to the 
previously published report (Volz et al. 2009) − some loss of function but not complete 
loss. There were also no problems in our study with frozen striatal tissue not settling 
sufficiently by gravity, which was an issue noted in the study by Volz et al. (2009).  
SERT function was still able to be measured after one week of freezing and with little 
loss of uptake capacity occurring compared to unfrozen controls in which uptake was 
measured immediately after removal from the animal.  A previous study that 
investigated the effect of freezing of rat and human brain samples on the uptake of DA 
and 5-HT found that in rat forebrain there was a non-significant decrease in both Km 
and Vmax of radiolabelled 5-HT uptake with their freezing protocol, in which tissue 
was stored frozen at -70°C for 1 to 3 weeks (Stenstrom et al. 1985).  Overall the 
decrease in function in our study (0-22%) was less than what was observed by Volz et 
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al. with frozen tissue for DAT RDEV, in which decreases of 55-60% were reported 
(Volz et al. 2006).  It is uncertain whether this difference is due to the different 
properties of DAT and SERT, or if it is because our protocol does not including a prior 
„cool down‟ period of the tissue before freezing. The lack of change in Km with 
freezing in our study suggests that the SERT transporters that remain functional have 
not been altered by freezing with regard to the binding and interaction of 5-HT with the 
transporter protein.  
 
To conclude this section, RDEV was successfully established for measuring SERT 
function in cells transfected with GFP-hSERT and in rat striatal tissue samples.  
Measurements on DAT function by RDEV are relatively common; however, the use of 
RDEV for measuring SERT function was novel, with only one report of its use toward 
the end of the study, and that in synaptosome preparations, not cells and tissue 
homogenates.  RDEV was able to measure changes in SERT function due to changes in 
ion concentration and temperature and generated consistent kinetic data to that seen 
following the addition of fluoxetine and anisomycin in cells and tissue samples.  5-HT 
uptake was also successfully measured in rat striatal samples frozen for one week.  The 
utilisation of RDEV to measure SERT function in these samples will lead to an increase 
in information on SERT and the effect that drugs of abuse and potential therapies have 
on SERT function. 
 
 
3.5.5 The effect of KOPr agonists on SERT function in the rat striatum 
SERT is found in many different areas of the brain, and its main function is as a 
regulator of mood.  SERT is also involved in many mental disorders and also addiction 
(Murphy et al. 2008).  The serotonergic system is involved in cocaine abuse, with SERT 
inhibition leading to inhibition of the priming effect of cocaine in squirrel monkeys 
(Czoty et al. 2002), and inhibition of cocaine seeking during drug extinction and cue-
induced reinstatement of cocaine in rats (Burmeister et al. 2003).  SERT and KOPr have 
also been shown to interact, with 5-HT essential for some of the effects of KOPr.  
Treatment with KOPr agonists leads to side effects such as depression and dysphoria, 
which also implicate 5-HT in KOPr-mediated effects (Redila and Chavkin 2008).  
Therefore, as we have the ability to measure SERT function using RDEV, the effect of 
acute KOPr agonists on SERT function was investigated.  Acute KOPr activation by 
U50,488H, salvinorin A, and DS-1-240 in our study led to a decrease in SERT function 
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after a 15 min incubation.  This increase in 5-HT in the synapse may be involved with 
the decrease in drug seeking seen in laboratory animals in cocaine reinstatement 
experiments.   
 
5-HT has also been shown to regulate the DA pathway, with activation of 5-HT 
receptors regulating DA release (reviewed in Alex and Pehek 2007).  Increased 
extracellular 5-HT leads to activation of 5-HT receptors and then downstream activation 
or inhibition of DA release.  5-HT receptors also play a role in the effects of drugs of 
abuse such as cocaine and morphine, with agonism of the 5-HT receptor subtype 2C in 
rat PFC leading to decreased cocaine-induced hyperactivity and also inhibited stimulus 
effects of cocaine (Filip and Cunningham 2003).  Antagonism of these receptors leads 
to a potentiation of DA release in the NAc and striatum after cocaine treatment, but 
agonism of these receptors does not decrease the DA increase caused by cocaine, 
although it did inhibit morphine-induced DA release (Willins and Meltzer 1998; 
Navailles et al. 2004).  These studies demonstrate that the 5-HT pathway is important 
for drug addiction, and pharmacotherapies that target 5-HT and DA pathways may be 
more effective in attenuating drug seeking then those that just target one.   
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3.6 Conclusion 
To conclude, this chapter demonstrated that acute KOPr agonism leads to increased 
DAT function in the striatum, NAc, and medial PFC and that this may be mediated by 
increased cell surface expression of DAT.  Salvinorin A and its analogues showed 
similar effects to those of the classic KOPr agonists U50,488H and U69,593.  The 
increase in uptake observed for all of the compounds was nor-BNI reversible, 
confirming its effect to be mediated through the KOPr pathway.   The effects of 
salvinorin A were non-significantly nor-BNI reversible, and with further repeats this 
may also reach significance.  RDEV was also successfully used to measure SERT 
function in rat tissue and transfected cells.  Addition of KOPr agonists led to decreased 
SERT function in the striatum which may play a role in the decreased cravings seen 
after KOPr agonist treatment in reinstatement experiments.  Further investigation into 
how these compounds elicit their effects on DAT and SERT will give greater 
information on their function, will highlight potential differences between classic and 
novel KOPr agonists, and may lead to useful information for the development of 
successful pharmacotherapies for addiction. 
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Chapter 4:  Effects of KOPr agonists on the function and expression of 
DAT in a cell system 
 
4.1 Introduction 
Cell models are often used when investigating the effect of drugs on monoamine 
transporters as they allow for greater manipulation than is possible in the whole animal.  
Therefore, our aim was to investigate if the KOPr agonists U50,488H, salvinorin A, DS-
1-240, and DS-3-216 alter DAT function in a cell model as they do in a tissue model 
(Chapter 3), and if any increases seen are due to increased cell surface expression.  Cell 
studies were conducted in mammalian HEK-293 cells co-transfected with myc-rKOPr 
and YFP-hDAT.   
 
4.1.1 4-(4-(dimethylamino)-styrl)-N-methylpyridinium (ASP
+
) uptake 
ASP
+
 is a fluorescent analogue of the neurotoxic compound 1-methyl-4-
phenylpyridinium (MPP
+) which is used to induce Parkinson‟s Disease-like phenotypes 
in laboratory animals (Schwartz et al. 2003).  ASP
+
 is a substrate for the monoamine 
transporters and fluoresces red when it comes into contact with lipids; therefore, it can 
be used to investigate binding and uptake through monoamine transporters in live cells 
in culture using confocal microscopy (Schwartz et al. 2003).  This technique is unique 
as it allows differentiation between binding and uptake of ASP
+
. It is a very sensitive 
method as it takes real-time, space-resolved measurements in single cells.  Once inside 
the cell ASP
+
 binds irreversibly to the mitochondria.  ASP
+
 uptake has been utilised to 
measure DAT (Bolan et al. 2007; Zapata et al. 2007; Oz et al. 2010a), SERT (Oz et al. 
2010b), and NET (Schwartz et al. 2003; Schwartz et al. 2005) activity in cells.  Binding 
of ASP
+
 to these transporters occurs rapidly, and uptake of ASP
+
 occurs in a linear 
fashion over a period of at least 10 min (Figure 4.1), allowing for acute affects of drugs 
to be measured in a within-cell design.  Chronic drug effects can also be measured in a 
between-cell manner by comparing cells that have been incubated with drug before 
ASP
+
 uptake with cells incubated with vehicle.  The technique was established using 
NET-transfected cells by Schwartz et al. (2003) who demonstrated that ASP
+
 uptake by 
NET was Na
+
, Cl
-
, cocaine, and temperature dependent.  These researchers also 
demonstrated ASP
+
 uptake in cultured neurons and in cells transfected with SERT and 
NET (Schwartz et al. 2003).  Further studies on NET investigated the binding and 
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transport of ASP
+
 and found that binding occurred rapidly, but only resulted in transport 
of ASP
+
 in 1 out of 1000 events (Schwartz et al. 2005).   
 
ASP
+
 uptake studies have also been used to investigate how cellular receptors regulate 
DAT function.  Using co-transfected cells, ASP
+
 uptake was used to demonstrate 
modulation of DAT function by the dopamine receptor subtypes D2 (Bolan et al. 2007) 
and D3 (Zapata et al. 2007), and by the cannabinoid agonist anandamide (Oz et al. 
2010a).  This technique has also been adapted for high-throughput screening in both 
transfected cells and neuronal cultures (Mason et al. 2005).  It has also been used to 
measure the effect of the human immunodeficiency virus-1 transactivating factor (Tat) 
on DAT function in transfected cells in order to examine changes in DAT function and 
expression in human immunodeficiency virus-associated neurological disease (Perry et 
al. 2010).  More recently ASP
+
 uptake by SERT has been characterised (Oz et al. 
2010b). Uptake by SERT was sensitive to changes in Na
+
, Cl
-
, temperature, cocaine, 
fluoxetine and p38 MAPK. 
.   
 
 
 
 
 
 
 
 
 
Figure 4.1:  Binding and uptake of ASP
+
 to YFP-hDAT HEK-293 cells.  The initial 
binding phase is followed by a linear uptake phase for at least 10 min after ASP
+
 
addition.   
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4.1.2 Total internal reflection fluorescence microscopy (TIRFM) 
TIRFM is a microscopy technique in which the laser beam is bent greater than a critical 
angle, allowing an evanescent field of only 100 nM from the coverslip to penetrate the 
sample.  The critical angle is given by: 
 
θc = sin
-1
(n1/n3) 
 
in which θc is the critical angle, n1 the refractive index of the liquid, and n3 the refractive 
index of the solid (i.e. the glass bottom of the dish) (Axelrod 2001). The TIRF angle 
must be larger than the critical angle so that the laser beam is entirely internally 
reflected rather than refracted through the sample.  TIRFM gives images that are free of 
background fluorescence compared to images gained by epi-fluorescence (Figure 4.2) 
and gives greater detail to the region of the sample that is adhered to the coverslip.  
TIRFM is useful for measuring changes that occur at the cell membrane of live cells 
containing fluorescent membrane proteins as the 100 nM penetration depth allows 
visualisation of movement of fluorophores from the cytosol to the plasma membrane.  
The most studied transporter by TIRFM is glucose transporter 4 (GLUT4) which when 
stimulated by insulin acts to take up glucose into insulin-sensitive fat and muscle cells.  
From TIRFM experiments on adipocytes, it has been discovered that GLUT4 storage 
vesicles move within an intracellular tethering matrix to the cell surface (Li et al. 2004a) 
These vesicles move along a microtubule network (Chen et al. 2008), and in the 
presence of insulin, they are tethered to the plasma membrane in clatherin-coated pits 
(Huang et al. 2007).  Over time, these vesicles fuse with the plasma membrane in an 
actin-dependent (Lopez et al. 2009), v-SNARE-dependent manner (Zhao et al. 2009), 
leading to increased GLUT4 in the plasma membrane (Lizunov et al. 2005).   
 
TIRFM has also been used to investigate the cell surface expression of DAT and SERT.  
DAT studies in N2A cells expressing YFP-hDAT have shown that DA and 
amphetamine cause an initial increase in DAT cell surface expression within 30 s, 
followed by a decrease in expression levels. This effect was SNARE and PKC 
dependent and was inhibited by cocaine (Furman et al. 2009a).  Also the effect of Tat on 
DAT cell surface expression  was studied, with Tat causing an increase in DAT cell 
surface expression that was ryanodine receptor, calcium, and calpain mediated (Perry et 
al. 2010).  A decrease in cell surface expression of SERT due to the effect of MDMA 
has also been demonstrated (Kivell et al. 2010).  All these studies illustrate the ability of 
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TIRFM to sensitively measure cell surface expression of fluorescently-tagged proteins, 
and to study the mechanisms by which changes in transport function occur.   
 
4.1.3 Cell surface biotinylation 
Cell surface biotinylation is another technique commonly used to measure changes in 
cell surface expression and is often partnered with TIRFM to confirm the results of 
TIRFM.  It is generally not as sensitive as TIRFM as it measures changes in a pool of 
heterologous cells. This can be a particular issue with co-transfected samples since not 
all cells are transfected with the same number of plasmids, leading to variable results 
over different dishes.  Also, as the sulfonate group of the EZ-link Sulfo-NHS-biotin can 
only bind to proteins found on the cell surface, proteins found within cell membrane 
invaginations are not always bound.  This can lead to the internal fraction looking larger 
than it really is, as proteins in the invaginations are counted as internal rather than cell 
surface proteins (Furman et al. 2009a). However, this technique has been successful in 
demonstrating an increase in cell surface expression after DRD3 and DRD2 receptor 
activation (Bolan et al. 2007; Zapata et al. 2007), and after acute DA and amphetamine 
treatment (Furman et al. 2009a).  Cell surface biotinylation has also successfully been 
used to demonstrate decreases in cell surface expression of DAT after incubation with 
the cannabinoid anandamide (Oz et al. 2010a), after 1-2 h incubations with 
amphetamine in NAc and striatal synaptosomes preparations (Richards and Zahniser 
2009), after incubation with methamphetamine (Xie and Miller 2009) and after 
inhibition of MAPK pathways (Moron et al. 2003).  This technique is useful as it can be 
used to investigate the effect of drugs of interest on brain tissue synaptosome 
preparations from animals that have been treated with the drug.  This gives more 
relevant data to the in vivo situation compared to treating cells in vitro with the drugs of 
interest, especially if whole brain circuitry is required for some of the effects to be 
observed. 
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Figure 4.2:  Comparison of DIC (A) confocal (B), epi-fluorscence (C) and TIRF (D) 
microscopy.  Images were taken of the same cell using DIC (A), confocal (B), epi-
fluorescence (C), and TIRFM (D).  Notice the increased detail and clarity of the TIRFM 
image compared to the others.. 
 110 
 
4.2 Aim 
The aim of this chapter, therefore, was to use confocal microscopy and cell surface 
biotinylation to investigate the cellular effects of other salvinorin A-based compounds 
such as DS-1-240 and DS-3-216 on the function and expression of YFP-hDAT in cells 
co-transfected myc-rKOPr in addition to YFP-hDAT.  The effects of the KOPr 
antagonist nor-BNI and the Gi/o inhibitor PTX on transporter function was also 
explored.  It is hypothesised that the novel KOPr agonists would cause concentration-
dependent increases in ASP
+
 uptake, which will be inhibited by nor-BNI and PTX, and 
that this increase in uptake will occur as a result of an increase in YFP-hDAT cell 
surface expression in these cells.  Results gained from this chapter will confirm data 
gained from previous studies on salvinorin A and give new information on the effects of 
the novel KOPr agonists DS-1-240 and DS-3-216.  
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4.3 Methods 
4.3.1 Confocal microscopy 
HEK-293, COS7, and N2A cells were cultured and transfected as described in section 
2.1.2 and 2.1.3.  Two days after transfection, cells were used for the confocal 
microscopy ASP
+
 uptake experiments as described in section 2.5. 
 
4.3.2 Cell surface biotinylation 
HEK-293 cell surface biotinylation was carried out 48 h after transfection, as described 
in section 2.3. 
 
4.3.3 Total internal reflection fluorescence 
TIRFM was carried out on transfected HEK-293 cells 48 h after transfection. as 
described in section 2.6. 
 
4.3.4 Cell staining to visualise myc-rKOPr 
Transfected HEK-293 cells were stained 48 h after transfection.  The cells were first 
fixed in ice-cold methanol:acetic acid (1:1) for 7 min at room temperature and then 
washed 3 x in PBS for 5 min each wash.   Cells were blocked with PBS containing 
0.25% Tween-20 and 1% BSA for 30 min at room temperature.   After blocking, the 
anti-myc antibody (1:10 dilution, Abcam) was added to PBS containing 1% BSA and 
the cells were incubated overnight at 4°C.  The antibody solution was then removed and 
the cells washed 3 x in PBS containing 0.25% tween-20 for 5 min each wash, and then 
incubated with anti-mouse Cy5 secondary antibody (1:100 dilution, Amersham) for 1 h 
at room temperature in the dark.  Cells were kept in the dark at 4°C until they were 
imaged by confocal microscopy.  YFP-hDAT was imaged with the 473 nm laser (YFP 
filter: 485 nm excitation; 545 nm emission), and Cy5 tagged myc-rKOPr was imaged 
using the 635 nm laser (Cy5 filter: 655 nm excitation; 695 nm emission).   
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4.4 Results 
4.4.1 Initial considerations 
4.3.1.1 Co-expression of YFP-hDAT and myc-rKOPr in HEK-293, N2A, and COS7 cells 
HEK-293, N2A, and COS7 cells co-expressing YFP-hDAT and myc-rKOPr were fixed 
and stained to visualise both YFP-hDAT and myc-rKOPr.  It was found that in all three 
cell lines, myc-rKOPr and YFP-hDAT were co-expressed. Expression levels in COS7 
cells, however, were much lower than those in HEK-293 and N2A cells even after 
optimisation of transfection protocols (Appendix 2). 
 
4.4.1.2 ASP
+ 
uptake method validation 
ASP
+
 uptake and binding studies were conducted in HEK-293 cells co-transfected with 
myc-rKOPr and YFP-hDAT.  Initial experiments confirmed that increased expression of 
YFP-hDAT led to increased ASP
+
 accumulation at 200 s (Figure 4.4).  Figure 4.5 shows 
ASP
+
 accumulation in cells over a period of 300 s and demonstrates that uptake in YFP-
hDAT and myc-rKOPr transfected cells is much higher than that in non-transfected 
cells.  Other preliminary studies were conducted to find the time when the compounds 
had the largest effect on ASP
+
 uptake.  It was found that salvinorin A caused a 
maximum uptake 60-120 s after ASP
+
 addition, with increases in uptake seen within the 
first 60 s of addition.  The classic KOPr agonist U50,488H had a longer onset of action, 
and had its maximal effect at 100-160s.   Compounds DS-1-240 and DS3-214 showed 
an even longer lag period, and their maximum effects were seen after 200-260 s (Table 
4.1, Appendix 2).  These time points for the maximal uptake rates for each compound 
were then used for all experiments conducted.  During these initial experiments the level 
of YFP-hDAT expression that gave functional changes in DAT after KOPr agonist 
addition was also verified as a ratio of at least two myc-rKOPr to one YFP-hDAT for 
functional changes to be observed (B. Kivell, personal communication).  It was found 
that cells expressing YFP-hDAT that gave an AFU value of between 250 and 1000 
showed increased ASP
+
 uptake after KOPr agonist addition.  Cells with an AFU for 
YFP-hDAT below 100 were classed as non-transfected as they did not show linear 
ASP
+
 uptake curves.   
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Figure 4.3:  Co-expression of YFP-hDAT and myc-rKOPr in cell lines used in this 
study.  HEK-293 (left column), N2A (middle column), and COS7 (right column) were 
stained for myc-rKOPr and imaged for YFP-hDAT and Cy5-myc-rKOPr to investigate 
co-expression of the proteins.  YFP-hDAT and myc-rKOPr were co-expressed to 
varying degrees in each cell in all three cell lines, though expression levels were very 
low in COS7 cells. Expression levels of YFP-hDAT and myc-rKOPr varied between 
cells. 
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Figure 4.4:  ASP
+
 uptake and YFP intensity have a positive correlation in HEK-
293 cells.  Increases in YFP-hDAT expression showed increased ASP
+
 accumulation at 
250 s (r
2
 =0.4628, p<0.001 compared to 0). 
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Figure 4.5:  Time course of ASP+ uptake by HEK-293 cells transiently transfected 
with YFP-hDAT and myc-rKOPr (see DVD for movie).  Note the transfected 
(yellow) cells (containing both YFP-hDAT and myc-rKOPr and indicated by a red 
arrow) take up greater amounts of ASP
+
 (red) compared to non-transfected cells 
(indicated by a white arrow).  Once ASP
+
 is internalised it binds to the mitochondria 
within the cell. 
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Table 4.1:  Time taken for compounds to have their maximal effect on ASP
+ 
uptake 
rate (Appendix 2) 
 
KOPr agonist Time taken for maximal effect (s) 
U50,488H 100-160 
Salvinorin A 60-120 
DS-1-240 200-260 
DS-3-216 200-260 
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4.4.2 Acute changes in the function of DAT due to treatment with KOPr agonists 
In order to investigate the effects of U50,488H, salvinorin A, and salvinorin A 
analogues on DAT function, ASP
+
 uptake was measured (Figure 4.6).  U50,488H, 
salvinorin A, DS-1-240, and DS-3-214 all caused a concentration-dependent increase of  
ASP
+
 uptake into HEK-293 cells.  Salvinorin A showed the largest effect, with 10 µM 
causing a 40% increase in uptake (p<0.001); whereas, its two analogues showed effects 
more similar to U50,488H with 10 µM causing an increase in uptake of around 20% 
(p<0.001 for U50,488H and DS-1-240, and p<0.01 for DS-3-216).  The KOPr 
antagonist nor-BNI (1 µM) completely inhibited the increase caused by 10 µM of all the 
compounds (p<0.001 for U50,488H and salvinorin A, and p <0.01 for DS-1-240 and 
DS-3-216 compared to 10 µM).  KOPr is a G0/i G protein-coupled receptor and is 
sensitive to PTX; therefore, the stimulatory effect of the agonists should be blocked by 
PTX.  PTX (100 ng/mL) inhibited the effects of 10 µM of all of the compounds studied, 
indicating that the effects of the compounds were due to KOPr activation (p<0.001 for 
U50,488H and salvinorin A, and p<0.01 for Ds-1-240 and DS-3-216, One-way 
ANOVA followed by Bonferroni post test; n = 46-64).  Addition of the vehicle control 
DMSO rather than KOPr agonists led to a non-significant decrease in the rate of ASP
+
 
uptake, which is most likely due to photo-bleaching or the movement of the cells out of 
the focal plane over time. Neither nor-BNI nor PTX had an effect on ASP
+
 uptake on 
their own (Figure 4.7).  
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Figure 4.6:  Changes in ASP
+
 uptake after KOPr agonist addition is concentration- 
dependent and inhibited by nor-BNI and pertussis toxin.  U50,488H (A), salvinorin  
A (B), DS-1-240 (C), and DS-3-216 (D) caused concentration-dependent increases in 
ASP
+
 uptake rate, measured at the time of maximum uptake rate.  This effect (at 10 µ) 
was significantly reversed by the addition of the KOPr antagonist nor-BNI (1 µM) (n = 
46-64 cells).  The addition of DMSO (0) as the vehicle control did not lead to a 
significant decrease in uptake from 0 for any of the agonists (One sample Student‟s t-
test). Experiments were carried out over 3 transfections with at least 2 dishes used per 
transfection.  *p <0.05, **p <0.01, ***p <0.001 compared to the vehicle control without 
drug (0).  
##
p <0.01, 
###
p <0.001 compared to 10 μM drug.  One-way ANOVA followed 
by a Bonferroni post test.    
U50,488H 
Salvinorin A 
DS-1-240 
DS-3-216 
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Figure 4.7:  nor-BNI and PTX have no effect on uptake of ASP
+
 on their own.  
Incubation of HEK-293 cells with nor-BNI for 30 min and PTX for 16-24 h had no 
effect on ASP
+
 uptake at 200 s after ASP
+
 addition compared to control cells (n = 31-47 
cells, over three transfections with at least 2 dishes used per transfection, One-way 
ANOVA followed by Bonferroni post test). 
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4.4.2.1 The effect of KOPr agonists in different cell lines 
To confirm the results seen in HEK-293 cells, the KOPr agonists were also screened in 
another kidney cell line, COS7 (green monkey kidney cells) and also a neuronal cell 
line, N2A (mouse neuroblastoma cells).  Both cell lines showed a positive correlation 
between YFP-hDAT expression and ASP
+
 uptake (Figure 4.8 and Figure 4.9).  Addition 
of 10 µM of the agonists caused a significant increase in ASP
+
 uptake in both cell lines 
of between 10 and 25%, and this effect was blocked by the addition of nor-BNI (1 µM) 
and PTX (100 ng/mL) (Figure 4.8f and Figure 4.9f).  Neither nor-BNI nor PTX caused 
changes in uptake themselves (Figure 4.8 and Figure 4.9).  While the increases in 
uptake were significant, they were less than the effect seen in HEK-293 cells.  These 
data confirm the results with HEK-293 cells and suggest that HEK-293 cells, which 
show a larger ASP
+
 effect than the other two cell lines and are much easier to transfect, 
are a good model for measuring DAT function in isolated cells. 
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Figure 4.8: Addition of 10 µM of KOPr agonists to COS7 cells causes an increase 
in ASP
+
 uptake that is reversible by nor-BNI and PTX.  U50,488H (A), salvinorin A 
(B), DS-1-240 (C), and DS-3-216 (D) (10 µM) all caused  significant increases in DAT 
function in COS7 cells.  This effect was significantly blocked by the addition of nor-
BNI (1 µM, 30 min) and PTX (100 ng/ml, 16-24 h).  The addition of DMSO as the 
vehicle control did not lead to a significant decrease in uptake from 0 for any of the 
agonists (One sample Student‟s t-test).  nor-BNI and PTX alone did not cause changes 
in the uptake of ASP
+ 
(E).  There was a positive correlation between YFP-hDAT 
expression and ASP
+
 uptake in COS7 cells (R
2
 = 0.5774) that was significantly different 
from 0 (p<0.0001).   n = 25-35, experiments were carried out over 3 transfections with 
at least 3 dishes used per transfections.  *p<0.05, **p <0.01, ***p <0.001 compared to 
DMSO control.  
#
p <0.01, 
###p <0.001 compared to 10 μM.  One-way ANOVA followed 
by a Bonferroni post test.    
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Figure 4.9: Addition of 10 µM of KOPr agonists to N2A cells causes an increase in 
ASP
+
 uptake that is reversible by nor-BNI and PTX.  U50,488H (A), salvinorin A 
(B), DS-1-240 (C) and DS-3-216 (D) (10 µM) caused a significant increase in DAT 
function in N2A cells.  This effect was significantly blocked by the addition of nor-BNI 
(1 µM, 30 min) and PTX (100 ng/ml, 16-24 h).  The addition of DMSO as a vehicle 
control did not lead to a significant decrease in uptake from 0 for any of the agonists 
(One sample Student‟s t test).  nor-BNI and PTX alone did not cause changes in the 
uptake of ASP
+ 
(E).  There was a positive correlation between YFP-hDAT expression 
and ASP
+
 uptake seen in these cells (R
2
 = 0.7054) which was significantly different 
from the DMSO control (p<0.0001).  n = 25-35, experiments were carried out over 3 
transfections with at least 3 dishes used per transfection.  **p <0.01, ***p <0.001 
compared to the DMSO control.  
#
p <0.01, 
###p <0.001 compared to 10 μM.  One-way 
ANOVA followed by a Bonferroni post test.    
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4.4.3 The effect of a 30 min incubation with KOPr agonists on ASP
+
 uptake 
 To investigate whether the KOPr agonists had a prolonged effect on DAT function, the 
effect on ASP
+
 uptake of a 30 min incubation of HEK-293 cells with KOPr agonists 
was measured.  This experiment is a between-cell design, and makes comparisons 
between groups of cells incubated with either vehicle or KOPr agonist.  Cells were 
incubated for 30 min with the KOPr agonist (10 µM), and then ASP
+
 containing the 
KOPr agonist was added and uptake was measured over 5 min. The total ASP
+
 uptake 
after 5 min was then normalised to YFP-hDAT expression and compared across 
treatment groups.  These experiments were carried out using two sets of ASP
+ 
stock and 
are therefore presented separately.  The control graphs (Figure 4.10c and d) represent 
the average YFP-hDAT expression over the different treatment groups, and these values 
did not differ significantly.  U50,488H and salvinorin A both caused a significant 
increase in ASP
+
 uptake after 30 min (Figure 4.10a, p<0.05 and p<0.01, respectively); 
whereas, DS-1-240 and DS-3-2216 had no effect (Figure 4.10b), although the decrease 
seen with DS-1-240 was almost significant (Student‟s t-test, p = 0.0861). 
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Figure 4.10:  Long-term effects of KOPr agonists on ASP
+
 uptake in HEK-293 
cells.  A) U50,488H and salvinorin A significantly increased ASP
+
 uptake after 30 min; 
whereas, B) DS-1-240 and DS3-216 had no significant effect.  C,D) YFP-hDAT 
expression was consistent over the replicates.  n = 30-40 cells over 3 transfections with 
a minimum of 2 dishes per transfection.  One-way ANOVA followed by a Bonferonni 
post test, *p<0.05, **p<0.01. 
 125 
 
4.4.4 Acute cell surface expression studies 
4.4.4.1 ASP
+
 binding studies 
To investigate whether the rapid increase in function observed following KOPr agonist 
addition was caused by an increase in the cell surface expression of YFP-hDAT, ASP
+
 
binding studies, cell surface biotinylation, and TIRFM were carried out on HEK-293 
cells.  ASP
+
 binding studies were carried out on cells that had been incubated in the test 
KOPr agonist for the time required to give the maximal functional change in ASP
+
 
uptake (Table 4.1).  Medium containing the test compound was then replaced with 
ASP
+
 containing the test compound, and 1 min of data was collected, taking images 
with the shortest wait between them (about 1.7 s).  The slope of the line was analysed 
from 3 to 7 s and this was normalised to YFP-hDAT expression (Figure 4.11b).   Data 
showed that there was a non-significant increase seen with U50,488H, salvinorin A, and 
DS-3-216, and a significant increase of ASP
+ 
binding to YFP-hDAT after DS-1-240 
treatment. 
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Figure 4.11:  KOPr agonists cause no changes in binding of ASP
+
 to YFP-hDAT.  
(A) Incubation of cells with KOPr agonists for the time required to give a maximal 
effect caused a non-significant increase in ASP
+
 binding to YFP-hDAT for U50,488H, 
salvinorin A, and DS-3-216 and a significant increase in binding for DS-1-240.  B) 
There was no significant difference between the YFP-hDAT expression of the cells 
analysed between groups.  n = 36-52 over 4 transfections with a minimum of 2 plates 
per transfection.  ***p<0.001, one-way ANOVA followed by a Bonferroni post test.   
 
A 
B 
 127 
 
4.4.4.2 Cell surface biotinylation studies 
Cell surface biotinylation studies were also carried out to determine whether the 
changes in function seen by ASP
+
 uptake were due to changes in cell surface expression 
of YFP-hDAT.  Initial experiments were carried out with cells incubated for the time 
taken for the compounds to have their maximal functional effect (salvinorin A: 60 s, 
U50,488H and U69,593: 100 s, DS-1-240 and DS-3-216: 200 s) (Figure 4.12a).  The 
classic KOPr agonist U69,593 was also used in this study, and the time to maximal 
effect measured for U50,488H was selected.  As U69,593 was dissolved in absolute 
ethanol rather than DMSO, it was presented in a separate graph with its own vehicle 
(Figure 4.12b).  After the gels were scanned for YFP-hDAT, they were immunoblotted 
for GAPDH, which is found only intracellularly in HEK-293 cells, to confirm that the 
cells had not been lysed before the biotin had been added which would lead to false 
positives.  There was no detectable increase in cell surface expression of YFP-hDAT at 
these time points for any of the compounds studied (Figure 4.12a and b) and no 
GAPDH was present in any of the cell surface fractions measured.  
 
4.4.4.3 Total internal reflection fluorescence microscopy 
To confirm either the positive result gained from the ASP
+
 binding assays or the 
negative result gained from the cell surface biotinylation assays, the more sensitive 
technique, TIRFM, was also conducted at the early time points.  TIRFM experiments 
were run for 300 s with addition of the compound occurring at 100 s and images taken 
every 5 s.  The results confirmed cell surface biotinylation data as no significant 
changes in YFP-hDAT cell surface density were found for any of the KOPr agonists 
(Figure 4.14a-e).   
 
Overall these data suggest that the initial increase in transport function of YFP-hDAT 
after KOPr activation is not due to increases in cell surface expression of YFP-hDAT, 
but as there was an increase in ASP
+
 binding to the cells it suggests that there is an 
increase in active YFP-hDAT on the cell surface.     
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Figure 4.12:  KOPr agonists do not alter cell surface expression of YFP-hDAT at 
short time points.  Cells were treated for the time taken for the agonists to have their 
maximal functional effect and then cell surface biotinylated.  There was no detectable 
change in cell surface expression after agonist treatment for any compound tested.  
Shown is a representative gel for YFP-hDAT and Western blot for GAPDH 
respectively. T = total fraction, I = internal fraction, CS = cell surface fraction (n = 8-11 
preparations). Data are presented as average ± SEM.  One-way ANOVA followed by 
Bonferroni post test showed no significant differences from the control.   
A 
B 
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Figure 4.13:  KOPr agonists do not alter cell surface expression of YFP-hDAT at 
short time points as measured by TIRFM.  U50,488H (A), U69,593 (B), salvinorin A 
(C), DS-1-240 (D), and DS-3-216 (E) did not alter cell surface expression of YFP-
hDAT at 200 s after drug treatment (n = 12-16).  Shown are representative images taken 
at time 0 and 300 s for each treatment (F).  Two-way ANOVA followed by Bonferroni 
post test. 
 130 
 
4.4.5 Chronic effects of KOPr agonists on cell surface expression of YFP-hDAT 
As there were changes in uptake at 30 min with U50,488H and salvinorin A (Figure 
4.10), the effect of a 30 min incubation with all of the test compounds on cell surface 
expression of YFP-hDAT was investigated using TIRFM and cell surface biotinylation.  
Using cell surface biotinylation, a 30 min incubation with salvinorin A (Figure 4.16), 
U69,593 (Figure 4.15)  and DS-3-216 (Figure 4.18) all caused increased cell surface 
expression of YFP-hDAT. Significant increases of 25% ± 11.5% (salvinorin A), 37% ± 
14.7% (U69,593), and 23% ± 7.3% (DS-3-216) were obtained.   TIRFM studies were 
conducted over a period of 40 min, with one image taken every minute.  The test 
compound was added after 10 min of baseline recording, and a further 30 min of images 
were collected.  TIRFM studies confirmed the increases in cell surface expression for 
salvinorin A and U69,593 with significant increases of 11.5% ± 3.5% and 9.3% ± 3%, 
respectively.  While DS-3-216 showed an increase of 6.1% ± 2.1% after 30 min 
treatment, the increase was not significant.  Interestingly, U50,488H (Figure 4.15) and 
DS-1-240 (Figure 4.18) had no effect on cell surface expression, suggesting there may 
be differences between how these compounds regulate DAT, or that any changes that 
may occur are too small for these techniques to measure. 
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Figure 4.14: A 30 min incubation with U50,488H does not change cell surface 
expression of YFP-hDAT.  (A) TIRFM studies were carried out on HEK-293 cells 
expressing YFP-hDAT and myc-rKOPr, with agonist addition occurring at 10 min and 
treatment lasting for 30 min.  There were no changes seen in cell surface expression of 
YFP-hDAT throughout the 30 min incubation, Two-way ANOVA followed by 
Bonferroni post test (n = 12-16).  Shown is a representative cell with images taken at -
10, 0, 10, 20, and 30 min. (B) Cells were also incubated with U50,488H for 30 min 
before biotinylation studies were carried out.  No changes were seen in cell surface 
expression of YFP-hDAT after 30 min, one-way ANOVA followed by Bonferroni post 
test. T = total, I = internal, CS = cell surface. Values are mean ± SEM (n = 9-13). 
B 
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Figure 4.15: A 30 min incubation with salvinorin A led to a significant increase in 
cell surface expression of YFP-hDAT.  (A) TIRFM studies showed that after a 29 min 
incubation with salvinorin A, a significant increase in YFP-hDAT was seen. Two-way 
ANOVA followed by Bonferroni Post test, *p<0.05.  A representative cell is shown 
with images at -10, 0, 10, 20, and 30 min.  (n = 7-9).  (B) Cells were also incubated with 
salvinorin A for 30 min before cell surface biotinylation experiments.  A significant 
increase in cell surface expression of YFP-hDAT was seen One-way ANOVA followed 
by Bonferroni Post test, **p<0.01.  (n = 12-16).  T = total, I = internal, CS = cell 
surface. 
B 
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Figure 4.16: A 30 min incubation with U69,593 led to a significant increase in cell 
surface expression of YFP-hDAT.  (A) TIRFM studies showed that after a 29 min 
incubation with U69,593 a significant increase in YFP-hDAT was seen.  Two-way 
ANOVA followed by Bonferroni Post test, *p<0.05, **p<0.01 (n = 12).  A 
representative cell is shown with images at -10, 0, 10, 20, and 30 min.  (B) Cells were 
also incubated with U69,593 for 30 min before cell surface biotinylation experiments.  
A significant increase in cell surface expression of YFP-hDAT was seen.  One-way 
ANOVA followed by Bonferroni Post test, *p<0.05. (n = 6-8).  T = total, I = internal, 
CS = cell surface. 
B 
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Figure 4.17: A 30 min incubation with DS-1-240 does not change cell surface 
expression of YFP-hDAT.  (A) TIRFM studies were carried out on HEK-293 cells 
expressing YFP-hDAT and myc-rKOPr, with drug addition occurring at 10 min.  There 
were no changes seen in cell surface expression of YFP-hDAT throughout the 30 min 
incubation with the drug, two-way ANOVA followed by Bonferroni post test (n = 9-
10).  Shown is a representative cell with images taken at -10, 0, 10, 20, and 30 min.  (B) 
Cells were also incubated with DS-1-240 for 30 min before biotinylation studies were 
carried out.  No changes were seen in cell surface expression of YFP-hDAT after 30 
min, one-way ANOVA followed by Bonferroni post test (n = 12-13). T = total, I = 
internal, CS = cell surface. 
B 
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Figure 4.18: A 30 min incubation with DS-3-216 led to a significant increase in cell 
surface expression of YFP-hDAT.  (A) TIRFM studies showed that after a 29 min 
incubation with DS-3-216, a non-significant increase in YFP-hDAT was seen, two-way 
ANOVA followed by Bonferroni post test (n = 12-19).  A representative cell is shown 
with images at -10, 0, 10, 20, and 30 min.  (B) Cells were also incubated with DS-3-216 
for 30 min before cell surface biotinylation experiments.  A significant increase in cell 
surface expression of YFP-hDAT was seen, one-way ANOVA followed by Bonferroni 
post test (n = 9).  T = total, I = internal, CS = cell surface.  
B 
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4.5 Discussion 
Previous studies have identified that acute KOPr activation increases DAT function in 
rat brain tissue and in cultured cells (Chapter 3, T. Shippenberg, unpublished data, 
Thompson et al. 2000).   Here we showed that the classic KOPr agonists U50,488H and 
U69,593 and the novel agonists salvinorin A, DS-1-240, and DS-3-216 all caused acute 
increases in DAT function in cells transfected with YFP-hDAT and myc-rKOPr, and 
this increase in function was  nor-BNI- and PTX-sensitive.  Salvinorin A and U50,488H 
also caused increased DAT function after a 30 min incubation, with DS-1-240 and DS-
3-216 having no significant effects on ASP
+
 uptake.  One way in which increases in 
transporter function can occur is through increased cell surface expression.  The RDEV 
results of Chapter 3 from rat brain tissue suggested that there was an increase in Vmax 
but not Km with the KOPr agonists, suggesting increased cell surface expression..  As 
the model used for those experiments was the low to infinite trans model, it was 
expected that these changes in cell surface expression either occurred immediately, or 
after a longer incubation since the compound of interest is present in the RDEV 
chamber for up to 1 h.  In HEK-293 cells co-transfected with YFP-hDAT and myc-
rKOPr, none of the compounds had an effect on cell surface expression of YFP-hDAT 
at the short time points studied, but there was an trend towards an increase in ASP
+
 
binding to YFP-hDAT, which suggests there may be an increase in active YFP-hDAT at 
the cell surface.  After a longer 30 min incubation, salvinorin A and U69,593 caused 
significant increases in YFP-hDAT expression at the cell surface in both TIRFM and 
cell surface biotinylation studies. DS-3-216 showed a significant increase in cell surface 
expression in biotinylation studies but a non-significant increase with TIRFM.  The 
other compounds studied: U50,488H and DS-1-240, showed no change in cell surface 
expression at this later time point. These results are summarised in Table 4.2.   
 
4.5.1 Preliminary experiments 
Preliminary experiments were carried out to find the time of maximal effect of the 
agonists on DAT function.  This was so that these time points could be used for 
subsequent experiments with confidence that an effect would not be missed.  By taking 
slope measurements every 30 s, it was found that salvinorin A had the fastest onset of 
action, followed by U50,488H and then DS-1-240 and DS-3-216 (Table 4.1).  This may 
reflect the fast onset of action reported for salvinorin A in animals studies, where it is 
seen to reach the brain within 40 s after i.v. administration (Hooker et al. 2008).  These 
data also mirror that found with RDEV in rat brain tissue (Chapter 3), in which the 
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effect of salvinorin A was measured after 1 min; whereas, the other agonists‟ activities 
were seen at 4 min.   
 
Pilot experiments were also carried out to confirm the co-expression of YFP-hDAT and 
myc-rKOPr in all the cell lines used for this study (Figure 4.3).  When cells are co-
transfected, it is assumed that if one of the plasmids is expressed in a cell, the other will 
be as well.  Figure 4.3 demonstrated that YFP-hDAT and myc-rKOPr were co-
expressed in the same cells, with varying amounts of both plasmids seen in different 
cells.  As there needs to be a ratio of about two KOPr to one DAT to see functional 
effects of KOPr activation (B. Kivell, personal communication), and as  different cells 
express varying amounts of both plasmids, initial data was also used to find a suitable 
range of YFP-hDAT expression levels to collect data from.  It was found in this study 
that cells that had as AFU value for YFP-hDAT between 250 and 1000 showed 
increases in ASP
+
 uptake after KOPr agonist addition.  This demonstrates that cells 
containing YFP-hDAT between this range contained the correct ratio of KOPr to DAT 
for modulation of DAT to occur.  Data from cells with an AFU within this range were 
used for all future confocal microscopy experiments.  It was also found that cells with 
an AFU for YFP-hDAT below 100 did not demonstrate linear uptake curves and; 
therefore, cells with an AFU for YFP below 100 were classed as non-transfected cells.   
 
4.5.2 Functional changes 
All of the KOPr agonists led to increased ASP
+
 uptake at the acute time points between 
60 s and 200 s (Figure 4.6, 4.8, 4.9).  In HEK-293 cells, salvinorin A had the largest 
effect, with an increase of 40% at 1 min; whereas‟ the effects of the other agonists 
investigated were not maximal until 100 s (U50,488H) or 200 s (DS-1-240 and DS-3-
216) after agonist addition.  U50,488H, DS-1-240, and DS-3-216 had lesser effects on 
ASP
+
 uptake by YFP-hDAT and caused increases of about 20% in HEK-293 cells.  
However, in the other cell types used to confirm these results, all compounds tested 
caused changes in uptake of between 10 and 25%, with salvinorin A not showing an 
increased effect relative to the other compounds, as was seen in HEK-293 cells.  This is 
most likely due to HEK-293 cells having differences in subtypes and amounts of 
signlling molecules compared to the other two cell lines.  Overall, uptake in HEK-293 
cells was higher than that seen in the other cell systems.  Both N2A and COS7 cells are 
more difficult to transfect then HEK-293 cells, and even though more Lipofectamine 
2000 reagent was used and double the plasmid DNA for each protein was used, 
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transfection rates were generally lower than that of HEK-293 cells.  Therefore from this 
data it was decided that all further experiments would be carried out in HEK-293 cells.  
Even though it would be best to carry out these experiments in a neuronally-derived cell 
line, such as N2A cells, there has been evidence that HEK-293 cells have neuronal 
properties (Shaw et al. 2002).  HEK-293 cells stained for several proteins that are only 
expressed in neuronal cells, such as neurofilament subunit M and L, and also stained for 
SERT which is not present in the kidney.  Shaw et al. proposed that the transformation 
of HEK-293 cells with adenovirus 5 led to this neuronal protein expression, with 
adenovirus appearing to target neuronal cells rather than kidney cells.  As there is a 
small population of cells with neuronal properties in the developing kidney the author 
suggests that these cells were targeted for transformation, leading to a kidney cell line 
which shows neuronal characteristics rather than displaying a strictly renal epithelial 
phenotype (Shaw et al. 2002). 
 
The KOPr-1 is a Gi/o G protein-coupled receptor and is sensitive to PTX.  PTX is a toxin 
produced by the bacterium Bordetella purtussis that causes whooping cough.  PTX 
catalyses the ADP ribosylation of the α subunit of G proteins, preventing interaction 
with GPCR and preventing the transfer of GDP to GTP, keeping the Gα subunit in a 
GDP-bound state (Pizza et al. 1988).  Incubation of HEK-293, N2A, and COS7 cells for 
16-24 h with PTX before ASP
+
 addition led to a complete inhibition of the effect of the 
KOPr agonists, confirming that these compounds work through a KOPr-1 pathway.  A 
previous unpublished report also found that the effect of salvinorin A on DAT function 
was inhibited by PTX (T. Shippenberg, unpublished data).  In HEK-293 cells, 
phosphorylation of ERK1/2 by the KOPr agonist U50,488H was inhibited by addition 
of PTX (200 ng/mL, 18 h before experiment) (Bruchas et al. 2007b), confirming our 
results in HEK-293 cells.  Interestingly, it has been shown that DS-3-216 (MOM-salB) 
appears to have PTX insensitive effects in immortalised astrocytes in which incubation 
with 100 ng/mL of PTX for 16-24 h had no effect on DS-3-216-induced ERK1/2 
phosphorylation (McLennan et al. 2008).  Immortalised astrocytes treated with the 
classic KOPr agonist U69,593 in the presence of PTX showed no phosphorylation of 
ERK1/2, indicating that the phosphoryltion of ERK1/2 by DS-3-216 in the presence of 
PTX was specific to DS-3-216 (McLennan et al. 2008).  The phosphorylation of MAPK 
by U50,488H in CHO cells expressing hKOPr was also inhibited by prior incubation 
with PTX, but U50,488H internalisation was not inhibited by PTX, suggesting that 
activation of G proteins is not necessary for hKOPr internalisation  (Li et al. 1999).  
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There have been no studies carried out on DS-1-240 with PTX, so the present study is 
the first to show that activation of YFP-hDAT by DS-1-240 is mediated through a Gi/o 
PTX sensitive mechanism.  The data in this study show that the increase in ASP
+
 uptake 
by YFP-hDAT is PTX-sensitive, suggesting that the modulation of DAT by the agonists 
investigated is carried out via a Gi/o dependent KOPr pathway.  
 
Nor-BNI is a long-acting KOPr antagonist that has previously been shown to block the 
effects of U50,488H (Negus et al. 1997; Bruchas et al. 2006), salvinorin A (Chavkin et 
al. 2004; Braida et al. 2009), and DS-3-216 (McLennan et al. 2008; Wang et al. 2008) in 
animal and cell models.  Our data also show that incubation with nor-BNI attenuates the 
effects of these agonists, along with DS-1-240, on YFP-hDAT function in all the cell 
lines studied.  This confirms that the increase in ASP
+
 uptake by YFP-hDAT seen by 
these agonists is KOPr mediated.   
 
After a 30 min incubation with the KOPr agonist compounds, only U50,488H and 
salvinorin A caused a significant increase in ASP
+
 uptake by YFP-hDAT (Figure 4.10).  
Both DS-3-216 and DS-1-240 have been shown to have longer half lives than that of 
salvinorin A (Harding et al. 2005; Wang et al. 2008) and are more potent at activating 
KOPr then salvinorin A (Harding et al. 2005; Wang et al. 2008).  Therefore, it was 
expected that these compounds would lead to increased ASP
+
 uptake by YFP-hDAT 
after 30 min.  One explanation could be that the more potent induction of cell surface 
internalisation of human KOPr by DS-3-216 compared to both salvinorin A and 
U50,488H (Wang et al. 2008) leads to a decrease in the interaction between KOPr and 
DAT.  A study carried out in 2008 showed that while U50,488H, salvinorin A, and DS-
3-216 all induced a 40% decrease in human KOPr cell surface expression after 30 min, 
DS-3-216 was much more potent, with EC50 values of 97.1 nM, 522 nM, and 7.4 nM, 
respectively (Wang et al. 2008).  DS-3-216 was also much more potent than U50,488H 
and salvinorin A at down-regulating KOPr by decreasing total mature KOPr, with DS-
3-216 showing an EC50 value of 6.3 nM, compared to U50,488H and salvinorin A 
which gave values of 125 nM and 142 nM, respectively (Wang et al. 2008).  It has also 
been shown using co-immunoprecipitation and BRET that KOPr and DAT physically 
interact, and this is proposed to contribute to KOPr‟s ability to up-regulate DAT 
function (T. Shippenberg, unpublished data).  This increase in potency for down-
regulation and internalisation may inhibit the interaction of KOPr and DAT, leading to 
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no change in function seen at this time point for DS-3-216 and DS-1-240.  Further 
studies will be needed to test this hypothesis.   
 
4.5.3 Cell surface expression changes 
As one of the ways in which DAT function is increased is by increasing cell surface 
expression, we investigated whether treatment with KOPr agonists could lead to 
increases in the cell surface expression of YFP-hDAT in HEK-293 cells.  Activation of 
DRD2 and DRD3 receptors have both been shown to lead to increased DAT function 
and a rapid increase in cell surface expression of DAT (Bolan et al. 2007; Zapata et al. 
2007).  In the present study we found that while activation of KOPr led to a rapid 
increase in DAT function, there was no significant increase in YFP-hDAT cell surface 
expression during this time-frame with either TIRFM or cell surface biotinylation 
(Figure 4.12, 4.13).  This data suggest that something other than cell surface expression 
is causing the increase in ASP
+
 uptake seen with KOPr agonism at these rapid time 
points.  As there was an increase in binding of ASP
+
 to YFP-hDAT (Figure 4.11) it may 
be due to increased activation of previously inactive DAT already present on the cell 
surface.  Another way in which transporters can be up-regulated is by increasing uptake 
turnover rates, which is another possibility for increased ASP
+
 binding to YFP-hDAT 
(Meiergerd et al. 1994b).  
 
To investigate if the increases in uptake of ASP
+
 observed at 30 min with the KOPr 
agonists U50,488H and salvinorin A, were due to increased cell surface expression of 
DAT, cell surface biotinylation and TIRFM experiments were carried out for all the 
compounds investigated (Figure 4.14-4.18).  Interestingly, there was no change in cell 
surface expression of YFP-hDAT seen with the classic agonist U50,488H but there was 
with the positive control, U69,593.  This suggests that these two classic agonists may 
activate slightly different pathways and have different long-term effects.  Previous 
studies have identified differences between the effects of U50,488H and U69,593 on 
KOPr mediated pathways.  A study investigating the effects of chronic (20 h) 
incubation of CHO cells expressing hKOPr found that salvinorin A, U50,488H, and 
U69,593 all decreased the expression of the G protein subunit Gαi3; whereas, only 
U50,488H increased expression of G12, providing evidence towards biased agonism that 
often occurs in tolerance to opioid agonists (Xu et al. 2008).  Furthermore, a study 
carried out to investigate the effects of KOPr on amphetamine-induced hyperlocomotion 
found that while both U69,593 and U50,488H initially decreased the hyperlocomotion 
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response, after 40 min U50,488H appeared to increase hyperlocomotion; whereas, 
U69,593 continued to attenuate it (Vanderschuren et al. 2000).  The authors concluded 
that these different effects may be due to a KOPr-independent mechanism that is 
somehow activated by U50,488H.   
 
The RDEV data of Chapter 3 suggested that there was an increase in cell surface 
expression of DAT after U50,488H and DS-1-240 treatment.  Possible reasons why this 
may not have occurred in the cell studies of this chapter include the time point chosen to 
measure changes in cell surface expression, with a longer incubation (30-60 min) 
possibly leading to increased expression that wasn‟t seen in the cell studies.  Also not 
all data from tissue models will translate to a cell model due to the differences between 
rat brain tissue samples and, for example, a kidney cell line like HEK-293.  As HEK-
293 cells do not express the same proteins as NAc tissue, there may be many other 
interacting factors that are involved in the increased cell surface expression in tissue 
samples compared to isolated cells.  For example dopaminergic neurons contain DA 
receptors that are not present in HEK-293 cells, and the signalling pathways within the 
rat brain tissue may be regulated differently to those found within HEK-293 cells. 
 
After a 30 min incubation with salvinorin A, there was a significant increase in cell 
surface expression of YFP-hDAT, measured by both cell surface biotinylation and 
TIRFM.  There were also significant increases seen with the novel compound DS-3-216 
with cell surface biotinylation but not TIRFM.  This was unexpected as ASP
+
 uptake 
studies at this time point showed no changes in uptake, but these results do match the 
increases seen in the RDEV studies.  No increase in cell surface expression was 
observed with DS-1-240 at 30 min. 
 
Both cell surface biotinylation and TIRFM experiments have limitations.  As mentioned 
previously, cell surface biotinylation studies can overestimate the intracellular fraction 
due to biotin being unable to bind to proteins found within tight invaginations on the 
plasma membrane.  Biotin can also have a low efficiency of binding to cell membrane 
proteins.  TIRFM studies allow a small evanescent field to be visible from the cover 
slip.  In our experiments we set our TIRFM system so that the evanescent field was 
close to 100 nm from the coverslip, which means that DAT contained in vesicles close 
to the plasma membrane would be measured as cell surface DAT.  This means that 
when these vesicles fuse to the plasma membrane they are not measured as an increase 
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in cell surface expression.  However as vesicles of DAT further away from the cell 
membrane move towards and fuse with the membrane an increase in fluorescence is 
measured.  TIRF experiments also do not allow measurement of the whole cell 
memebrane and therefore if the cell shape, adhesion, or motility occurs this may effect 
the measurements gained.  Our results showed a larger increase in cell surface 
expression of YFP-hDAT with cell surface biotinylation compared to TIRFM.  This 
difference between techniques has previously been observed  (Furman et al. 2009a) and 
is thought to occur due to the abovementioned limitations of both techniques. 
 
Overall, short-term exposure of HEK-293 cells to KOPr agonists did not alter cell 
surface expression of transfected YFP-hDAT, which suggests that the initial increase in 
YFP-hDAT function is modulated by a trafficking-independent process.  After a 30 min 
incubation of the cells with the agonists, the addition of U69,593, salvinorin A, and DS-
3-216 led to increased cell surface expression of YFP-hDAT, with no changes observed 
for U50,488H and DS-1-240.  
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Table 4.2:  Summary of results of Chapter 4 
KOPr 
agonist 
Increased 
ASP
+
 
uptake 
acute  
 (< 5 min) 
Increased 
ASP
+
 
uptake at 
30 min 
Increased cell 
surface 
expression of 
YFP-hDAT, 
acute 
 (< 5 min) 
Increased 
cell surface 
expression 
of YFP-
hDAT at 30 
min 
Increased 
binding of ASP
+
 
acute  
 (< 5 min) 
U50,488H Yes Yes No No Not significant 
U69,593 Not 
investigated 
Not 
investigated 
No Yes Not  
investigated 
Salvinorin 
A 
Yes Yes No Yes Not significant 
DS-1-240 Yes No  No No Yes 
DS-3-216 Yes No No Yes Not significant 
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4.6 Conclusion 
To conclude, all of the KOPr agonists investigated led to increased YFP-hDAT 
function, as measured by ASP
+
 uptake, at acute time points.  This increase in function 
was not caused by an increase in cell surface expression at these time points as 
measured by cell surface biotinylation and TIRFM.  However, there was a non-
significant increase in ASP
+
 binding observed which suggests that the increase in uptake 
may be due to increased active DAT at the cell surface.  At a 30 min time point 
salvinorin A and U50,488H still caused a significant increase in ASP
+
 uptake.  Cell 
surface expression studies at this time point showed that salvinorin A, U69,593, and 
DS-3-216 led to increased cell surface expression of YFP-hDAT, whereas no change 
was observed with U50,488H or DS-1-240.  This implies that the KOPr agonists studied 
may have different effects on DAT.  This study demonstrated that the modulation of 
DAT by KOPr can be measured successfully in a cell model, and that further 
investigation into the effects of these agonists on DAT function is warranted.   
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Chapter 5: Involvement of the ERK1/2 signalling pathway and lipid 
rafts on the modulation of DAT by KOPr 
 
5.1 Introduction 
Cell membranes are thought to contain sphingolipid- and cholesterol-dense areas called 
lipid rafts.  Lipid rafts are localised areas of the plasma membrane in which cell 
membrane proteins can be more easily regulated, and these areas of unique lipid 
composition are thought to be involved in processes such as endocytosis and cell 
signalling (Kenworthy et al. 2004).  Although many studies support the existence of 
these regions, there is still contention as to their existence and the role in which they 
play in the cell (Reviewed by Pike 2003).  It is also not known exactly how these rafts 
are structured. There are several different hypotheses put forward on the types of lipid 
raft that are found in cells, including stable immobile rafts, stable mobile rafts, dynamic 
partitioning in which molecules move in and out of, and no rafts at all (Kenworthy et al. 
2004).      
 
Both KOPr and DAT have been found within lipid-rich regions of the cell membrane, as 
well as throughout the rest of the cell membrane (Xu et al. 2006; Adkins et al. 2007; 
Foster et al. 2008).  Regulation of DAT by the PKC activator PMA differs between lipid 
rafts and non-lipid rafts within the cell membrane, suggesting that DAT found in lipid 
rafts may have a different regulatory role then DAT distributed within the rest of the 
cell membrane (Foster et al. 2008).  Interestingly, lipid raft disruption by the cholesterol 
depleter, methyl-β-cyclodextrin (MβC), does not lead to movement of DAT from lipid 
rafts into the surrounding membrane, which is what occurs with the NET and SERT 
associated within lipid rafts (Foster et al. 2008), but cholesterol depletion did lead to 
decreased function of DAT.  One report demonstrated that this effect was not due to 
changes in DAT cell surface expression (Adkins et al. 2007), but another found that 
DAT expression decreased by 16% in the cell membrane (Foster et al. 2008).  These 
differences may be due to the different cell lines used, with the first study using murine 
N2A cells (Adkins et al. 2007) and the other pig renal epithelial cells (LLCPK1) (Foster 
et al. 2008).  Overall these data suggest that lipid rafts are involved in the functional 
regulation of DAT and that disruption of lipid rafts leads to a decrease in function, 
possibly as a result of a decrease in cell surface expression.     
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One study has reported that KOPr is localised within lipid rafts (Xu et al. 2006).  In 
CHO cells expressing FLAG-hKOPr, disruption of lipid rafts with MβC led to an 
increase in affinity of hKOPr for U50,488H, an increase in interaction between hKOPr 
and Gi/o, and an increase in ERK1/2 activation (Xu et al. 2006).  It was suggested that 
lipid rafts are involved in the coupling of GPCR to G proteins and may be involved in 
the conformation of the KOPr receptor.  Overall these data show that the lipid raft 
environment is important for the functional regulation of both KOPr and DAT, and the 
disruption of this environment leads to dysregulation of the signalling systems that 
activate and regulate these two transport proteins. 
 
A signalling pathway that both KOPr and DAT share is the ERK1/2 pathway.  KOPr 
activation leads to activation of ERK1/2 (Belcheva et al. 2005; Kim et al. 2006; 
McLennan et al. 2008), and activation of ERK1/2 leads to increased DAT function and 
cell surface expression (Moron et al. 2003; Bolan et al. 2007; Zapata et al. 2007).  The 
ERK1/2 pathway is also involved in the action of drugs of abuse, with acute cocaine 
and amphetamine causing a rapid and transient increase in ERK1/2 phosphorylation that 
is mediated through DRD1 receptors and NMDA receptors (Valjent et al. 2000; Valjent 
et al. 2005).  Thus, the link between novel KOPr agonists and the ERK1/2 pathway may 
be significant in identifying potential pharmacotherapies for drug abuse. 
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5.2 Aims 
The aim of this chapter is to investigate possible ERK1/2-related mechanisms in which 
KOPr activation leads to increased DAT function and the role of lipid raft localisation 
in this process.  Both KOPr and DAT are found within lipid rafts and both have links to 
ERK1/2 signalling. One relationship to be tested is whether the increase in cell surface 
expression seen with both U69,593 and salvinorin A is affected by ERK1/2 inhibition.  
It is hypothesised that lipid raft disruption and inhibition of ERK1/2 will prevent the 
increases in DAT function caused by KOPr activation, and that ERK1/2 inhibition will 
also inhibit the increased cell surface expression of DAT after a 30 min incubation with 
these drugs (see Chapter 4).   
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5.3 Methods 
5.3.1 Western blotting for total protein 
HEK-293 cells were plated and transfected as previously described (sections 2.1.2 and 
2.1.3).  To investigate if the increase in cell surface expression seen with U69,593 and 
salvinorin A is due to changes in total protein, YFP-hDAT-transfected HEK-293 cells 
were treated with 10 µM of each KOPr agonist for 30 min.  The cells were lysed for 1 
hr at 4°C on a rocker in 400 µL of RIPA buffer containing 0.01% protease inhibitor.  
Cell lysates were transferred into microcentrifuge tubes and centrifuged in a benchtop 
microcentrifuge for 30 min at 4°C at 16,000 g.  A 50 µL sample was removed from 
each lysate and 15 µL of 5 x reducing buffer containing 10% β-mercaptoethanol was 
added (Appendix 1) and 20 µL loaded onto a 10% SDS-PAGE gel (Appendix 1).  The 
gel was run for 90 min at 120 V, and the fluorescence of YFP-hDAT was read on a 
fluorescence laser scanner ((Fujifilm FLA-5100, Fuji Film).  The proteins on the gel 
were then transferred onto a PVDF membrane as described in section 2.4.  Tubulin was 
probed as a loading control, YFP-hDAT was normalised to tubulin and then normalised 
to controls on each gel to allow comparisons between gels. 
 
5.3.2 Lipid raft disruption 
HEK-293 cells were plated and transfected as previously described (sections 2.1.2 and 
2.1.3), and ASP
+
 uptake experiments were carried out (Section 2.5.1).  To disrupt lipid 
rafts, cells were incubated for 10 min with 10 mM MβC (Sigma) prior to the ASP+ 
uptake measurements.  Data were analysed as previously described (Section 2.5.3).  To 
investigate the effect of lipid raft disruption on basal ASP
+
 uptake of transfected and 
non-transfected cells, the uptake before addition of the compound was calculated and 
then normalised to the YFP-hDAT expression for each cell.  Cells were classed as non-
transfected if their YFP-hDAT expression was under 100 AFU. Only cells with a YFP-
hDAT expression of between 250 and 1000 AFU were used in the study, as described in 
Chapter 4.  
 
5.3.3 Fluorescence recovery after photo-bleaching (FRAP) 
5.3.3.1 Experimental protocol 
HEK-293 cells were plated and transfected in 35 mm glass-bottom dishes as previously 
described (section 2.1.2 and 2.1.3).  FRAP was conducted as previously described (X. 
Yu, personal communication, Adkins et al. 2007).  An Olympus Fluoview FV1000 
confocal microscope was used to conduct FRAP.  The culture medium was replaced 
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with 1 mL of 37°C KREBS buffer, and the cells were placed in a heated cell chamber 
on the microscope stage and left to equilibrate for 5 min.  Using the 40X water objective 
lens, a single cell with a distinct plasma membrane was brought into focus and zoomed 
in on.  Using the time controller, a protocol was created so that 4 pre-bleach images 
were taken 10 s apart using the 473 laser with the YFP filter (485 nm excitation; 545 nm 
emission).  The pre-bleach imaging was followed by bleaching of a ROI of the plasma 
membrane of the cell.  ROIs were elliptic in shape with an average diameter of 4 µm.  
Bleaching was conducted over 200 images taken at maximum speed with the 473 laser 
set at 100%.  After bleaching, post-bleaching images were collected, with 27 images 
taken 10 s apart.  This allowed enough time for maximum recovery of the bleached 
region.  For MβC-treated samples, cells were treated with 10 mM MβC for 10 min 
before replacement of the culture medium with KREBS buffer. 
 
5.3.3.2 Data analysis 
To analyse the FRAP data, the pre- and post-bleach images were appended using 
Fluoview FV1000 software.  Then three ROIs were taken using the Fluoview FV1000 
software.  These three ROIs were: a) the bleached region, b) the whole cell (a control 
for estimating unintentional photo-bleaching), and c) a non-fluorescent background 
control. The integrated fluorescence was determined at different time points for these 
three regions.  The bleached region was then corrected for background and 
unintentional photo-bleaching and normalised so that the pre-bleach fluorescence 
intensity was 1.  The normalised data were then entered into GraphPad Prism, and the 
FRAP parameters Mf (mobile fraction, or recovery plateau) and t1/2 (time taken for half 
Mf to be reached) were found using a one-phase exponential association non-linear 
regression model.           
 
5.3.4 Western blotting for P-ERK1/2 
HEK-293 cells were plated and transfected in 35 mm plastic petri dishes as previously 
described (sections 2.1.2 and 2.1.3).  
 
For time course experiments, cells were serum-starved for 30 min in DMEM followed 
by UV treatment for 1 h (positive control), or treatment with KOPr agonist for 0 s, 60 s,, 
100 s (U50,488H only), 200 s (DS-1-240 and DS-3-216 only), 5, 10, 20, 30, and 60 
min.  For inhibitor experiments, cells were serum-starved for 30 min and then treated 
with the MEK inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(o-
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aminophenylmercapto)butadiene (U0126, 20 µM, Sigma) for 30 min before KOPr 
agonist addition.  MEK directly phosphorylates ERK1/2; therefore, the inhibition of 
MEK prevents the activation of ERK1/2.  KOPr agonist was added for the time that 
caused the largest activation of P-ERK1/2 in the time course experiments (salvinorin A 
= 60 s and U50,488H, DS-1-240, and DS-3-216 = 5 min).  Cells were then washed 2 x 
with sterile PBS and lysed at 4 °C with gentle shaking in 200 µL of RIPA buffer 
containing 0.01% protease inhibitor (Sigma) and 0.01% phosphatase inhibitor (Sigma).  
Cell lysates were then transferred into microcentrifuge tubes and centrifuged at 16,000 g 
for 30 min at 4°C.  A 50 µL sample was removed and mixed with 15 µL of running 
buffer (Appendix 1), and 20 µL of sample was loaded onto a 10% SDS-PAGE gel 
(Appendix 1).  Gels were run at 120 V for 90 min, then scanned directly for YFP-hDAT 
on a Fuji-Film gel scanner.  After scanning, the proteins were transferred to PVDF 
membrane, and Western blotting was conducted as described in section 2.4.  P-ERK1/2 
(1:500, overnight, Santa Cruz) was immunoblotted first and detected using anti-mouse 
Cy5 (1:2,500, 1 h, GE Healthcare).  Membranes were then stripped for 40 min in 
stripping buffer (Appendix 1) then washed 3 x in T-TBS before reblocking.  ERK1/2 
(1:1,000, overnight, Cell Signalling) was then immunoblotted and detected using anti-
rabbit Cy 3 (1;2,500, 1 h, GE Healthcare).   
 
To analyse data, band intensities were measured using Image J, and P-ERK1/2 was 
normalised to total ERK1/2 expression.  
 
5.3.5 ASP
+
 uptake for P-ERK1/2 inhibition 
Acute ASP
+
 experiments and data analysis were carried out as previously described 
(Section 2.5) except cells were incubated with 20 µM U0126 for 30 min before ASP
+
 
addition to inhibit MEK/ERK signalling. 
 
5.3.6 Biotinylation and TIRFM for P-ERK1/2 inhibition 
Cell surface biotinylation and TIRFM experiments were carried out as previously 
described (Section 2.6 and 2.3, respectively), except that cells were incubated with 20 
µM of U0126 for 30 min before KOPr agonist addition. 
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5.4 Results 
5.4.1 Total YFP-hDAT protein 
To investigate if the increases in cell surface expression induced by U69,593, salvinorin 
A, and DS-3-216 were due to increases in total YFP-hDAT protein in the cells, Western 
blotting was performed on cell lysates after incubation of the cell for 30 min with 
U69,593, U50,488H, salvinorin A, DS-1-240, and DS-3-216.  Protein lysates were run 
on SDS-PAGE gels and scanned to visualise YFP-hDAT fluorescence on the gel and 
then Western transferred and immunoblotted for anti-tubulin as a loading control.  
Results showed that there was no significant increase in total YFP-hDAT protein in the 
cell after a 30 min incubation with any of the compounds investigated (Figure 5.1).  
This indicates that the increases in cell surface expression caused by U69,593, 
salvinorin A and DS-3-216 were not due to an overall increase in YFP-hDAT protein 
but due to increased exocytosis of YFP-hDAT to the plasma membrane. 
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Figure 5.1:  Treatment for 30 min with KOPr agonists has no effect on total YFP-
hDAT protein in HEK-293 cells.  HEK-293 cells were treated with U50,488H, 
salvinorin A, DS-1-240, DS-3-216, U69,593, or their vehicles for 30 min before lysing 
and analysing for total YFP-hDAT protein and tubulin.  Shown are a fluorescent scan of 
representative gel and the corresponding anti-tubulin Western blot.  There was no 
significant change in total YFP-hDAT protein with any of the treatments (n= 5-6 
preparations).  One-way ANOVA followed by Bonferroni post test. 
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5.4.2 Lipid raft disruption 
KOPr and DAT are found within lipid rafts (Xu et al. 2006; Adkins et al. 2007), and 
both proteins co-localise in transfected cells (T. Shippenberg, unpublished data).  
Therefore, disruption of lipid rafts would be expected to attenuate the effects of KOPr 
agonists on DAT function. MβC disrupts lipid rafts by desorbing cholesterol from the 
cell membrane (Lawrence et al. 2003).  Treatment of non-transfected and transfected 
HEK-293 cells with 10 mM MβC for 10 min led to significant increases in uptake of 
ASP
+ 
of 100% (from 126 ± 17 to 247 ± 40 AFU) and 50% (from 556 ± 23 to 777 ± 42 
AFU), respectively (Figure 5.2).  These increases in ASP
+
 uptake are most likely due to 
the disruption of lipid rafts increasing cell permeability, leading to an increase in 
passive ASP
+
 movement into the cell.  The non-specific uptake (non-transfected cells) 
was then removed from transfected cell uptakes from each of the groups to investigate 
the specific effects of lipid raft disruption on YFP-hDAT function in these cells (Table 
5.1).  Interestingly, there was a significant increase of 23% in ASP
+
 uptake in MβC-
treated cells after the non-specific uptake was removed, suggesting that rather than 
decreasing YFP-hDAT function, lipid raft disruption increased YFP-hDAT transport 
function in these cells. 
 
To confirm that MβC was disrupting lipid rafts, FRAP was also carried out.  FRAP is a 
technique in which a region of a living cell membrane expressing fluorescent membrane 
proteins is bleached and the recovery of fluorescence is measured.  As the cell 
membrane is a fluid environment, FRAP measures the diffusion of the fluorophore 
through the cell membrane and also measures any exocytosis (insertion) of the 
fluorophore that occurs (Figure 5.3a).  For this experiment an average recovery of 
74.3% was seen for control experiments and 74.6% for MβC-treated samples (Figure 
5.3b).  FRAP ROIs were used that were large enough to include both lipid raft and non-
lipid raft regions of the cell membrane.  Lipid rafts have been shown to be between 10 
and 200 nm in diameter (Adkins et al. 2007), and an average ROI of 4 µm was used, 
which was consistent between MβC-treated (average ROI of 3.975 µm) and non-treated 
groups (average ROI of 4.095 µm) (Figure 5.3c).  Treatment of cells with MβC led to a 
significant increase in t1/2 of 57% and no change to Mf, suggesting that lipid raft 
disruption led to a decreased mobility of YFP-hDAT, changing cell membrane 
dynamics (Figure 5.3d and e).   
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To measure the effect of lipid raft disruption on KOPr activation of YFP-hDAT 
function, cells were treated with 10 mM MβC 10 min before ASP+ uptake studies were 
conducted.  The treatment of cells with MβC led to a significant attenuation of the 
increase in DAT function caused by 10 µM KOPr agonist with all agonists used (Fig 
5.4a-d).    As these ASP
+
 uptake experiments measure a change in function due to KOPr 
agonist treatment within the same cell, it can be inferred that the inhibition seen was due 
to interference with the KOPr/DAT interaction rather than a direct disruption of DAT 
function, since the cells were still able to take up ASP
+
 while in the presence of MβC.  
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Figure 5.2:  Effect of MβC in non-transfected and transfected cells on ASP+ 
uptake.  (A) There were significant differences between ASP
+
 uptake in non-
transfected vs transfected cells for each treatment group.  There was a non-signficant 
increase in ASP
+
 uptake in non-transfected + MβC cells compared to non-transfected 
cells without  MβC (p = 0.0652).  Uptake by transfected cells was signficantly different 
between the MβC-treated and control groups (One-way ANOVA).  (B) YFP-hDAT 
expression was consistent between groups, with transfected groups having a 
significantly higher YFP-hDAT epxression then non-transfected controls (n = 20-27 
cells, over 3 separate transfections, one-way ANOVA followed by Bonferroni post test.  
***p<0.001 compared to non-transfected control, ###p<0.001 compared to non-
transfected + MβC control, ^^^p<0.001 compared to transfected control.   
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Table 5.1:  The effect of MβC treatment on ASP+ uptake 
 Control cells MβC treated cells 
Non-transfected 126.0 ± 16.93 247.3 ± 39.87* 
Transfected 556.5 ± 23.48 777.6 ± 42.28*** 
Transfected – non-transfected 430.5 ± 23.07 530.3 ± 42.81* 
Mean ± SEM, Student‟s t-test between control and MβC-treated cells, *p<0.05, 
***p<0.001.    
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Figure 5.3:  FRAP in HEK-293 cells expressing YFP-hDAT and myc-rKOPr with 
and without 10 mM MβC.  (A) Time course of a representative FRAP experiment 
showing a pre-bleach image, a bleach image and post-bleach images at 50, 100, 150, 
and 200 s (For representative movie see DVD).  (B)  The average fluorescence recovery 
vs. time after bleaching in the FRAP experiments conducted.  Recovery after 260 s was 
74.3% of initial fluorescence for control samples, and 74.6% for MβC-treated samples.  
(C)  The sizes of the ROI of bleach regions between control and MβC treatment were 
the same, with averages of 3.975 µM and 4.095 µM, respectively.  (D)  The average t1/2 
of recovery of control vs. MβC-treated cells. MβC treatment led to a significant increase 
in recovery t1/2.  (E)  The average Mf of recovery was not different between control and 
MβC-treated groups (n = 5-6 cells, **p<0.01, Student‟s t-test).  
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Figure 5.4:  Lipid raft disruption attenuates the KOPr agonist-induced increase in 
DAT function.  HEK-293 cells expressing YFP-hDAT and myc-rKOPr were incubated 
with MβC (10 mM) for 10 min before ASP+ uptake studies were conducted.  Results 
showed that the addition of MβC significantly blocked the effect of 10 µM (A) 
U50,488H, (B) salvinorin A, (C) DS-1-240, and (D) DS-3-216 at their maximal time of 
function (100, 60, 200, 200 s respectively).  Addition of DMSO as a vehicle control did 
not lead to a significant decrease in uptake compared to 0 for any of the compounds 
tested (One-sample Student‟s t-test; n = 38-54 cells). (E) MβC led to a significant 
increase in ASP
+
 uptake on its own (Student‟s t test, ***p<0.001).  One-way ANOVA 
followed by Bonferroni post test, *p<0.05, **p< 0.01, ***p< 0.001 compared to the 
DMSO control, ##p< 0.05, ###p<0.001 compared to 10 µM KOPr agonist. 
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5.4.3 ERK1/2 activation 
Previous studies have shown that KOPr agonists activate ERK1/2 (Belcheva et al. 2005; 
Kim et al. 2006; McLennan et al. 2008), and ERK1/2 activation leads to increased DAT 
function (Zapata and Shippenberg 2002; Moron et al. 2003; Bolan et al. 2007).  A novel 
MOPr agonist herkinorin, which is based on the structure of Sal A, has also been shown 
to cause ERK1/2 activation (Groer et al. 2007), as has the novel KOPr agonist DS-3-
216 (McLennan et al. 2008).  As ERK1/2 activation increases DAT function, the 
ERK1/2 pathway is a possible link between KOPr and DAT.  Therefore, the effect of 
the KOPr agonists in this study on ERK1/2 activation was investigated, as well as the 
effect of ERK1/2 inhibition on DAT function.  Initial time course studies were 
conducted to find the time where ERK1/2 phosphorylation peaked after KOPr agonist 
addition in HEK-293 cells expressing YFP-hDAT and myc-rKOPr.  This was carried 
out by Western blotting for P-ERK1/2 followed by stripping the membrane and 
reprobing for ERK1/2.  All compounds activated ERK1/2, with salvinorin A causing the 
fastest phosphorylation at 1 min, and the other agonists causing ERK1/2 
phosphorylation at 5 min (Figure 5.6a and b to Figure 5.9a and b).  ERK1/2 is activated 
by direct phosphorylation by MEK.  The selective MEK1/2 inhibitor U0126 should 
therefore inhibit ERK1/2 phosphorylation.  Inhibition of MEK1/2 (20 µM U0126, 30 
min) attenuated the increase in P-ERK1/2, as measured by Western blotting (Figure 
5.6c and d to Figure 5.9c and d).  
 
 All of the KOPr agonists investigated increased P-ERK1/2, and this phosphorylation 
was inhibited by U0126.  Therefore, experiments investigating if inhibition of P-
ERK1/2 causes an inhibition of the increase in DAT function caused by KOPr 
activation were conducted.  A previous study showed that U0126 decreased cell surface 
expression of DAT (Moron et al. 2003), but at a much higher concentrations than those 
used in our study (50 µM compared to 20 µM); therefore, the effect of U0126 
incubation on YFP-hDAT cell surface expression was also tested.  We found that a 30 
min incubation with U0126 in HEK-293 cells co-transfected with YFP-hDAT and myc-
rKOPr caused no decrease in YFP-hDAT cell surface expression on its own (Figure 
5.5a).  Initial ASP
+
 uptake studies were carried out to find out whether U0126 on its 
own could directly lead to inhibition of ASP
+
 uptake.  Again, we found there was no 
change in uptake of ASP
+
 at 200 s after U0126 incubation compared to controls (Figure 
5.5b).   
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ASP
+
 uptake studies carried out after a 30 min incubation with U0126 showed a 
complete inhibition of the increase in ASP
+
 uptake induced by all the KOPr agonists 
tested (Figure 5.6e to Figure 5.9e).   This suggests that the ERK1/2 pathway is involved 
in the interaction between KOPr and DAT. 
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Figure 5.5:  Effect of the MEK1/2 inhibitor U0126 on untreated HEK-293 cell. (A) 
YFP-hDAT fluorescence microscopy images of DAT- and KOPr-transfected HEK-293 
cells untreated with KOPr agonists. A representative time-course of HEK-293 cells 
incubated with U0126 for 30 min is presented.  There was no significant internalisation 
of YFP-hDAT by U0126.  (B) Summary of results of ASP
+
 uptake in cells incubated 
with U0126 for 30 min.  No significant effect on ASP
+
 uptake was seen ( n = 51-58 
cells, p = 0.7722, Student‟s t-test). 
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Figure 5.6:  U50,488H modulates DAT function through an ERK1/2 dependent 
pathway.  (A) Fluorescent scan of representative gel showing YFP-DAT expression 
(top), and representative Western blots showing P-ERK1/2 expression (middle) and 
ERK1/2 expression (bottom) after U50,488H treatment. UV (1 h) was used as a positive 
control for ERK1/2 activation but was not graphed.  (B) P-ERK1/2 expression was 
normalised to ERK1/2 expression and expressed graphically as a fold change (mean ± 
SEM) compared to time 0. There was a significant increase in P-ERK1/2 at 5 min (P-
ERK1, p = 0.0101, P-ERK2, p = 0.0104, Student‟s t-test, n = 4)  (C,E) Inhibition of the 
ERK1/2 activation by U50,488H occurred after a 30 min pre-treatment with U0126 (20 
µM) (One-way ANOVA followed by Bonferroni post test, **p<0.01 compared to 
appropriate control, ##p<0.001 compared to appropriate U50,488H-treated control, n 
=6.  (D) The increase in uptake caused by a 100 s incubation with U50,488H was 
attenuated by U0126 (One-way ANOVA followed by Bonferroni post test, **p<0.01 
compared to the DMSO control, ##p<0.01 compared to U50,488H treated control, n = 
40-57). The addition of DMSO as a vehicle control had no effect on uptake compared to 
0 (one-sample Student‟s t-test). 
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Figure 5.7:  Salvinorin A modulates DAT function through an ERK1/2 dependent 
pathway.  (A) Fluorescent scan of representative gel showing YFP-hDAT expression 
(top), representative Western blot membrane showing P-ERK1/2 expression (middle) 
and ERK1/2 expression (bottom) after salvinorin A treatment.  UV (1 h) was used as a 
positive control for ERK1/2 activation but was not graphed.  (B) P-ERK1/2 expression 
was normalised to ERK1/2 expression and expressed graphically as a fold change 
compared to time 0.  After 1 min there was a significant increase in P-ERK1/2 (One-
way ANOVA followed by Bonferroni post test, *p<0.05, n = 4)  (C,E) Inhibition of 
ERK1/2 activation by salvinorin A occurred after a 30 min pre-treatment with U0126 
(20 µM) (One-way ANOVA followed by Bonferroni post test, *p<0.01 compared to 
appropriate control, ###p<0.001 compared to appropriate salvinorin A-treated control, n 
=6.  (D) A representative Western blot of the effect of U0126 on the salvinorin A-
induced phosphorylation of ERK1/2. (E) The increase in uptake after a 60 s incubation 
with salvinorin A was attenuated by pre-treatment with U0126 (One-way ANOVA 
followed by Bonferroni post test, ***p<0.001 compared to DMSO control, ###p<0.001 
compared to salvinorin A-treated control, n = 32-50. The addition of DMSO as a 
vehicle control had no effect on uptake from 0 (one-sample Student‟s t-test).   
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Figure 5.8:  DS-1-240 modulates DAT function through an ERK1/2 dependent 
pathway.   (A) Fluorescent scan of representative gel showing YFP-hDAT expression 
(top), representative Western blot membrane showing P-ERK1/2 expression (middle) 
and ERK1/2 expression (bottom) after DS-1-240 treatment.  UV (1 h) was used as a 
positive control for ERK1/2 activation but was not graphed.  (B) P-ERK1/2 expression 
was normalised to ERK1/2 expression and expressed graphically as a fold change 
compared to time 0.  After 3 and 5 min there was a significant increase in P-ERK1/2 
(One-way ANOVA followed by Bonferroni post test, *p<0.01, n = 4).  (C,E) Inhibition 
of ERK1/2 activation by DS-1-240 occurred after pre-treatment with U0126 (20 µM, 30 
min) One-way ANOVA followed by Bonferroni post test, *p<0.05, **p<0.01 compared 
to appropriate control, ###p<0.001 compared to appropriate DS-1-240 treated control, n 
=6.  (D) A representative Western blot of the effect of U0126 on the DS-1-240-induced 
phosphorylation of ERK1/2.  (E) The increase in uptake caused by a 200s incubation 
with DS-1-240 was attenuated after incubation with U0126.  One-way ANOVA 
followed by Bonferroni post test, ***p<0.001 compared to DMSO control, ###p<0.001 
compared to DS-1-240 treated control, n = 32-50, respectively. The addition of DMSO 
as a vehicle control did not lead to a significant decrease in uptake from 0 (One sample 
Student‟s t-test).   
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Figure 5.9:  DS-3-216 modulates DAT function through an ERK1/2 dependent 
pathway.  (A) Fluorescent scan of representative gel showing YFP-hDAT expression 
(top), representative Western blot membrane showing P-ERK1/2 expression (middle) 
and ERK1/2 expression (bottom) after DS-3-216 treatment.  UV (1 h) was used as a 
positive control for ERK1/2 activation but was not graphed.  (B) P-ERK1/2 expression 
was normalised to ERK1/2 expression and expressed graphically as a fold change 
compared to time 0 (B).  After 5 min there was a significant increase in P-ERK1/2 (P-
ERK1, p = 0.0496, P-ERK2, p = 0.0394, student t test, n = 4)  C,E) Inhibition of 
ERK1/2 activation by DS-3-216 occurred after a 30 min pre-treatment with U0126 (20 
µM) (One-way ANOVA followed by Bonferroni post test, **p<0.01, ***p<0.001 
compared to appropriate control, ###p<0.001 compared to appropriate DS-3-216 treated 
control, n =6).  (D) A representative Western blot of the effect of U0126 on the DS-3-
216-induced phosphorylation of ERK1/2.  (E) The increase in uptake caused by a 200 s 
incubation with DS-3-216 was attenuated after incubation with U0126.  (One-way 
ANOVA followed by Bonferroni post test, ***p<0.001 compared to DMSO control, 
###p<0.001 compared to U50,488H treated control, n = 40-57 respectively). The 
addition of DMSO as a vehicle control did not lead to a significant decrease in uptake 
from 0 (One-sample Student‟s t-test).   
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5.4.4 ERK1/2 activation and cell surface expression of YFP-hDAT 
ERK1/2 activation leads to increased DAT function and also cell surface expression 
(Moron et al. 2003).  Incubation with salvinorin A and U69,593 for 30 min caused an 
increase in cell surface expression of YFP-hDAT that was seen with both TIRFM and 
cell surface biotinylation techniques.  We therefore investigated whether inhibition of 
ERK1/2 phosphorylation inhibited the increase in DAT cell surface expression seen 
with U69,593 and salvinorin A.  For these experiments, cells were incubated with the 
MEK1/2 inhibitor U0126 (20 µM) for 30 min before addition of salvinorin A or 
U69,593.  Cell surface biotinylation was carried out after 30 min incubation with the 
KOPr agonist.  TIRFM studies were carried out for a total period of 40 min, with 10 
images taken 1 min apart before KOPr agonist addition for baseline readings and then 
30 images taken 1 min apart to capture any changes in cell surface expression.   
 
Control experiments were carried out with U0126, and the two vehicles used for this 
study, ethanol (for U69,593) and DMSO (for salvinorin A).  As Figure 5.10 shows, 
U0126 had no effect on cell surface expression as measured by TIRFM for both 
ethanol- (Figure 5.10a) and DMSO- (Figure 5.10c) treated cells.  In cell surface 
biotinylation experiments, ethanol on its own caused a significant increase in 
intracellular YFP-hDAT (p<0.01, with no change in cell surface expression (Figure 
5.10b). With DMSO, there was no significant change in YFP-hDAT expression (Figure 
5.10d). 
 
Treatment of cells with U69,593 led to a non-significant increase of 7% in cell surface 
expression using TIRF microscopy (Two-way ANOVA, data compared to vehicle data 
shown in Figure 5.11a) and a significant increase of 37% with cell surface biotinylation 
(p<0.01) compared to vehicle controls (Figure 5.11a-c).  When the final data points for 
TIRFM (25 min to 29 min) were compared between vehicle and U69,593 (Student‟s t-
test), there was a significant increase in uptake (p<0.001).  Pre-treatment for 30 min 
with U0126 (20 µM) followed by U69,593 showed a small, non-significant decrease in 
cell surface expression of YPF-hDAT measured by TIRFM but a significant increase in 
cell surface expression by cell surface biotinylation (p<0.01).  Overall, these data 
suggest that U0126 may not alter the change in cell surface expression seen with 
U69,593 after a 30 min incubation, and that the MEK/ERK pathway therefore may not 
be involved in the U69,593-induced increase in DAT cell surface expression.    
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Treatment of cells with salvinorin A significantly increased YFP-hDAT cell surface 
expression as measured by TIRFM (Figure 5.12c) (compared to vehicle data shown in 
Figure 11c, two-way ANOVA, followed by Bonferroni post test, with vehicle versus 
salvinorin A showing significance; p<0.001).  Treatment at 28 min showed a significant 
difference between vehicle (Bonferroni post test, p<0.05).  At 28 min there was also a 
significant difference between salvinorin A treatment and U0126 pre-treated salvinorin 
A using the Bonferroni post test (p<0.01).  Cell surface biotinylation studies also 
showed a significant 18.5% increase in cell surface YFP-hDAT after a 30 min 
salvinorin A treatment (p<0.05).  However, there was no significant change seen 
between cells treated with salvinorin A and those pre-treated with U0126 followed by 
salvinorin A.  This may be due to the sample size being too small or the U0126 
inhibition being less than complete. 
 
Overall these data suggest that there may be differences in the signalling pathways used 
by U69,593 and salvinorin A in their regulation of cell surface expression of YFP-
hDAT, but the changes in surface expression do not appear to be large enough to reach 
significance.  Further experiments are needed to verify this difference between the two 
compounds.    
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Figure 5.10:  The effect of U0126 on the cell surface expression of YFP-hDAT in 
vehicle-treated HEK-293 cells.  (A,C) In TIRFM experiments, after pre-treatment of 
cells for 30 min with U0126 (20 µM), there was no effect of ethanol or DMSO on cell 
surface expression (n = 9-12).  (B,D) In biotinylation experiments, there was no change 
in cell surface expression after DMSO in control or U0126 pre-treated cells; however, 
prior treatment with U0126 led to a small, but significant increase in the intracellular 
fraction following ethanol treatment (n = 6) (One-way ANOVA followed by a 
Bonferroni post test, **p<0.01. 
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Figure 5.11:  U0126 does not inhibit the increase in cell surface expression induced 
by U69,593.  A) Representative TIRFM images at -10, 0, 10, 20, and 30 min after 
U69,593 treatment.  Treatments with U69,593 (10 µM) (top row) and U69,593 after 
pre-treated with U0126 (bottom panel) are shown.  B) U69,593 increased YFP-hDAT 
expression by 7% and the increase was not significantly different from cells pre-treated 
with U0126 (two-way ANOVA followed by Bonferroni post test, n = 10-16).  From 25-
29 min, the increase in cell surface expression after U69,593 treatment was significantly 
different from vehicle-treated samples (from figure 5.10a, p<0.001, Student‟s t-test,).  
C) Cell surface biotinylation experiments showed a significant increase in cell surface 
expression of YFP-hDAT after a 30 min incubation with U69,593, and this increase was 
not inhibited by pre-treatment with U0126 (One-way ANOVA followed by a 
Bonferroni post test, **p<0.01 compared to vehicle control, n = 6).  T = total, I = 
internal, CS = cell surface.  
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Figure 5.12:  U0126 inhibited the salvinorin A-induced increase in cell surface 
expression.  A) Representative TIRFM images at -10, 0, 10, 20, and 30 min after 
salvinorin A treatment.  Treatments with salvinorin A (10 µM) (top row) and salvinorin 
A after pre-treated with U0126 (bottom panel) are shown.  B) TIRFM experiments 
showed that salvinorin A significantly increased YFP-hDAT expression by 5.6%, 
compared to vehicle control (from figure 5.10c, two-way ANOVA followed by 
Bonferroni post test, p<0.001; at 28 min).  This increase was also significantly different 
from salvinorin A cells pre-treated with U0126 ( **p<0.01, Student‟s t-test, n = 10-20).  
C) In cell surface biotinylation experiments, salvinorin A (30 min) caused a significant 
increase in cell surface expression of YFP-hDAT, which was not observed after U0126 
pre-treatment.  However, there was no significant difference between the salvinorin A 
treated cell surface fraction and salvinorin A after pre-treatment with U0126 (One-way 
ANOVA followed by a Bonferroni post test, *p<0.05 compared to vehicle control, n = 
6). T = total, I = internal, CS = cell surface. 
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5.5 Discussion 
Both KOPr and DAT can be found within lipid rafts (Xu et al. 2006; Adkins et al. 2007; 
Foster et al. 2008) but no studies have been conducted on the effects of lipid raft 
disruption on the interaction between the two.  As KOPr activation leads to an initial 
increase in DAT function (Chapter 4), the effect of lipid raft disruption and inhibition of 
the ERK1/2 pathway on DAT function was investigated.  A 30 min incubation with 
salvinorin A or U69,593 also increased cell surface expression in transfected HEK-293 
cells (Chapter 4), and therefore the effect of ERK1/2 inhibition was also investigated to 
see if this increase in cell surface expression was facilitated through this pathway.  
Experiments to determine if total YFP-hDAT protein expression changed over a 30 min 
incubation with these compounds were also carried out.   It was found that total YFP-
hDAT protein did not change after a 30 min incubation with the KOPr agonists.  The 
disruption of lipid rafts led to inhibition of the increase in function of YFP-hDAT at 
acute time points, and all the KOPr agonists tested caused activation of ERK1/2.  
Inhibition of ERK1/2 inhibited the increased YFP-hDAT transport function seen after 
an acute incubation with all of the KOPr agonists.  ERK1/2 inhibition also appeared to 
prevent the effect of a 30 min incubation with salvinorin A on increased YFP-hDAT 
expression at the cell surface, but did not inhibit the effect of U69,593.  This suggests 
that the increase in cell surface expression observed by these two compounds may occur 
through different pathways.   
 
5.5.1 Total protein 
One of the ways in which protein cell surface regulation could occur is through 
increases in total protein within the cell (Meiergerd et al. 1994a).  As salvinorin A, 
U69,593, and DS-3-216 all caused increased cell surface expression of YFP-hDAT in 
HEK-293 cells co-transfected with myc-rKOPr and YFP-hDAT, the effect of these 
compounds on YFP-hDAT total protein was investigated after a 30 min incubation with 
the compounds.  It was found that none of the KOPr agonists studied caused significant 
changes in YFP-hDAT total protein in these cells (Figure 5.1), suggesting that this is 
not the cause for the increased cell surface expression seen with some of the KOPr 
agonists.   
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5.5.2 Lipid raft disruption 
Previous studies have identified that HEK-293 cells contain cholesterol-rich regions, 
thought to be lipid rafts (O'Connell and Tamkun 2005; Adkins et al. 2007).  The 
disruption of lipid rafts inhibited the effect of the KOPr agonists on DAT function.  It 
has previously been reported that lipid raft disruption leads to an increase in KOPr 
agonist effects on KOPr (Xu et al. 2006) and a decrease in DAT function (Adkins et al. 
2007; Foster et al. 2008).  Interestingly, we found that treatment of cells with MβC led 
to an overall increase in uptake of ASP
+ 
in both non-transfected and transfected cells 
(Figure 5.2).  When non-specific ASP
+
 uptake (non-transfected cells) was removed 
from the transfected cell uptake, there was a significant increase in ASP
+
 uptake of 23% 
in the MβC-treated group (Table 5.1).  As the non-specific uptake included the effects 
due to increased permeability caused by MβC treatment, this effect would be expected 
to be due to increased specific uptake by YFP-hDAT.  This is opposite to that reported 
from the two previous studies, that showed that MβC decreased DAT function by 16% 
and 30% (Adkins et al. 2007; Foster et al. 2008).  Both of these studies used [
3
H]DA 
uptake and also used different cell lines, and; therefore, the difference between theirs 
and our results may be due to the technique and cells used. MβC treatment has also been 
shown to affect cell cytoskeletal components such as actin (Kenworthy et al. 2004).  As 
DAT is also found in non-lipid raft environments there is the possibility that MβC 
treatment caused changes in function of these non-lipid raft transporters as well.   
 
Confirmation of lipid raft disruption was carried out using FRAP (Figure 5.3).  We 
found that depletion of cholesterol by MβC caused an increase in t1/2 and no change to 
Mf.  This microscopy technique measures the movement of diffusing fluorescently-
tagged proteins into a photobleached region of the cell membrane, either from lateral 
diffusion in the cell membrane or exocytosis from inside the cell.  This technique has 
the ability to measure the kinetics of diffusion, giving t1/2 values (rate of movement back 
into the bleached region) and Mf values (total recovery of the bleached region).  
Another parameter, D, the diffusion coefficient, is calculated from t1/2 and the radius of 
the bleach region.  It requires the first post-bleach image to be taken immediately after 
bleaching has finished (Snapp et al. 2003).  This coefficient is calculated so that 
experiments carried out using different equipment can be directly compared, and is 
generally published instead of t1/2 values.  The confocal microscope used in this study 
does not have the capability to measure D as it is not equipped with a tornado system 
and therefore cannot take a post-bleach image immediately after the bleach due to 
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zooming in and out.  Thus, in our study, the change in t1/2 cannot be directly compared 
to previously published data.  But an increase in t1/2 does suggest that diffusion of YFP-
hDAT in MβC-treated cells occurs more slowly than in control cells.  As t1/2 is 
dependent on the surrounding environment of the cell and cell trafficking, a decreased 
t1/2 suggests that the membrane environment has become more difficult to diffuse 
through.  The only other study that has investigated YFP-hDAT movement in HEK-293 
cells using FRAP published only D values, which in their study increased after MβC 
treatment (Adkins et al. 2007).  An increased D value suggests an increase in protein 
mobility, which is the opposite of that seen in our study.  One possibility for the 
difference between their study and ours is that the bleach region used in our study was 
larger than that of the Adkins et al. study, which had an average bleach region of 1-3 
µM (Adkins et al. 2007).  As the bleach region used in our study was larger, it would 
have included more non-lipid raft cell membrane compared to the previous study, and 
MβC has been shown to also affect proteins within non-lipid raft environments due to 
its interaction with the actin cytoskeleton (Kenworthy et al. 2004).  Although our result 
disagrees with the only other DAT study, there have been many other studies that have 
shown decreased mobility (decreased D) after lipid raft disruption for other membrane 
proteins, found both within lipid and non-lipid environments (Kenworthy et al. 2004; 
O'Connell and Tamkun 2005; Vrljic et al. 2005; Nishimura et al. 2006; Baier et al. 
2010). For example, nAChR mobility decreased in CHO cells after MβC treatment 
(Baier et al. 2010).   This decrease was thought to be due to cholesterol depletion 
leading to solid phase clumps forming in the membrane, as other studies on MHC II 
receptors and voltage gated potassium channels have reported the formation of these 
clumps (O'Connell and Tamkun 2005; Nishimura et al. 2006).  It has also been 
demonstrated that increased cholesterol content in model lipid bilayers leads to 
increased fluidity of the membrane by interfering with tight packing of the phospholipid 
fatty acid tails, supporting the observation that decreasing cell membrane cholesterol 
would lead to decreased mobility (Korlach et al. 1999). 
 
There is a lot of disagreement about whether depletion of cholesterol from the cell 
membrane should lead to increased or decreased mobility of lipid raft proteins.  A 
decrease in mobility for lipid raft proteins may be due to a decrease in the cholesterol-
phospholipid complex, leading to the formation of solid-like phospholipid regions 
within the cell membrane, decreasing mobility (Nishimura et al. 2006); whereas, an 
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increase in mobility of lipid raft proteins may be due to disbanding of solid lipid rafts, 
freeing lipid raft proteins (Adkins et al. 2007). 
 
As the ASP
+
 uptake experiments carried out in our study measure the changes in uptake 
before and after KOPr agonist addition within the same cell, it allows for any effect of 
MβC on YFP-hDAT function to be disregarded as the cell is still capable of ASP+ 
uptake and the experiment is analysed using a within-cell design.  Prior incubation of 
cells with MβC led to an inhibition of the effect of the KOPr agonists on YFP-hDAT 
function (Figure 5.4).  This could be for a number of reasons: first, the disruption of the 
lipid rafts may have interfered with the interaction between KOPr and DAT.  This could 
be either through inhibition of one of the pathways needed to communicate between the 
two, or directly by inhibiting a physical interaction between the two proteins.  
Alternatively, lipid raft disruption could lead to a conformation change in KOPr or 
DAT, preventing interactions from occurring and blocking the KOPr-mediated increase 
in DAT function.  As MβC lipid raft disruption leads to an increase in the effect of 
U50,488H on KOPr, we expect that it is more likely that disruption of lipid rafts would 
lead to conformational changes of YFP-hDAT that may prevent its coupling to KOPr or 
remove its ability to be regulated by KOPr-activated pathways.   
 
Overall, lipid raft disruption inhibited the effect of KOPr agonists on DAT function. 
Lipid raft disruption by MβC also led to a decrease in DAT mobility as measured by 
FRAP.  Interestingly, lipid raft disruption also appeared to increase DAT function in 
these cells, which is something that needs to be investigated further. 
  
5.5.3 ERK1/2 pathway 
The ERK1/2 pathway has been implicated in the regulation of DAT function and cell 
surface expression (Zapata and Shippenberg 2002; Moron et al. 2003; Bolan et al. 2007) 
and is also known to be activated by KOPr agonism (Belcheva et al. 2005).  Stimulation 
of the DRD2 and D3 receptors increases function of DAT by increasing DAT cell 
surface expression through an ERK1/2 dependent pathway (Zapata and Shippenberg 
2002; Bolan et al. 2007).  Activation of ERK1/2 is also involved in the rewarding 
effects of drugs of abuse. For example, cocaine-induced hyperlocomotion in laboratory 
rats was  inhibited by treatment with ERK1/2 inhibitors (Valjent et al. 2000).  In the 
present study, we investigated the effects of the KOPr agonists on ERK1/2 
phosphorylation, and the effect of ERK1/2 inhibition on DAT function.  All the KOPr 
 179 
 
agonists led to increased P-ERK1/2 between 1 and 5 min after addition of the agonist 
(Figure 5.6 to 5.9).  This increase was inhibited by the MEK1/2 inhibitor U0126.  
U0126 also inhibited the effect of these agonists on ASP
+
 uptake into DAT/KOPr 
transfected cells.  This demonstrates that the ERK1/2 pathway is involved in the 
interaction between KOPr and DAT in these cells.  There has been only one reported 
study that has investigated the effect of DS-3-216 on ERK1/2 activation in primary and 
immortalised rat astrocytes (McLennan et al. 2008).  A significant increase in ERK1/2 
phosphorylation was seen from 3 to 15 min in primary astrocytes and 5 to 10 min in 
immortalised astrocytes, with a peak occurring in both cell types at 5 min.  In our study 
DS-3-216 led to a significant increase in P-ERK1/2 after 5 min, which then rapidly 
dropped off until levels at 30 min were the same as the control.  Therefore, it appears 
that the activation in HEK-293 cells is short-lived compared to those in primary 
astrocyte cultures.  This is most likely due to differences in endogenous levels of 
proteins required for this signalling pathway, leading to different activation patterns in 
HEK-293 cells compared to glial cells.    A previous study by Bruchas et al. (2006) 
showed that U50,488H also caused significant ERK1/2 activation in AtT-20 pituitary 
tumour cells (Bruchas et al. 2006).  The increase peaked 15 min after U50,488H 
addition and was significantly increased for up to 30 min.  Their study used 10 µM (-
)U50,488H, which is the more active form of U50,488H; whereas, our study used 10 
µM (+/-)U50,488H.  Therefore, even though we used the same concentration of the 
agonist, the potency would be less than that of Bruchas et al. which may lead to weaker 
activation of ERK1/2.   
 
Complete inhibition of ERK1/2 by U0126 was obtained at the concentration used 
(Figure 5.6 to 5.9), and this led to an inhibition of the increased function of DAT 
following KOPr activation (Figure 5.6 to 5.9).  Previous studies carried out 
investigating DAT and ERK1/2 have shown that inhibition of ERK1/2 by the MEK 
inhibitors U0126 and PD98059 led to a decrease in DAT function.  This was found to 
be due to decreased cell surface expression of DAT in rat striatal synaptosomes and 
EM4 cells expressing FLAG-hDAT (Moron et al. 2003). In our study, incubation of 
HEK-293 cells expressing YFP-hDAT and myc-rKOPr did not lead to decreased cell 
surface expression of YFP-hDAT or to a decrease in function (Figure 5.4).  This is most 
probably due to the lower concentration of MEK inhibitor used in our study (20 µM) 
compared to the 50 µM used in the previous study (Moron et al. 2003).  Interestingly, 
ethanol following U0126 treatment caused a small increase in intracellular levels of 
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YFP-hDAT (Figure 5.10).  However, as this increase was not observed with TIRFM or 
with the DMSO vehicle control, it was probably due to an artefact of the cell surface 
biotinylation studies.  Biotin is unable to bind to proteins found within cell membrane 
invaginations, so proteins in these invaginations are classed as being part of the 
intracellular fraction, rather than the cell surface fraction, and this may account for this 
observation. 
 
Overall, addition of KOPr agonists led to an increase in active ERK1/2 between 1-5 min 
after addition, and inhibition of ERK1/2 led to complete inhibition of the increase in 
DAT function due to KOPr activation, thus, demonstrating that the ERK1/2 pathway is 
involved in the interaction between KOPr and DAT. 
 
5.5.4 Cell surface expression studies and ERK1/2 
DAT cell surface regulation can be controlled by ERK1/2 phosphorylation (Moron et al. 
2003).  In our study, we investigated whether inhibition of ERK1/2 activation could 
inhibit the increase in YFP-hDAT cell surface expression seen after 30 min with 
U69,593 or salvinorin A.  Experiments were carried out with addition of salvinorin A 
and U69,593 as positive controls (Figure 5.11 and 5.12).  Cell surface biotinylation data 
showed similar significant increases in cell surface expression as shown in the data of 
Chapter 4 (U69,593: increase of 37% in both chapters, salvinorin A: increase of 25% in 
Chapter 4 and 18.5% in this chapter).  TIRFM experiments also showed similar 
increases in cell surface expression after U69,593 treatment of 7% in this chapter, 
compared to 11.5% in chapter 4, and for salvinorin A of 5.6% in this chapter compared 
to 9.3% in chapter 4.  Both of these treatments led to significant increases at later time 
points compared to vehicle control (Figure 5.10, 5.11, 5.12).  The differences in the 
magnitude of the effects between the two different techniques are discussed in Chapter 
4.   
 
In TIRFM studies, treatment of cells with U0126 before U69,593 reduced the KOPr 
agonist‟s induction of YFP-hDAT cell surface expression, however, no inhibition of the 
effect of U69,593 was seen in cell surface biotinylation studies.  This suggests that there 
may still be increases in cell surface expression after U69,593 treatment when the 
ERK1/2 pathway is completely inhibited.  Inhibition of ERK1/2 signalling by U0126 
significantly inhibited the effect of salvinorin A on YFP-hDAT cell surface expression 
at 30 min using TIRFM.  Cell surface biotinylation data showed an inhibition of the 
 181 
 
effect of salvinorin A, however, there was no significant difference between U0126 
non- and pre-treated samples.  As the effect of salvinorin A was inhibited by ERK1/2 
inhibition but the effects of the classic KOPr agonist U69,593 were not, these results 
suggest that salvinorin A regulates DAT cell surface expression through a different 
pathway than U69,593.   
 
Overall these data suggest that the classic KOPr agonist U69,593 and the novel KOPr 
agonist salvinorin A may work through different pathways.  As these compounds appear 
to have slightly different modes of action on DAT, compounds based on the structure of 
salvinorin A may have good potential for development as pharmaceuticals for treatment 
of addiction as they may have decreased or at least different side effects as a result of 
the different pathways they activate. 
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5.6 Conclusion 
This chapter demonstrated that KOPr and DAT interact through the ERK1/2 pathway 
and that lipid rafts are also likely to play a role in the interaction between the two.  
Treatment with the MEK1/2 inhibitor U0126 inhibited the increase in DAT function 
caused by KOPr activation.  U0126 also inhibited the salvinorin A-induced increase of 
DAT cell surface expression, but did not appear to inhibit the effects of U69,593, 
suggesting that these compounds may act through different pathways.  Disruption of 
lipid rafts by the cholesterol depleter MβC also prevented the KOPr agonist-induced 
increases in ASP
+
 uptake, supporting the hypothesis that lipid rafts play an important 
role in regulation of DAT by KOPr. 
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Chapter 6: Final Discussion 
6.1 Significance and key findings 
6.1.1 Significance 
Drug addiction is a major social and economic issue in New Zealand, and current 
therapeutic treatments often have poor long-term success rates or are addictive 
themselves.  There are also no FDA approved pharmacotherapies available for 
psychostimulants such as cocaine and methamphetamine.  Relapse is also an issue, with 
80% of drug addicts relapsing at least once during their lifetime (Shippenberg et al. 
2007).  There is therefore a need for further investigation into pharmacotherapies for 
drug addiction to improve success rates and decrease side effects, and to treat addiction 
for all drugs of abuse.  
 
DAT plays an important role in the brain‟s natural reward pathway and is a major target 
for drugs of abuse such as cocaine and amphetamines.  Previous studies have shown 
that acute KOPr activation attenuates the effects of drugs of abuse in laboratory animals 
(Schenk et al. 1999; Collins et al. 2001a; Morani et al. 2009), and there is evidence that 
this occurs partially through increased DAT function (Thompson et al. 2000).  
Treatment with KOPr agonists can also lead to side effects such as depression and 
dysphoria (Redila and Chavkin 2008), which implicate the 5-HT system in their mode 
of action.  KOPr antagonists show anti-depressant effects (Mague et al. 2003) and 
prevent stress-induced reinstatement in animal models of addiction (Beardsley et al. 
2005; Carey et al. 2007).  This further suggests that modulation of the 5-HT system 
occurs via KOPr and demonstrates the potential use of KOPr ligands and peptides for 
pharmacotherapies.  Although there have been several KOPr agonists studied clinically 
as anti-addictive pharmacotherapies there has been little or no success, most likely due 
to the low dose used to avoid side effects (Walsh et al. 2001b; Preston et al. 2004).  This 
suggests that, while promising, classic KOPr agonists may not be useful as 
pharmacotherapies for drug addiction.  Therefore, given the success in animal models of 
addiction, research carried out on novel KOPr agonists still has the potential to provide 
successful pharmacotherapies without the negative side effects seen with the classic 
agonists. 
 
The novel KOPr agonist salvinorin A differs from the classical agonist by having a non-
nitrogenous structure.  Therefore, salvinorin A and its analogues provide a new family 
of KOPr agonists to study as potential pharmacotherapies. It is hoped that their side 
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effect profiles will differ and be less disruptive than what is seen with the classic 
agonists (Roth et al. 2002; Prisinzano et al. 2005).  Investigating the effects of 
salvinorin A and its analogues on DAT and SERT will provide more information on 
how this novel agonist functions, and this information may help lead to successful 
pharmacotherapies for drug addiction. KOPr antagonists which are also based on the 
structure of salvinorin A  may also lead to pharmacotherapies for depression and help to 
prevent stress-induced relapse to drug taking.    
 
6.1.2 Key findings 
The key findings of this study are summarised in Table 6.1. 
6.1.2.1 KOPr modulates DAT and SERT in isolated rat brain tissue 
The KOPr agonists U50,488H, U69,593, salvinorin A, DS-1-240, and DS-3-216 all 
increased DAT function in the striatum, NAc, and medial PFC of drug naïve rat brains.  
Function was measured by RDEV. Salvinorin A had a faster onset of action (1 min) 
compared to the other agonists investigated, which increased uptake only after 4 min 
exposure.  For all compounds studied, there was an increase in Vmax.  This suggests 
that the increase in uptake seen may be partially due to increases in cell surface 
expression of DAT.  Uptake of DA after salvinorin A treatment (500 nM) produced a 
linear substrate-velocity plot, which did not allow Vmax and Km values to be 
extrapolated.  This may be due to the salvinorin A being metabolised or degraded, and 
fouling the electrode, thus preventing accurate measurements.  The increase in uptake 
seen with all compounds was inhibited by prior incubation with the KOPr antagonist 
nor-BNI, confirming that this effect was KOPr-mediated.  These data support previous 
unpublished data demonstrating the effect of acute U69,593 and salvinorin A treatment 
on DAT function in the rat NAc (T. Shippenberg, unpublished data), and also 
demonstrate that the novel KOPr agonists DS-3-216, and DS-1-240 and U50,488H act 
in a similar manner.  The results also confirm that KOPr activation increases DAT 
function, resulting in a decrease in DA in the synapse, rather than just targeting DA 
receptors to prevent release.  
 
Two of the most common causes of relapse to drug taking are stress and depression 
(Reviewed in Bruchas et al. 2010), and both the KOPr and the 5-HT system are 
involved in these pathways (Land et al. 2009; Goldman et al. 2010).  As previous 
studies have demonstrated that KOPr activation attenuates drug seeking through a 
mechanism involving 5-HT (Zakharova et al. 2008a; Ruedi-Bettschen et al. 2010), the 
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effect of  acute KOPr agonists on SERT function was measured using RDEV.  The 
establishment of RDEV to measure SERT function allowed the investigation of the 
effect of the KOPr agonists U50,488H, salvinorin A, and DS-1-240 on SERT transport 
in the rat striatum.  These three KOPr agonists caused decreased SERT function after 15 
min treatment.  Thus, KOPr, in addition to stimulating DAT function, is also capable of 
decreasing SERT function. This is important because of the important role of SERT in 
depression and stress, which are both major causes of relapse.   
 
Overall these data confirm previous studies that KOPr can regulate both DAT and 
SERT in specific rat brain regions.  As all of these compounds have shown anti-
addictive properties in animal models (Morani et al. 2009, A. Morani, unpublished 
data), the results of this study provides information as to how these compounds may be 
functioning to produce these effects.  The increase in uptake of DA by DAT would 
contribute to the decrease in drug seeking behaviour observed in animals pre-treated 
with a KOPr agonist before drug-induced reinstatement tests.  The decreased uptake of 
5-HT after KOPr agonism may help decrease the negative depressive behaviour 
observed during withdrawal from drug taking and help to prevent relapse back to drug 
taking.   
 
6.1.2.2 KOPr modulates DAT in cells co-transfected with YFP-hDAT and myc-rKOPr  
These experiments used cell models, as they allow greater manipulation compared to 
animal models.  The effects of KOPr agonists on ASP
+
 uptake by DAT was investigated 
in HEK-293 cells, N2A cells, and COS7 cells. All of the compounds investigated gave 
dose-dependent increases in ASP
+
 uptake by YFP-hDAT in all cell lines tested, and this 
uptake was inhibited by both the KOPr antagonist nor-BNI and the Gi/o inhibitor PTX.  
These results confirmed that the effect of these compounds was due to activation of 
KOPr and occurs through a Gi/o specific pathway.  In this model cell system, salvinorin 
A also showed a much shorter lag before a response was seen than the other 
compounds, with the maximal increase in ASP
+
 uptake seen after only 60 s.  This 
matches previous work which showed that salvinorin A has a very fast onset of action 
(Hooker et al. 2008) and confirms what we found in our RDEV study.  The effect of a 
30 min incubation of drugs in HEK-293 cells was also investigated.  U50,488H and 
salvinorin A caused a significant increase in DAT function, but the novel analogues DS-
1-240 and DS-3-216 had no effect.  This demonstrates some inherent differences 
between salvinorin A and its analogues in addition to differences in potency.    
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Overall these data confirm the use of cell models and ASP
+
 uptake techniques as an 
effective technique for accurately measuring changes in YFP-hDAT function due to 
KOPr activation.  Results gained in this part of the study match data gained in our 
RDEV study, and suggest that further investigation of how these compounds regulate 
DAT is warranted.   
 
6.1.2.3 KOPr modulation of the cell surface expression of DAT 
Since one of the major ways in which DAT function is regulated is through changes in 
cell surface expression, the effect of the KOPr agonists were investigated on cell surface 
expression of YFP-hDAT in HEK-293 cells.  Acute incubations with KOPr agonists had 
no effect on YFP-hDAT cell surface expression, measured either by cell surface 
biotinylation or TIRF techniques.  ASP
+
 binding studies found a non-significant 
increase of ASP
+
 binding to YFP-hDAT with U50,488H, salvinorin A, and DS-3-216, 
and a significant increase in binding after DS-1-240 treatment.  This suggests that   
inactive DAT on the cell surface is activated by KOPr agonism, leading to increased 
binding and uptake of ASP
+
.  After a 30 min incubation, U69,593 and salvinorin A 
significantly increased YFP-hDAT cell surface expression measured by both 
techniques, and DS-3-216 also showed significant increases in expression in the cell 
membrane with cell surface biotinylation.  This suggests that longer-term exposure to 
these three compounds leads to an increase in YFP-hDAT expression in these cells.  
This also suggests that the long-term increase in uptake seen with salvinorin A by ASP
+
 
uptake may be partially due to increased cell surface expression of DAT.  This result 
also demonstrated that U50,488H and U69,593 have different effects on DAT, and that 
the novel agonists also display differences among themselves in regulating DAT.   
 
Cell surface biotinylation studies have been used to measure changes in DAT cell 
surface expression after activation of both D2 and D3 DA receptors (Bolan et al. 2007; 
Zapata et al. 2007). TIRFM has also successfully been used to measure changes in DAT 
cell surface expression after exposure to DA and amphetamine (Furman et al. 2009a).  
As previously mentioned, both of these techniques have limitations.  For example, due 
to the inability of biotin to bind to proteins found within invaginations on the cell 
membrane, cell surface biotinylation often overestimates the intracellular fraction and 
underestimates the cell surface fraction.  For TIRFM, the major limitation is the size of 
the evanescent field that only includes proteins that are very close to the cell membrane.  
This leads to inaccurate measurements of changes in protein cell surface expression 
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since proteins moving in and out of the cell membrane that are very close to the 
membrane will be measured as expressed on the cell surface when they are just below 
the cell surface.   
 
Overall these data demonstrate that the initial increase in function caused by KOPr 
agonists is not trafficking-dependent since no changes in cell surface expression were 
seen after acute exposures, but that there may be increased active DAT found on the cell 
surface due to activation of inactive DAT already present.  After a longer 30 min 
incubation with these agonists, U69,593, salvinorin A, and DS-3-216 all caused 
increased cell surface expression of YFP-hDAT, which may account for some of the 
increase in ASP
+
 uptake observed at this time point with salvinorin A.   
 
6.1.2.4 KOPr modulates DAT through ERK1/2, is dependent on lipid rafts and does not 
lead to increased total DAT protein 
One of the ways in which increased cell surface expression of proteins can occur is 
through an increase in total protein within the cell.  Therefore we investigated whether 
the increase in cell surface expression observed at 30 min with U69,593, salvinorin A, 
and DS-3-216 was due to increased total YFP-hDAT protein within the cell.  It was 
found that after a 30 min incubation, none of the KOPr agonists used in this study 
caused an increase in total YFP-hDAT protein in HEK-293 cells. 
 
As KOPr agonism leads to activation of ERK1/2 (Belcheva et al. 2005; Kim et al. 2006; 
McLennan et al. 2008), and ERK1/2 activation causes increased DAT function and cell 
surface expression (Moron et al. 2003; Bolan et al. 2007; Zapata et al. 2007), the 
ERK1/2 pathway was investigated to see if this pathway provided a link between KOPr 
and DAT.  It was found that all the agonists activated the ERK1/2 pathway in HEK-293 
cells, with a peak occurring at 1 min for salvinorin A, and 5 min for the other KOPr 
agonists.  This activation of ERK1/2 by KOPr was inhibited by the MEK1/2 inhibitor 
U0126, and this inhibition led to attenuation of the functional effect of these compounds 
on DAT.  These data demonstrate that ERK1/2 is a signalling pathway that functions to 
regulate DAT and that it is modulated by KOPr activation.   
As salvinorin A and U69,593 caused increases in cell surface expression after a 30 min 
incubation, we next investigated whether inhibition of ERK1/2 could inhibit this 
increase.  Although the increase in cell surface expression by salvinorin A was inhibited 
by U0126, the changes caused by U69,593 were not significantly inhibited.  These data 
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suggest that the increase in cell surface expression observed after treatment with these 
two compounds may be occurring through different pathways.   
 
Both KOPr and DAT are found throughout the cell membrane, including within lipid 
rafts, which are important regions of cell membranes that are involved in regulation of 
signalling pathways (Kenworthy et al. 2004).  Disruption of lipid rafts by the cholesterol 
depleter MβC inhibited the effect of KOPr activation on DAT.  This inhibition could 
have occurred from: disruption of the physical interaction between KOPr and DAT, 
interruption of the signalling pathways between the proteins, or changes in confirmation 
of DAT or KOPr.  Further investigation is needed to identify which of these possible 
scenarios is occurring.  
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Table 6.1:  Summary of key findings in this study 
                                        KOPr agonists 
 U50,488H  U69,593  Salvinorin A  DS-1-240  DS-3-216  
DAT  tissue  Increased 
uptake  
-  Increased 
uptake  
Increased 
uptake  
Increased 
uptake  
Km/Vmax  No change/ 
Increased  
No change/ 
Increased  
Inconclusive No change/ 
Increased  
No change/ 
Increased  
ASP
+ 
uptake 
(acute time)  
Increased 
uptake  
Increased 
uptake  
Increased 
uptake  
Increased 
uptake  
Increased 
uptake  
Nor-BNI and 
PTX sensitive 
change in 
uptake 
Yes - Yes Yes Yes 
ASP
+ 
binding  Non-
significant 
increase  
-  Non-
significant 
increase  
Non-
significant 
increase  
Significant  
increase  
Cell surface 
expression  
(acute time)  
No change  No change  No change  No change  No change  
ASP
+ 
uptake 
(30 min)  
Increased 
uptake  
-  Increased 
uptake  
No change  No change  
Cell surface 
expression 
(30 min)  
No change  Increased  Increased  No change  Increased  
ERK1/2  Uptake 
dependent on 
ERK1/2  
Uptake 
dependent on 
ERK1/2  
Uptake 
dependent on 
ERK1/2  
Uptake 
dependent on 
ERK1/2  
Uptake 
dependent on 
ERK1/2  
Lipid raft 
disruption  
Uptake 
dependent on 
lipid rafts  
Uptake 
dependent on 
lipid rafts  
Uptake 
dependent on 
lipid rafts  
Uptake 
dependent on 
lipid rafts  
Uptake 
dependent on 
lipid rafts  
Cell surface 
expression 
and ERK1/2  
-  Independent of 
ERK1/2  
Dependent on 
ERK1/2  
-  -  
SERT tissue  Decreased 
uptake  
-  Decreased 
uptake  
Decreased 
uptake  
-  
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6.2 Future Directions 
As KOPr increases DAT function after chronic cocaine treatment in the NAc 
(Thompson et al. 2000), it would be interesting to investigate the effect of the novel 
compounds on DAT and SERT function after chronic cocaine administration.  This 
could be achieved using RDEV to measure DAT and SERT function in isolated rat 
brain tissue from rats treated with cocaine and an acute dose of the KOPr agonist.  This 
would give more information about the interaction between drugs of abuse, the 
transporters, and KOPr activation.  This experiment was attempted during this project, 
and the NAc, striatum, and medial PFC were collected from rats treated once daily with 
cocaine (20 mg/kg) for 10 days, followed by a single treatment with a KOPr agonist 
(treated animals were provided by A. Morani).  However, due to the RDEV machine 
breaking down at this time, the experiment was unable to be completed.    
 
It would also be interesting to investigate the effect of KOPr agonism on cocaine effects 
on DA binding and transport in a cell model.  This could be achieved using ASP
+
 
uptake studies, and the binding and uptake of ASP
+
 to cells treated with cocaine could 
be compared to cells pre-treated with KOPr agonist before cocaine treatment.  This 
would give more mechanistic information on how KOPr agonists inhibit the effects of 
cocaine on DAT. 
 
To investigate whether KOPr activation leads to increased active DAT at the cell 
surface, studies can be conducted to investigate changes seen in dimer or oligomer DAT 
at the cell surface.  DAT dimers and oligomers are important for trafficking and 
function in the cell (Hastrup et al. 2001; Torres et al. 2003)  This experiment can be 
carried out by treating myc-rKOPr- and YFP-hDAT-transfected cells with a KOPr 
agonist and then chemically cross-linking DAT.  Cell surface biotinylation can then be 
carried out to specifically investigate the DAT protein present at the cell surface.  This 
technique has previously been used to investigate the effect of DA and amphetamine on 
the production of DAT oligomers from dimer precursors (Chen and Reith 2008).  This 
study would help to elucidate whether this is the method by which acute KOPr agonists 
increase binding and uptake of ASP
+
 to DAT. 
 
To further investigate the role of lipid rafts in the interaction between KOPr and DAT, it 
would be useful to carry out co-immunoprecipitation studies with samples treated with 
or without the lipid raft disrupter MβC.  This would confirm whether disrupting lipid 
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rafts disrupts the physical interaction between KOPr and DAT or whether changes seen 
are due to altered signalling pathways.  Native PAGE or cross-linking followed by cell 
surface biotinylation could also be carried out to investigate whether the lipid raft 
disruption protocol used in this study disrupts DAT oligomers, and this would help 
elucidate if the effect seen was due to production of active DAT.  
 
It would also be useful to carry out proteomic studies using 2D-difference in gel 
electrophoresis and mass spectrometry to investigate changes in protein expression after 
treatment of cells with the KOPr agonists.  Changes in protein expression could be 
compared between the classic and novel KOPr agonists, which may lead to increased 
information about differences these compounds may have.  This could also be carried 
out in rats treated with the agonists, and could help give more information on side 
effects by identification of proteins involved in different pathways. 
 
Furthermore, as new novel KOPr agonists and antagonists are synthesised it would be 
interesting to also carry out screening on these compounds ability to modulate DAT and 
SERT.  It has been previously suggested that mixed action KOPr agonists may be better 
pharmacotherapies as they would have decreased side effects (Prisinzano et al. 2005).  It 
would therefore be interesting to investigate their effects on DAT and SERT if they 
show potential in animal models of addiction. 
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6.3 Overall significance 
Overall this research has led to a greater understanding of how KOPr agonists increase 
DAT function.  We found that DAT is regulated by KOPr through the ERK1/2 pathway, 
and that the rapid increases in uptake of substrate are trafficking-independent and lipid 
raft-dependent.  It also confirms that KOPr agonism regulates SERT function in tissue, 
causing a decrease in uptake of 5-HT after 15 min treatment.  While there were 
differences observed between the effect of the classic KOPr agonists and the novel 
salvinorin-based agonists, these differences were small; therefore, from these data the 
novel agonists do not appear to regulate DAT in a significantly different way to the 
classic agonists.  However, as these compounds show different side effect profiles in 
animals (A. Morani, unpublished data), further investigation is warranted to determine 
the specific mechanisms by which these agonists alter DAT and SERT function.  As 
DAT plays a major role in drug addiction, and SERT plays an important role in 
depression and stress, this research may help build a picture for a successful 
pharmacotherapy for drug addiction.  
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Appendix 1: Solutions 
 
Chapter 2 solutions 
10 x Phosphate Buffered Saline (PBS) 
    Concentration  g/L 
NaCl    1.4 M     80 
KCl    26.8 mM    2.0 
Na2HPO4   81.0 mM    26.8 
KH2PO4    14.7 mM   2.4 
pH 7.4   
 
LB Agar 
        g/L 
NaCl        10 
Yeast Extract       5.0 
Bactotryptone       10 
Yeast Agar       10 
 
LB Broth 
        g/L 
NaCl        10 
Yeast Extract       5.0 
Bactotryptone       10 
 
PBS Ca/Mg 
1 x PBS containing: 
    Concentration  g/L 
CaCl2    0.1 mM   0.111 
MgCl2.6H2O   1 mM    0.203 
    pH 8.0 
 
PBS Ca/Mg Glycine 
PBS Ca/Mg containing 
    Concentration  g/L 
Glycine   100 mM   75 
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RIPA buffer 
    Concentration  g/L 
Tris-HCl   10 mM   1.2 
NaCl    150 mM   8.766 
EDTA    1 mM    0.37 
Triton-X-100   1%    10 mL 
SDS    0.1%    1.0 
Sodium deoxycholate  1%    10 
    pH 7.5 
 
5 x Reducing buffer 
    Concentration   
Tris-HCl, pH 6.8  62.5 mM 
SDS    2% 
Glycerol   20% 
Bromophenol Blue  1% 
 
Gels 
Enough for 2 gels 
10% Separating Gel 
dH2O        8 mL 
1.5 M Tris pH 8.8      5 mL 
10% SDS       200 µL 
Acrylamide (30% acrylamide/Bis solution   6.66 mL 
10% APS       100 µL 
TEMED       10 µL 
100% isopropanol was layered over the gel while it was setting and was poured off 
before the stacking gel was added. 
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4% Stacking Gel 
dH2O        6.1 mL 
0.5 M Tris pH 6.8      2.5 mL 
10% SDS       100 µL 
Acrylamide       1.33 mL 
10% APS       50 µL 
TEMED       10 µL 
 
10 x Running buffer 
    Concentration   g/L 
SDS    35 mM    10 
Tris-HCl   250 mM    30.3 
Glycine   1.9 M     144.1 
 
Western Transfer Buffer 
    Concentration   g/L 
Glycine   190 mM    14.4 
Tris-HCl   25 mM    3.03 
Methanol   20%     200 mL 
 
10 x TBS 
    Concentration   g/L 
Tris HCl   500 mM    60.5 
NaCl    1.5 M     87.6 
    pH 7.5  
T-TBS 
1 x TBS containing 0.1% Tween-20 
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KREBS Buffer 
    Concentration  g/L 
NaCl     130 mM   7.6 
KCl     1.3 mM   0.10 
CaCl2    2.2 mM    0.24 
MgSO4.6H2O    1.2 mM   0.27 
KH2PO4    1.2 mM   0.16 
HEPES    10 mM   2.6 
D-Glucose    10 mM   1.8 
pH 7.4  
 
 
Chapter 3 solutions 
Saline 
    Concentration  g/L 
NaCl     138 mM   8.0 
KCl     4.1 mM   0.31 
Na2HPO4    5.1 mM   0.80 
KH2PO4    5.0 mM   0.68 
D-glucose    2% wt/vol   20 
pH 7.3 
 
 
Krebs, Na
+
 free 
    Concentration  g/L 
Choline   130 mM   8.1 
KCl     1.3 mM   0.10 
CaCl2    2.2 mM    0.24 
MgSO4.6H2O    1.2 mM   0.27 
KH2PO4    1.2 mM   0.16 
HEPES    10 mM   2.6 
D-Glucose    10 mM   1.8 
pH 7.4  
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Krebs Cl
-
 free 
    Concentration  g/L 
Sodium acetate  130 mM   17.7 
Potassium acetate  1.3 mM   0.13 
Calcium acetate  2.2 mM    0.39 
MgSO4.6H2O    1.2 mM   0.27 
KH2PO4    1.2 mM   0.16 
HEPES    10 mM   2.6 
D-Glucose    10 mM   1.8 
pH 7.4  
 
Chapter 5 solutions 
Stripping buffer  
    Concentration  g/L 
SDS    69 mM   20 
0.05 M Tris HCl, pH 6.8     992,5 mL 
β-mercaptoethanol      7.5 mL 
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Appendix 2:  Chapter 4 
 
A2.1 ASP
+
 uptake: Time of maximal effect 
Iniital ASP
+
 uptake studies were conducted to investigate when the KOPr agonists had 
their largest effect within a 5 min period.  The uptake of ASP
+
 was compared to uptake 
before agonist addition as described in Chapter 4.  It was found that U50,488H had its 
maximal effect at 100-160 s after addition (Figure A2.1a), Salvinorin A had its maximal 
effect 60-120 s after addition (Figure A2.1b), and DS-1-240 and DS-3-216 had their 
maximal effects at 200-260 s (Figure A2.1c and d).  These time points were used for all 
following studies where the effect of the agonist was measured at the acute time point. 
 
A2.2 Transfection optimisation of N2A and COS7 cells 
The co-transfection of HEK-293 cells with myc-KOPr and YFP-hDAT was already 
established in our laboratory before this research project began.  However, co-
transfection of N2A and COS-7 cells was not.  N2A and COS7 cells are not as easy to 
transfect as HEK-293 cells so optimisation was carried out to get maximum transfection 
efficiency.  This was carried out using three different protocols: 
 
Protocol One: Cells were transfected using the same protocol as HEK-293 cells 
Protocol Two: Cell were transfected with the same amount of DNA as HEK-293 cells 
but with 4 µL per dish of Lipofectamine 2000 rather than 3 µL. 
Protocol Three:  Cells were transfected with double the plasmid DNA of HEK-293 cells 
and 4 µL of Lipofectamine 2000. 
 
Transfected cells were looked at after 48 h using confocal microscopy and the protocol 
with the highest number of YFP-hDAT cells for each cell line were used for future 
experiments (Figure A2.2).  It was found that Protocol 3 produced the highest 
transfection rates in both N2A and COS7 cells. 
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Figure A2.1 Time of maximal effect of KOPr agonists on ASP
+
 uptake.  Initial 
experiments were carried out in HEK-293 cells transfected with myc-rKOPr and YFP-
hDAT to find the time of maximal effect of the KOPr agonists on ASP
+ 
uptake by YFP-
hDAT.  (A) U50,588H showed its maximal effect at 100-160 s, (B) salvinorin A 
showed its maximal effect at 60-120 s, (C,D) DS-1-240 and DS-3-216 showed their 
maximal effect at 200-260 s.  n = 46-60 cells, a minimum of 2 dishes over 3 
transfections.    
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Figure A2.2 N2A and COS7 cells transfected with YFP-hDAT and myc-rKOPr 
with three different protocols.  N2A cells and COS7 cells were transfected using three 
different protocols and then imaged to determine which protocol gave the highest 
transfection rates.  For both cell lines protocol three gave the highest number of 
transfected cells and this protocol was used for all further studies in these cell lines. 
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A2.3 Setting up TIRFM 
Initial TIRFM experiments were carried out to set up the technique in our laboratory 
following a previous study in which they found 10 µM DA led to an immediate increase 
in YFP-hDAT cell surface expression (Furman et al. 2009a).  Initial experiments carried 
out showed that in our system with our experimental set up we were able to measure 
this increase accurately with an increase of 10-15% after 120 s.  An increase of between 
10-15% was observed by Furman et al. (Furman et al. 2009a).  This demonstrates that 
our TIRFM system was working correctly (Figure A2.3).  Initial experiments also found 
that cells needed to be pre-incubated in the chamber for 20 min before experiments took 
place to minimise drift and that for 40 min studies the laser needed to be turned on and 
off between each image to prevent photobleaching.  It was also found that cells were 
healthier if they were kept in their growth media rather than in KREBs buffer, and 
saturated with carbogen.    
 
During these experiments we also found the best exposure time vs. laser intensity to 
use.  With our cells we found that a long exposure time (3 s) with a low laser power 
(0.1-0.3%) prevented photobleaching successfully and therefore we used this long 
exposure time for all future experiments. 
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Figure A2.3 DA causes increased YFP-hDAT cell surface expression.  Top panels: 
Incubation of HEK-293 cells with DA for 250 s caused an increase in YFP-hDAT cell 
surface expression as measured by TIRFM.  Images were taken before DA addition (-50 
s), at DA addition (0 s), and after DA addition (50, 100, 150, 200, 250 s). Graphical 
analysis indicates a rapid increase of YFP-hDAT, which plateaued after 70 s.  The graph 
represents the average, ± SEM for 6 cells in both control and DA treated groups. 
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Appendix 3:  Chapter 5 
A3.1 ERK1/2 optimisation 
A.3.1 Serum starvation time 
A protocol was used to measure ERK1/2 activation without serum, as serum causes 
basal ERK1/2 activation.  There are varying times of serum starvation published, with 
times between 30 min and 24 h (Belcheva et al. 2005; Bolan et al. 2007; Groer et al. 
2007; McLennan et al. 2008).  Initial experiments were carried out to find out which 
time was the best for our protocol.  HEK-293 cells started to look sick at the 16 h time 
point, and therefore Western blot analysis of basal ERK1/2 levels of the cells after 30 
min and 4 h serum starvation was performed.  As there was no real difference between 
basal ERK1/2 phosphorylation between these time points (Figure A3.1) and due to the 
timing of the experiment serum starving for 30 min was carried out for all future 
experiments. 
 
 
 
 
 
 
Figure A3.1:  Comparison between basal P-ERK1/2 levels after serum starvation 
for 30 min (left band) and 4 h (right band).  Cells were serum starved for 30 min or 4 
h and western blotting was carried out for P-ERK1/2 and ERK1/2.  There was no real 
difference between basal P-ERK1/2 between either treatment and therefore a 30 min 
serum starvation protocol was carried out for future experiments.    
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A3.2.2 Incubation time with P-ERK1/2 antibody 
Two different incubation times were tested with the P-ERK1/2 antibody, 1 h at room 
temperature, and overnight (20 h) at 4ºC.  As there was increased signal with the 
overnight incubation this time was used for all further experiments (Figure A3.2).  A 1 h 
incubation at room temperature with the ERK1/2 antibody produced a strong signal and 
therefore no other times were tested. 
 
 
 
 
 
 
 
 
 
 
 
Figure A3.2:  Comparison between a 1 h incubation with P-ERK1/2 antibody and 
a 20 h incubation.  Cells were serum starved for 30 min and then either left in the 
incubator for 1 h or UVed for 1 h.  Cells were then lysed and Western blot analysis was 
carried out for P-ERK1/2.  A 1 h incubation at room temperature and a 20 h incubation  
at 4ºC was carried out with the P-ERK1/2 primary antibody and results compared.  As 
shown, a 20 h incubation iwht the antibody gave stronger results than the 1 h and was 
therefore used for future experiments. 
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A3.2.3 Protein amount 
The amount of protein loaded on the gel was also optimised to get the best P-ERK1/2 
bands.  Cells were treated with salvinorin A and Western blotting was conducted as 
described in chapter 5.  Initially 25 µg of protein was loaded onto the gel, but only the 
UV positive control was visible, therefore, the protein concentration was doubled to 50 
µg and the results were much clearer (Figure A3.3).     
 
 
 
 
 
 
 
 
 
 
Figure A3.3:  Comparison between 25 µg of protein lysate and 50 µg of protein 
lysate.  As shown 50 µg of protein gave stronger results compared to 25 µg of protein 
after being treated with salvinorin A.  Therefore 50 µg of protein was used for all future 
experiments.   
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